WO2020041333A1 - Methods for treating cardiac valve disease - Google Patents
Methods for treating cardiac valve disease Download PDFInfo
- Publication number
- WO2020041333A1 WO2020041333A1 PCT/US2019/047295 US2019047295W WO2020041333A1 WO 2020041333 A1 WO2020041333 A1 WO 2020041333A1 US 2019047295 W US2019047295 W US 2019047295W WO 2020041333 A1 WO2020041333 A1 WO 2020041333A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- unsubstituted
- valve disease
- alkyl
- aryl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 224
- 208000015121 Cardiac valve disease Diseases 0.000 title claims abstract description 67
- 150000001875 compounds Chemical class 0.000 claims abstract description 153
- 208000027896 Aortic valve disease Diseases 0.000 claims abstract description 65
- 150000003839 salts Chemical class 0.000 claims abstract description 62
- 239000012453 solvate Substances 0.000 claims abstract description 44
- 239000000651 prodrug Substances 0.000 claims abstract description 34
- 229940002612 prodrug Drugs 0.000 claims abstract description 34
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 228
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 213
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 206
- -1 amino, substituted amino Chemical group 0.000 claims description 204
- 125000002252 acyl group Chemical group 0.000 claims description 177
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 177
- 125000004423 acyloxy group Chemical group 0.000 claims description 176
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 176
- 125000003118 aryl group Chemical group 0.000 claims description 165
- 239000001257 hydrogen Substances 0.000 claims description 152
- 229910052739 hydrogen Inorganic materials 0.000 claims description 152
- 125000000217 alkyl group Chemical group 0.000 claims description 150
- 125000003545 alkoxy group Chemical group 0.000 claims description 143
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 137
- 229910052736 halogen Inorganic materials 0.000 claims description 134
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 113
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 108
- 125000003107 substituted aryl group Chemical group 0.000 claims description 108
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 104
- 150000003573 thiols Chemical class 0.000 claims description 103
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 101
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 93
- 210000002889 endothelial cell Anatomy 0.000 claims description 89
- 150000002367 halogens Chemical class 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 59
- 108090000623 proteins and genes Proteins 0.000 claims description 51
- 230000014509 gene expression Effects 0.000 claims description 44
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 43
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 42
- 125000003342 alkenyl group Chemical group 0.000 claims description 39
- 125000000623 heterocyclic group Chemical group 0.000 claims description 37
- 238000003559 RNA-seq method Methods 0.000 claims description 36
- HQFNFOOGGLSBBT-AWNIVKPZSA-N XCT 790 Chemical compound C=1C=C(OCC=2C(=CC(=CC=2)C(F)(F)F)C(F)(F)F)C(OC)=CC=1\C=C(/C#N)C(=O)NC1=NN=C(C(F)(F)F)S1 HQFNFOOGGLSBBT-AWNIVKPZSA-N 0.000 claims description 34
- 241000282414 Homo sapiens Species 0.000 claims description 31
- 125000004442 acylamino group Chemical group 0.000 claims description 30
- 125000004104 aryloxy group Chemical group 0.000 claims description 30
- BGVLELSCIHASRV-QPEQYQDCSA-N (1z)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one Chemical compound C1=C(OC)C=C2N(CC)\C(=C\C(C)=O)SC2=C1 BGVLELSCIHASRV-QPEQYQDCSA-N 0.000 claims description 28
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 25
- RSINKZJTTORDAJ-UHFFFAOYSA-N 1,3-bis[4-[(4-methylpyrimidin-2-yl)sulfamoyl]phenyl]urea Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(NC(=O)NC=3C=CC(=CC=3)S(=O)(=O)NC=3N=C(C)C=CN=3)=CC=2)=N1 RSINKZJTTORDAJ-UHFFFAOYSA-N 0.000 claims description 19
- 101000642523 Homo sapiens Transcription factor SOX-7 Proteins 0.000 claims description 17
- 102100036730 Transcription factor SOX-7 Human genes 0.000 claims description 17
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 claims description 16
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 claims description 16
- 102100023489 Transcription factor 4 Human genes 0.000 claims description 16
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 16
- WOCXQMCIOTUMJV-UHFFFAOYSA-N cb1954 Chemical compound C1=C([N+]([O-])=O)C(C(=O)N)=CC(N2CC2)=C1[N+]([O-])=O WOCXQMCIOTUMJV-UHFFFAOYSA-N 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 claims description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- 238000012163 sequencing technique Methods 0.000 claims description 10
- OJPLJFIFUQPSJR-INIZCTEOSA-N RO4929097 Chemical compound N1C(=O)[C@@H](NC(=O)C(C)(C(=O)NCC(F)(F)C(F)(F)F)C)C2=CC=CC=C2C2=CC=CC=C21 OJPLJFIFUQPSJR-INIZCTEOSA-N 0.000 claims description 9
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 claims description 9
- ZMAODHOXRBLOQO-UHFFFAOYSA-N cytochalasin-A Natural products N1C(=O)C23OC(=O)C=CC(=O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 ZMAODHOXRBLOQO-UHFFFAOYSA-N 0.000 claims description 9
- 229960004127 naloxone Drugs 0.000 claims description 9
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 9
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000005700 Putrescine Substances 0.000 claims description 7
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 6
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 claims description 6
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 6
- 102100032401 Charged multivesicular body protein 2a Human genes 0.000 claims description 6
- 101150076092 Chmp2a gene Proteins 0.000 claims description 6
- 101001106090 Homo sapiens Receptor expression-enhancing protein 5 Proteins 0.000 claims description 6
- 102100021077 Receptor expression-enhancing protein 5 Human genes 0.000 claims description 6
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 claims description 6
- 229960003003 biperiden Drugs 0.000 claims description 6
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 claims description 6
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 claims description 6
- JHBCSXMWPZTKTF-UHFFFAOYSA-N n-(4-methylpyrimidin-2-yl)benzenesulfonamide Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC=CC=2)=N1 JHBCSXMWPZTKTF-UHFFFAOYSA-N 0.000 claims description 6
- 102100029761 Cadherin-5 Human genes 0.000 claims description 5
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 claims description 5
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 claims description 5
- 101700032040 SMAD1 Proteins 0.000 claims description 5
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- DFMXJRGGNCRUHZ-UHFFFAOYSA-N 6h-isoquinolin-7-one Chemical compound C1=CN=CC2=CC(=O)CC=C21 DFMXJRGGNCRUHZ-UHFFFAOYSA-N 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- 101000823782 Homo sapiens Y-box-binding protein 3 Proteins 0.000 claims description 3
- 102100022221 Y-box-binding protein 3 Human genes 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 claims description 3
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 claims description 3
- 238000010801 machine learning Methods 0.000 claims description 3
- 150000004702 methyl esters Chemical class 0.000 claims description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- WBSMIPAMAXNXFS-UHFFFAOYSA-N 5-Nitro-2-(3-phenylpropylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCCC1=CC=CC=C1 WBSMIPAMAXNXFS-UHFFFAOYSA-N 0.000 claims description 2
- 102100024387 AF4/FMR2 family member 3 Human genes 0.000 claims description 2
- 102100033792 ALX homeobox protein 1 Human genes 0.000 claims description 2
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 claims description 2
- 102100040069 Aldehyde dehydrogenase 1A1 Human genes 0.000 claims description 2
- 102100033816 Aldehyde dehydrogenase, mitochondrial Human genes 0.000 claims description 2
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims description 2
- 101710185050 Angiotensin-converting enzyme Proteins 0.000 claims description 2
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 claims description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 102100032556 C-type lectin domain family 14 member A Human genes 0.000 claims description 2
- 102100029303 Calcium-regulated heat-stable protein 1 Human genes 0.000 claims description 2
- 102100036375 Carbonic anhydrase-related protein Human genes 0.000 claims description 2
- 102100032231 Caveolae-associated protein 2 Human genes 0.000 claims description 2
- 102100027442 Collagen alpha-1(XII) chain Human genes 0.000 claims description 2
- 102100022640 Collagen alpha-1(XV) chain Human genes 0.000 claims description 2
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 claims description 2
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 claims description 2
- 102100028992 Cytochrome c oxidase subunit 6A1, mitochondrial Human genes 0.000 claims description 2
- 101700026669 DACH1 Proteins 0.000 claims description 2
- 102100028735 Dachshund homolog 1 Human genes 0.000 claims description 2
- 102100026662 Delta and Notch-like epidermal growth factor-related receptor Human genes 0.000 claims description 2
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims description 2
- 102100040278 E3 ubiquitin-protein ligase RNF19A Human genes 0.000 claims description 2
- 102100037358 EF-hand calcium-binding domain-containing protein 14 Human genes 0.000 claims description 2
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 claims description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 2
- 102100020856 Forkhead box protein F1 Human genes 0.000 claims description 2
- 102100030525 Gap junction alpha-4 protein Human genes 0.000 claims description 2
- 102100038367 Gremlin-1 Human genes 0.000 claims description 2
- 102100023952 Guanine nucleotide-binding protein subunit alpha-14 Human genes 0.000 claims description 2
- 102100027490 H2.0-like homeobox protein Human genes 0.000 claims description 2
- 108700039143 HMGA2 Proteins 0.000 claims description 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims description 2
- 102100035960 Hedgehog-interacting protein Human genes 0.000 claims description 2
- 101710164669 Hedgehog-interacting protein Proteins 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 claims description 2
- 101150073387 Hmga2 gene Proteins 0.000 claims description 2
- 102100034862 Homeobox protein Hox-B2 Human genes 0.000 claims description 2
- 102100028411 Homeobox protein Hox-B3 Human genes 0.000 claims description 2
- 102100028404 Homeobox protein Hox-B4 Human genes 0.000 claims description 2
- 102100029240 Homeobox protein Hox-B5 Human genes 0.000 claims description 2
- 102100025056 Homeobox protein Hox-B6 Human genes 0.000 claims description 2
- 102100025061 Homeobox protein Hox-B7 Human genes 0.000 claims description 2
- 102100040229 Homeobox protein Hox-D1 Human genes 0.000 claims description 2
- 102100034826 Homeobox protein Meis2 Human genes 0.000 claims description 2
- 101000833166 Homo sapiens AF4/FMR2 family member 3 Proteins 0.000 claims description 2
- 101000779615 Homo sapiens ALX homeobox protein 1 Proteins 0.000 claims description 2
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 claims description 2
- 101000890570 Homo sapiens Aldehyde dehydrogenase 1A1 Proteins 0.000 claims description 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 2
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 claims description 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 2
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 101000942280 Homo sapiens C-type lectin domain family 14 member A Proteins 0.000 claims description 2
- 101000989513 Homo sapiens Calcium-regulated heat-stable protein 1 Proteins 0.000 claims description 2
- 101000714515 Homo sapiens Carbonic anhydrase-related protein Proteins 0.000 claims description 2
- 101000869050 Homo sapiens Caveolae-associated protein 2 Proteins 0.000 claims description 2
- 101000861874 Homo sapiens Collagen alpha-1(XII) chain Proteins 0.000 claims description 2
- 101000899935 Homo sapiens Collagen alpha-1(XV) chain Proteins 0.000 claims description 2
- 101000915989 Homo sapiens Cytochrome c oxidase subunit 6A1, mitochondrial Proteins 0.000 claims description 2
- 101001054266 Homo sapiens Delta and Notch-like epidermal growth factor-related receptor Proteins 0.000 claims description 2
- 101000951342 Homo sapiens Dickkopf-related protein 3 Proteins 0.000 claims description 2
- 101000880230 Homo sapiens EF-hand calcium-binding domain-containing protein 14 Proteins 0.000 claims description 2
- 101000931494 Homo sapiens Forkhead box protein F1 Proteins 0.000 claims description 2
- 101000726582 Homo sapiens Gap junction alpha-4 protein Proteins 0.000 claims description 2
- 101001002170 Homo sapiens Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial Proteins 0.000 claims description 2
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 claims description 2
- 101000904077 Homo sapiens Guanine nucleotide-binding protein subunit alpha-14 Proteins 0.000 claims description 2
- 101001081101 Homo sapiens H2.0-like homeobox protein Proteins 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 101001019752 Homo sapiens Homeobox protein Hox-B2 Proteins 0.000 claims description 2
- 101000839775 Homo sapiens Homeobox protein Hox-B3 Proteins 0.000 claims description 2
- 101000839788 Homo sapiens Homeobox protein Hox-B4 Proteins 0.000 claims description 2
- 101000840553 Homo sapiens Homeobox protein Hox-B5 Proteins 0.000 claims description 2
- 101001077542 Homo sapiens Homeobox protein Hox-B6 Proteins 0.000 claims description 2
- 101001077539 Homo sapiens Homeobox protein Hox-B7 Proteins 0.000 claims description 2
- 101001037162 Homo sapiens Homeobox protein Hox-D1 Proteins 0.000 claims description 2
- 101001019057 Homo sapiens Homeobox protein Meis2 Proteins 0.000 claims description 2
- 101001079904 Homo sapiens Hyaluronan and proteoglycan link protein 1 Proteins 0.000 claims description 2
- 101000852593 Homo sapiens Inositol-trisphosphate 3-kinase B Proteins 0.000 claims description 2
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 claims description 2
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 claims description 2
- 101000994322 Homo sapiens Integrin alpha-8 Proteins 0.000 claims description 2
- 101001035232 Homo sapiens Integrin alpha-9 Proteins 0.000 claims description 2
- 101001011446 Homo sapiens Interferon regulatory factor 6 Proteins 0.000 claims description 2
- 101000578476 Homo sapiens Latexin Proteins 0.000 claims description 2
- 101001005668 Homo sapiens Mastermind-like protein 3 Proteins 0.000 claims description 2
- 101001011896 Homo sapiens Matrix metalloproteinase-19 Proteins 0.000 claims description 2
- 101001013158 Homo sapiens Myeloid leukemia factor 1 Proteins 0.000 claims description 2
- 101000973461 Homo sapiens NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 Proteins 0.000 claims description 2
- 101000928278 Homo sapiens Natriuretic peptides B Proteins 0.000 claims description 2
- 101001108364 Homo sapiens Neuronal cell adhesion molecule Proteins 0.000 claims description 2
- 101000603202 Homo sapiens Nicotinamide N-methyltransferase Proteins 0.000 claims description 2
- 101000601048 Homo sapiens Nidogen-2 Proteins 0.000 claims description 2
- 101001109685 Homo sapiens Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 claims description 2
- 101001069727 Homo sapiens Paired mesoderm homeobox protein 1 Proteins 0.000 claims description 2
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 claims description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 2
- 101001109765 Homo sapiens Pro-neuregulin-3, membrane-bound isoform Proteins 0.000 claims description 2
- 101000595907 Homo sapiens Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Proteins 0.000 claims description 2
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 claims description 2
- 101000898093 Homo sapiens Protein C-ets-2 Proteins 0.000 claims description 2
- 101000813321 Homo sapiens Protein FAM124B Proteins 0.000 claims description 2
- 101000911397 Homo sapiens Protein FAM89A Proteins 0.000 claims description 2
- 101000873612 Homo sapiens Protein bicaudal D homolog 1 Proteins 0.000 claims description 2
- 101000928408 Homo sapiens Protein diaphanous homolog 2 Proteins 0.000 claims description 2
- 101000994434 Homo sapiens Protein jagged-2 Proteins 0.000 claims description 2
- 101001098529 Homo sapiens Proteinase-activated receptor 1 Proteins 0.000 claims description 2
- 101001098557 Homo sapiens Proteinase-activated receptor 3 Proteins 0.000 claims description 2
- 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 claims description 2
- 101000712956 Homo sapiens Ras association domain-containing protein 2 Proteins 0.000 claims description 2
- 101000731728 Homo sapiens Rho guanine nucleotide exchange factor 17 Proteins 0.000 claims description 2
- 101000864743 Homo sapiens Secreted frizzled-related protein 1 Proteins 0.000 claims description 2
- 101000864070 Homo sapiens Smoothelin Proteins 0.000 claims description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 2
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 claims description 2
- 101000679548 Homo sapiens TOX high mobility group box family member 3 Proteins 0.000 claims description 2
- 101000620880 Homo sapiens Tartrate-resistant acid phosphatase type 5 Proteins 0.000 claims description 2
- 101000796022 Homo sapiens Thioredoxin-interacting protein Proteins 0.000 claims description 2
- 101000669960 Homo sapiens Thrombospondin type-1 domain-containing protein 1 Proteins 0.000 claims description 2
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 claims description 2
- 101000596772 Homo sapiens Transcription factor 7-like 1 Proteins 0.000 claims description 2
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 claims description 2
- 101000825086 Homo sapiens Transcription factor SOX-11 Proteins 0.000 claims description 2
- 101000825079 Homo sapiens Transcription factor SOX-13 Proteins 0.000 claims description 2
- 101000626577 Homo sapiens Transmembrane protein 178A Proteins 0.000 claims description 2
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims description 2
- 101000860430 Homo sapiens Versican core protein Proteins 0.000 claims description 2
- 101000666934 Homo sapiens Very low-density lipoprotein receptor Proteins 0.000 claims description 2
- 101000730643 Homo sapiens Zinc finger protein PLAGL1 Proteins 0.000 claims description 2
- 101001098858 Homo sapiens cGMP-dependent 3',5'-cyclic phosphodiesterase Proteins 0.000 claims description 2
- 101001098818 Homo sapiens cGMP-inhibited 3',5'-cyclic phosphodiesterase A Proteins 0.000 claims description 2
- 102100028084 Hyaluronan and proteoglycan link protein 1 Human genes 0.000 claims description 2
- 102100036404 Inositol-trisphosphate 3-kinase B Human genes 0.000 claims description 2
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 claims description 2
- 102100032817 Integrin alpha-5 Human genes 0.000 claims description 2
- 102100032825 Integrin alpha-8 Human genes 0.000 claims description 2
- 102100039903 Integrin alpha-9 Human genes 0.000 claims description 2
- 102100030130 Interferon regulatory factor 6 Human genes 0.000 claims description 2
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 claims description 2
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 claims description 2
- 102100027919 Latexin Human genes 0.000 claims description 2
- 102100025134 Mastermind-like protein 3 Human genes 0.000 claims description 2
- 102100030218 Matrix metalloproteinase-19 Human genes 0.000 claims description 2
- 108010009513 Mitochondrial Aldehyde Dehydrogenase Proteins 0.000 claims description 2
- 102100029691 Myeloid leukemia factor 1 Human genes 0.000 claims description 2
- 102100022198 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 Human genes 0.000 claims description 2
- 102100036836 Natriuretic peptides B Human genes 0.000 claims description 2
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 claims description 2
- 108090000772 Neuropilin-1 Proteins 0.000 claims description 2
- 102100038951 Nicotinamide N-methyltransferase Human genes 0.000 claims description 2
- 102100037371 Nidogen-2 Human genes 0.000 claims description 2
- 102000001753 Notch4 Receptor Human genes 0.000 claims description 2
- 108010029741 Notch4 Receptor Proteins 0.000 claims description 2
- 102100022669 Nuclear receptor subfamily 5 group A member 2 Human genes 0.000 claims description 2
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 claims description 2
- 102100033786 Paired mesoderm homeobox protein 1 Human genes 0.000 claims description 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 2
- 102100035194 Placenta growth factor Human genes 0.000 claims description 2
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 claims description 2
- 102100022659 Pro-neuregulin-3, membrane-bound isoform Human genes 0.000 claims description 2
- 102100035198 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Human genes 0.000 claims description 2
- 102100035251 Protein C-ets-1 Human genes 0.000 claims description 2
- 102100021890 Protein C-ets-2 Human genes 0.000 claims description 2
- 102100039198 Protein FAM124B Human genes 0.000 claims description 2
- 102100026733 Protein FAM89A Human genes 0.000 claims description 2
- 102100035898 Protein bicaudal D homolog 1 Human genes 0.000 claims description 2
- 102100036469 Protein diaphanous homolog 2 Human genes 0.000 claims description 2
- 102100032733 Protein jagged-2 Human genes 0.000 claims description 2
- 102100023068 Protein kinase C-binding protein NELL1 Human genes 0.000 claims description 2
- 102100037136 Proteinase-activated receptor 1 Human genes 0.000 claims description 2
- 102100037133 Proteinase-activated receptor 3 Human genes 0.000 claims description 2
- 108091007326 RNF19A Proteins 0.000 claims description 2
- 102100036900 Radiation-inducible immediate-early gene IEX-1 Human genes 0.000 claims description 2
- 102100033242 Ras association domain-containing protein 2 Human genes 0.000 claims description 2
- 102100032437 Rho guanine nucleotide exchange factor 17 Human genes 0.000 claims description 2
- 102100030058 Secreted frizzled-related protein 1 Human genes 0.000 claims description 2
- 102100029937 Smoothelin Human genes 0.000 claims description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 2
- 102100028848 Stromelysin-2 Human genes 0.000 claims description 2
- 102100022608 TOX high mobility group box family member 3 Human genes 0.000 claims description 2
- 102100022919 Tartrate-resistant acid phosphatase type 5 Human genes 0.000 claims description 2
- 108010033711 Telomeric Repeat Binding Protein 1 Proteins 0.000 claims description 2
- 102100036497 Telomeric repeat-binding factor 1 Human genes 0.000 claims description 2
- 102100031344 Thioredoxin-interacting protein Human genes 0.000 claims description 2
- 102100039311 Thrombospondin type-1 domain-containing protein 1 Human genes 0.000 claims description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 claims description 2
- 102100035097 Transcription factor 7-like 1 Human genes 0.000 claims description 2
- 102100030798 Transcription factor HES-1 Human genes 0.000 claims description 2
- 102100022415 Transcription factor SOX-11 Human genes 0.000 claims description 2
- 102100022435 Transcription factor SOX-13 Human genes 0.000 claims description 2
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 claims description 2
- 102100024892 Transmembrane protein 178A Human genes 0.000 claims description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims description 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims description 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims description 2
- 102100028437 Versican core protein Human genes 0.000 claims description 2
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 claims description 2
- 102100032570 Zinc finger protein PLAGL1 Human genes 0.000 claims description 2
- 108010079292 betaglycan Proteins 0.000 claims description 2
- 102100038953 cGMP-dependent 3',5'-cyclic phosphodiesterase Human genes 0.000 claims description 2
- 102100037093 cGMP-inhibited 3',5'-cyclic phosphodiesterase A Human genes 0.000 claims description 2
- NJHLGKJQFKUSEA-UHFFFAOYSA-N n-[2-(4-hydroxyphenyl)ethyl]-n-methylnitrous amide Chemical compound O=NN(C)CCC1=CC=C(O)C=C1 NJHLGKJQFKUSEA-UHFFFAOYSA-N 0.000 claims description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 20
- 208000015532 congenital bilateral absence of vas deferens Diseases 0.000 claims 2
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 claims 1
- 102000001759 Notch1 Receptor Human genes 0.000 claims 1
- 108010029755 Notch1 Receptor Proteins 0.000 claims 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 168
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 146
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 130
- 125000001309 chloro group Chemical group Cl* 0.000 description 83
- 125000005843 halogen group Chemical group 0.000 description 75
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 73
- 239000013543 active substance Substances 0.000 description 66
- 230000037396 body weight Effects 0.000 description 46
- 150000003384 small molecules Chemical class 0.000 description 42
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 32
- 230000000694 effects Effects 0.000 description 28
- 238000009472 formulation Methods 0.000 description 25
- 238000012384 transportation and delivery Methods 0.000 description 25
- 125000001424 substituent group Chemical group 0.000 description 24
- 201000010099 disease Diseases 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 239000003814 drug Substances 0.000 description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 17
- 208000004434 Calcinosis Diseases 0.000 description 15
- 230000002308 calcification Effects 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 230000001105 regulatory effect Effects 0.000 description 15
- 238000002592 echocardiography Methods 0.000 description 14
- 210000003102 pulmonary valve Anatomy 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000000829 suppository Substances 0.000 description 13
- 230000002103 transcriptional effect Effects 0.000 description 13
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 11
- 125000003710 aryl alkyl group Chemical group 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 10
- 125000001624 naphthyl group Chemical group 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 108020004459 Small interfering RNA Proteins 0.000 description 9
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 239000010432 diamond Substances 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 8
- 210000000664 rectum Anatomy 0.000 description 8
- 210000001215 vagina Anatomy 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 125000005418 aryl aryl group Chemical group 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 7
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 208000031481 Pathologic Constriction Diseases 0.000 description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 239000000227 bioadhesive Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 6
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 6
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 230000036262 stenosis Effects 0.000 description 6
- 208000037804 stenosis Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108700039887 Essential Genes Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000011859 microparticle Substances 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- 239000012062 aqueous buffer Substances 0.000 description 4
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 4
- VPUGDVKSAQVFFS-UHFFFAOYSA-N coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 125000004404 heteroalkyl group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 4
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 4
- GBROPGWFBFCKAG-UHFFFAOYSA-N picene Chemical compound C1=CC2=C3C=CC=CC3=CC=C2C2=C1C1=CC=CC=C1C=C2 GBROPGWFBFCKAG-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 210000001765 aortic valve Anatomy 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- ZDZHCHYQNPQSGG-UHFFFAOYSA-N binaphthyl group Chemical group C1(=CC=CC2=CC=CC=C12)C1=CC=CC2=CC=CC=C12 ZDZHCHYQNPQSGG-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 3
- 239000004305 biphenyl Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 3
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000008482 dysregulation Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000000806 elastomer Substances 0.000 description 3
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
- 0 *[C@](CICN1CCCCC1)([C@]1(C(C2)C=CC2C1)*#C)c1c(*)c(*)c(*)c(*)c1* Chemical compound *[C@](CICN1CCCCC1)([C@]1(C(C2)C=CC2C1)*#C)c1c(*)c(*)c(*)c(*)c1* 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 description 2
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 2
- ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical compound C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 description 2
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 2
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 2
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010065558 Aortic arteriosclerosis Diseases 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- 206010004552 Bicuspid aortic valve Diseases 0.000 description 2
- 108010062802 CD66 antigens Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010021779 GATA5 Transcription Factor Proteins 0.000 description 2
- 102000008412 GATA5 Transcription Factor Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 2
- QVXFGVVYTKZLJN-KHPPLWFESA-N [(z)-hexadec-7-enyl] acetate Chemical compound CCCCCCCC\C=C/CCCCCCOC(C)=O QVXFGVVYTKZLJN-KHPPLWFESA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- JDPAVWAQGBGGHD-UHFFFAOYSA-N aceanthrylene Chemical group C1=CC=C2C(C=CC3=CC=C4)=C3C4=CC2=C1 JDPAVWAQGBGGHD-UHFFFAOYSA-N 0.000 description 2
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 2
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 2
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229960000711 alprostadil Drugs 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010002906 aortic stenosis Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- BVUSIQTYUVWOSX-UHFFFAOYSA-N arsindole Chemical compound C1=CC=C2[As]C=CC2=C1 BVUSIQTYUVWOSX-UHFFFAOYSA-N 0.000 description 2
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- 208000021654 bicuspid aortic valve disease Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- QSQIGGCOCHABAP-UHFFFAOYSA-N hexacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC=CC=C6C=C5C=C4C=C3C=C21 QSQIGGCOCHABAP-UHFFFAOYSA-N 0.000 description 2
- PKIFBGYEEVFWTJ-UHFFFAOYSA-N hexaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC6=CC=CC=C6C=C5C=C4C=CC3=CC2=C1 PKIFBGYEEVFWTJ-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- PFTXKXWAXWAZBP-UHFFFAOYSA-N octacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC7=CC8=CC=CC=C8C=C7C=C6C=C5C=C4C=C3C=C21 PFTXKXWAXWAZBP-UHFFFAOYSA-N 0.000 description 2
- OVPVGJFDFSJUIG-UHFFFAOYSA-N octalene Chemical compound C1=CC=CC=C2C=CC=CC=CC2=C1 OVPVGJFDFSJUIG-UHFFFAOYSA-N 0.000 description 2
- WTFQBTLMPISHTA-UHFFFAOYSA-N octaphene Chemical compound C1=CC=C2C=C(C=C3C4=CC5=CC6=CC7=CC=CC=C7C=C6C=C5C=C4C=CC3=C3)C3=CC2=C1 WTFQBTLMPISHTA-UHFFFAOYSA-N 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- LSQODMMMSXHVCN-UHFFFAOYSA-N ovalene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3C5=C6C(C=C3)=CC=C3C6=C6C(C=C3)=C3)C4=C5C6=C2C3=C1 LSQODMMMSXHVCN-UHFFFAOYSA-N 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- PMJHHCWVYXUKFD-UHFFFAOYSA-N penta-1,3-diene Chemical compound CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 2
- SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 2
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 2
- JQQSUOJIMKJQHS-UHFFFAOYSA-N pentaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC=CC=C5C=C4C=CC3=CC2=C1 JQQSUOJIMKJQHS-UHFFFAOYSA-N 0.000 description 2
- 210000002824 peroxisome Anatomy 0.000 description 2
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 2
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
- DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- LNKHTYQPVMAJSF-UHFFFAOYSA-N pyranthrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC3=C(C=CC=C4)C4=CC4=CC=C1C2=C34 LNKHTYQPVMAJSF-UHFFFAOYSA-N 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 230000000754 repressing effect Effects 0.000 description 2
- FMKFBRKHHLWKDB-UHFFFAOYSA-N rubicene Chemical compound C12=CC=CC=C2C2=CC=CC3=C2C1=C1C=CC=C2C4=CC=CC=C4C3=C21 FMKFBRKHHLWKDB-UHFFFAOYSA-N 0.000 description 2
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 125000005580 triphenylene group Chemical group 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- PPWLAQVKIFDULF-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CC=C1 PPWLAQVKIFDULF-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- WQRPHHIOZYGAMQ-UHFFFAOYSA-N 3-methyl-n-phenylbutanamide Chemical compound CC(C)CC(=O)NC1=CC=CC=C1 WQRPHHIOZYGAMQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940122578 Acetylcholine receptor agonist Drugs 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229940121913 Alpha adrenoreceptor antagonist Drugs 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 206010050559 Aortic valve calcification Diseases 0.000 description 1
- 206010002917 Aortic valve sclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- UAIYNMRLUHHRMF-AATRIKPKSA-N BW B70C Chemical compound NC(=O)N(O)C(C)\C=C\C1=CC=CC(OC=2C=CC(F)=CC=2)=C1 UAIYNMRLUHHRMF-AATRIKPKSA-N 0.000 description 1
- 229940123031 Beta adrenoreceptor agonist Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 102100024155 Cadherin-11 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000032559 Germinal Center Kinases Human genes 0.000 description 1
- 108010004242 Germinal Center Kinases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 102100030590 Mothers against decapentaplegic homolog 6 Human genes 0.000 description 1
- 101710143114 Mothers against decapentaplegic homolog 6 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000997105 Mus musculus Nik-related protein kinase Proteins 0.000 description 1
- 102000014736 Notch Human genes 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000269319 Squalius cephalus Species 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- RSLNRVYIRDVHLY-UHFFFAOYSA-N Tulobuterol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)C1=CC=CC=C1Cl RSLNRVYIRDVHLY-UHFFFAOYSA-N 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001733 anti-osteogenic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 201000006800 aortic valve disease 1 Diseases 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000002014 arsindolyl group Chemical group [AsH]1C(=CC2=CC=CC=C12)* 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 150000001542 azirines Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960000749 biperiden hydrochloride Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- XXWCODXIQWIHQN-UHFFFAOYSA-N butane-1,4-diamine;hydron;dichloride Chemical compound Cl.Cl.NCCCCN XXWCODXIQWIHQN-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000003490 calendering Methods 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 239000011111 cardboard Substances 0.000 description 1
- 230000008209 cardiovascular development Effects 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- AKXCFAYOTIEFOH-XTNAHFASSA-N n-[(e)-[(4r,4as,7ar,12bs)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ylidene]amino]benzamide Chemical compound C1(/[C@H]2[C@]34CCN(CC=C)[C@@H]([C@@]4(CC1)O)CC1=CC=C(C(O2)=C13)O)=N\NC(=O)C1=CC=CC=C1 AKXCFAYOTIEFOH-XTNAHFASSA-N 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 108010000953 osteoblast cadherin Proteins 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000011087 paperboard Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940090048 pen injector Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960003056 phentolamine mesylate Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 210000003291 sinus of valsalva Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 108010057210 telomerase RNA Proteins 0.000 description 1
- 150000003553 thiiranes Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LLZRNZOLAXHGLL-UHFFFAOYSA-J titanic acid Chemical compound O[Ti](O)(O)O LLZRNZOLAXHGLL-UHFFFAOYSA-J 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 229960004846 tulobuterol hydrochloride Drugs 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- RNA-seq Whole transcriptome RNA sequencing
- Calcific aortic valve disease is a progressive disorder that ranges from mild valve thickening without obstruction of blood flow, termed aortic sclerosis, to severe calcification with impaired leaflet motion, termed aortic stenosis.
- Neurogenic locus notch homolog protein 1 (NOTCH1) (Nl) is a human membrane-bound transcription factor, and Nl haploinsufficiency (Nl +/ ), in which a single functional copy of the Nl gene is present, has been identified as a cause of CAVD.
- NOTCH1 Neurogenic locus notch homolog protein 1
- Nl +/ Nl haploinsufficiency
- the only current treatment for CAVD is valve transplant, necessitating over 100,000 valve transplants annually in the United States alone. Given that valve calcification progresses over time, there is an opportunity to intervene with a
- the present disclosure provides methods of treating cardiac valve disease, e.g., calcific aortic valve disease (CAVD), by administering to a subject in need thereof a cardiac valve disease, e.g., calcific aortic valve disease (CAVD), by administering to a subject in need thereof a cardiac valve disease, e.g., calcific aortic valve disease (CAVD), by administering to a subject in need thereof a
- CAVD calcific aortic valve disease
- a compound of any one of Formulae I-X or a pharmaceutically acceptable salt, solvate or prodrug thereof are also provided. Also provided are methods of identifying a candidate compound for treatment of cardiac valve disease, e.g., CAVD.
- Figure 1A depicts a map of gene network dysregulation by Nl haploinsufficiency (from targeted RNA-seq).
- Figure IB depicts a principle components analysis (PC A) plot of gene expression in WT or Nl +/ ECs (from targeted RNA-seq). The line through the graph divides WT+DMSO data points on the right and Nl +/ +DMSO data points on the left.
- PC A principle components analysis
- Figure 1C depicts a PCA plot of gene expression in Nl +/ ⁇ ECs treated with one of 1595 small molecules compared to Nl +/ ⁇ or WT ECs exposed to DMSO (from targeted RNA- seq). Squares indicate molecule-treated Nl +/ ⁇ whose network transcription was corrected sufficiently to classify as WT by the KNN algorithm.
- Figure ID depicts a hierarchical clustering of transcriptional profiles of Nl +/ ⁇ ECs
- Figure IE depicts percent of targeted RNA-seq validation replicates that classified as WT with true identities of DMSO-exposed WT, DMSO-exposed Nl , or small molecule-treated Nl (from targeted RNA-seq).
- Figure 2A depicts the effect of network-correcting molecules on genes dysregulated in Nl +/ ⁇ ECs (from whole transcriptome RNA-seq). Gene ontology (GO) pathways enriched in each gene cluster are indicated to the right.
- Figure 2B depicts correlation of gene expression in WT ECs with gene expression in Nl +/ ⁇ ECs exposed to DMSO or network-correcting molecules (from whole
- transcriptome RNA-seq transcriptome RNA-seq
- Figure 2C depicts correlation of Nl -dependent gene expression by siRNA repression of SOX7 and TCF4 regulatory nodes, which are upregulated by Nl haploinsufficiency (from whole transcriptome RNA-seq).
- Figure 2D depicts the repression of SOX7 and TCF4 regulatory nodes by network- correcting molecules (from whole transcriptome RNA-seq).
- Figure 2E depicts the extent of Nl -dependent network restoration in Nl +/ ⁇ ECs treated with network-correcting molecules or siRNA targeting SOX7 and TCF4 (from whole transcriptome RNA-seq). Positive values indicate correction towards or past WT expression level. Negative values indicate worsened dysregulation.
- Figure 3A depicts the percent correction of nodes within the Nl -dependent network to WT expression levels in N I ECs treated with network-correcting molecules or siRNA targeting SOX7 and TCF4.
- Figure 3C depicts the percentage of the AV calcified by Alizarin red staining in
- Figure 4A depicts a histogram of the number of network connections of each node within the Nl -dependent gene network as mapped by network inference based on targeted RNA-seq data.
- Figure 4B depicts the top 20 most connected nodes in the Nl -dependent gene network ordered from greatest to least valent.
- Figure 5 A depicts a hierarchical clustering of transcriptional profiles of Nl +/ ⁇ ECs
- Figure 5B depicts a hierarchical clustering of transcriptional profiles of Nl +/ ⁇ ECs
- Figure 6 A depicts a hierarchical clustering of transcriptional profiles of Nl +/ ⁇ ECs
- Figure 6B depicts a hierarchical clustering of transcriptional profiles of Nl +/ ⁇ ECs
- Figure 7 A depicts a hierarchical clustering of transcriptional profiles of Nl +/ ⁇ ECs
- Figure 7B depicts a hierarchical clustering of transcriptional profiles of Nl +/ ⁇ ECs
- Figure 8 A depicts a hierarchical clustering of transcriptional profiles of Nl +/ ⁇ ECs
- Figure 8B depicts a hierarchical clustering of transcriptional profiles of Nl +/ ⁇ ECs
- FIG. 9A depicts Cadherin 11 mRNA expression by whole transcriptome RNA-seq in Nl +/ ⁇ ECs treated with each network-correcting small molecule compared to N I or WT ECs exposed to DMSO. Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median.
- Figure 9B depicts SOX7 or TCF4 mRNA expression by whole transcriptome RNA-seq in A ' 7 ECs treated with siRNA targeting SOX7 and TCF4 compared to N 1 or WT ECs treated with control siRNA. Error bars represent standard error.
- Figure 9F depicts the percentage of the AV calcified by Alizarin red staining in
- Figure 9G depicts representative FACS analysis of unstained CD31/CD144 double positive iPSC-derived ECs on day 13 of differentiation.
- Figure 9H depicts representative FACS analysis of stained CD31/CD144 double
- Figure 10A depicts 37 network-correcting molecule candidates identified by KNN and hierarchical clustering algorithms.
- Figure 10B depicts the activity of 15 of 37 network-correcting molecule candidates identified by KNN and hierarchical clustering algorithms.
- Figure 10C depicts the activity of 22 of 37 network-correcting molecule candidates identified by KNN and hierarchical clustering algorithms.
- Figure 11 A depicts AV peak velocity and PV peak velocity by echocardiography in a small initial cohort of Nl +/ lmTR G2 mice treated with Fmoc-leu or DMSO. Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
- Figure 11B depicts AV max thickness and PV max thickness in a small initial cohort of Nl +/ 1mTR G2 mice treated with Fmoc-leu or DMSO.
- Figure 11C depicts the number of N1 m l ' R r ’ 2 mice with calcified AVs by Alizarin red staining after treatment with Fmoc-leu or DMSO for a small initial cohort.
- Figure 11C (right/bottom) depicts the percentage of the AV calcified by Alizarin red staining in Nl +/ /mTR G2 mice treated with Fmoc-leu or DMSO for a small initial cohort.
- Figure 12A depicts AV peak velocity and PV peak velocity by echocardiography in a small initial cohort of Nl +/ lmTR G2 mice treated with naloxone or saline. Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
- Figure 12B depicts AV max thickness and PV max thickness in a small initial cohort of Nl +/ lmTR G2 mice treated with naloxone or saline.
- Figure 12C depicts the number of Nl +/ /mTR G2 mice with calcified AVs by Alizarin red staining after treatment with naloxone or saline for a small initial cohort.
- Figure 13 depicts AV peak velocity and PV peak velocity by echocardiography in a small initial cohort of Nl +/ lmTR G2 mice treated with putrescine + CB1954 or DMSO. Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
- Figure 14 depicts AV peak velocity and PV peak velocity by echocardiography in a small initial cohort of Nl +/ hnTR G2 mice treated with RO4929097 or DMSO. Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
- Figures 15A and 15B depict AV peak velocity and PV peak velocity by echocardiography in a small initial cohort of Nl +/ lmTR G2 mice treated with
- GSK837149A or DMSO Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
- treatment refers to obtaining a
- Treatment covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease.
- the terms“individual,”“subject,”“host,” and“patient,” used interchangeably herein, refer to a mammal, including, but not limited to, murines (rats, mice), non-human primates, humans, canines, felines, ungulates (e.g., equines, bovines, ovines, porcines, caprines), etc.
- A“therapeutically effective amount” or“efficacious amount” means the amount of a compound that, when administered to a mammal or other subject for treating a disease, is sufficient to effect such treatment for the disease.
- The“therapeutically effective amount” may vary depending on the compound, the disease and its severity and the age, weight, etc., of the subject to be treated.
- the term“stem cell” refers to an undifferentiated cell that can be induced to proliferate.
- the stem cell is capable of self-maintenance, meaning that with each cell division, one daughter cell will also be a stem cell.
- Stem cells can be obtained from embryonic, post-natal, juvenile or adult tissue.
- progenitor cell refers to an undifferentiated cell derived from a stem cell, and is not itself a stem cell. Some progenitor cells can produce progeny that are capable of differentiating into more than one cell type.
- iPS cell induced pluripotent stem cell
- pluripotent stem cell induced from a somatic cell, e.g., a differentiated somatic cell.
- iPS cells are capable of self-renewal and differentiation into cell fate-committed stem cells, including neural stem cells, as well as various types of mature cells.
- alkyl by itself or as part of another substituent refers to a saturated branched or straight-chain monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane.
- Typical alkyl groups include, but are not limited to, methyl; ethyl, propyls such as propan- l-yl or propan-2-yl; and butyls such as butan-l-yl, butan-2-yl, 2-methyl-propan- l-yl or
- an alkyl group comprises from 1 to 20 carbon atoms. In other embodiments, an alkyl group comprises from 1 to 10 carbon atoms. In still other embodiments, an alkyl group comprises from 1 to 6 carbon atoms, such as from 1 to 4 carbon atoms.
- alkanyl groups include, but are not limited to, methanyl; ethanyl; propanyls such as propan-l-yl, propan-2-yl (isopropyl), cyclopropan- l-yl, etc.; butanyls such as butan-l-yl, butan-2-yl (sec-butyl), 2-methyl-propan- l-yl (isobutyl), 2-methyl-propan -2-yl (t-butyl), cyclobutan-l-yl, etc.; and the like.
- Alkylene refers to a branched or unbranched saturated hydrocarbon chain, usually having from 1 to 40 carbon atoms, more usually 1 to 10 carbon atoms and even more usually 1 to 6 carbon atoms. This term is exemplified by groups such as methylene (- CH 2 -), ethylene (-CH2CH2-), the propylene isomers (e.g., -CH2CH2CH2- and
- alkenyl by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom of an alkene.
- the group may be in either the cis or trans conformation about the double bond(s).
- Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-l- en-l-yl, prop-l-en-2-yl, prop-2-en-l-yl (allyl), prop-2-en-2-yl, cycloprop-l-en-l-yl; cycloprop-2-en-l-yl; butenyls such as but-l-en-l-yl, but-l-en-2-yl, 2-methyl -prop- l-en- l-yl, but-2-en-l-yl, but-2-en-l-yl, but-2-en-2-yl, buta-l,3-dien-l-yl, buta-l,3-dien-2-yl, cyclobut-l-en-l-yl, cyclobut-l-en-3-yl, cyclobuta-l,3-dien-l-yl, etc.; and the like
- Alkynyl by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of an alkyne.
- Typical alkynyl groups include, but are not limited to, ethynyl; propynyls such as prop- l-yn-l-yl, prop-2-yn-l-yl, etc.; butynyls such as but-l-yn-l-yl, but-l-yn-3-yl, but-3-yn- l-yl, etc.; and the like.
- “Acyl” by itself or as part of another substituent refers to a radical -C(0)R 30 , where R 30 is hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroaryl alkyl as defined herein and substituted versions thereof.
- Representative examples include, but are not limited to formyl, acetyl, cyclohexyl carbonyl,
- aminoacyl refers to the group -C(0)NR 21 R 22 , wherein R 21 and R 22
- “Alkoxy” by itself or as part of another substituent refers to a radical -OR 31 where R 31 represents an alkyl or cycloalkyl group as defined herein. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclohexyloxy and the like.
- Alkoxycarbonyl by itself or as part of another substituent refers to a radical -C(0)OR 31 where R 31 represents an alkyl or cycloalkyl group as defined herein. Representative examples include, but are not limited to, methoxycarbonyl, ethoxycarbonyl,
- Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2, 4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene,
- “Arylalkyl” by itself or as part of another substituent refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with an aryl group.
- Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-l-yl, 2-phenylethen-l-yl, naphthylmethyl, 2- naphthylethan-l-yl, 2-naphthylethen-l-yl, naphthobenzyl, 2-naphthophenylethan-l-yl and the like.
- an arylalkyl group is (C7-C30) arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C1-C10) and the aryl moiety is (C6-C20).
- an arylalkyl group is (C 7 -C 20 ) arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (Ci-C 8 ) and the aryl moiety is (C 6 -Ci 2 ).
- “Arylaryl” by itself or as part of another substituent, refers to a monovalent hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a ring system in which two or more identical or non-identical aromatic ring systems are joined directly together by a single bond, where the number of such direct ring junctions is one less than the number of aromatic ring systems involved.
- Typical arylaryl groups include, but are not limited to, biphenyl, triphenyl, phenyl-napthyl, binaphthyl, biphenyl-napthyl, and the like.
- arylaryl is an arylaryl group in which each aromatic ring comprises from 5 to 14
- carbons e.g., biphenyl, triphenyl, binaphthyl, phenylnapthyl, etc.
- each aromatic ring system of an arylaryl group is independently a (C 5 -C 14 ) aromatic. In certain embodiments, each aromatic ring system of an arylaryl group is independently a (C 5 -C 10 ) aromatic. In certain embodiments, each aromatic ring system is identical, e.g., biphenyl, triphenyl, binaphthyl, trinaphthyl, etc.
- “Cycloalkyl” by itself or as part of another substituent refers to a saturated or
- cycloalkyl groups include, but are not limited to, groups derived from cyclopropane, cyclobutane, cyclopentane, cyclohexane and the like.
- the cycloalkyl group is (C 3- C 10 ) cycloalkyl.
- the cycloalkyl group is (C 3 -C 7 ) cycloalkyl.
- “Cycloheteroalkyl” or“heterocyclyl” by itself or as part of another substituent refers to a saturated or unsaturated cyclic alkyl radical in which one or more carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatom.
- Typical heteroatoms to replace the carbon atom(s) include, but are not limited to, N, P, O, S, Si, etc. Where a specific level of saturation is intended, the nomenclature“cycloheteroalkanyl” or“cycloheteroalkenyl” is used. Typical
- cycloheteroalkyl groups include, but are not limited to, groups derived from epoxides, azirines, thiiranes, imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine and the like.
- “Heteroalkyl, Heteroalkanyl, Heteroalkenyl and Heteroalkynyl” by themselves or as part of another substituent refer to alkyl, alkanyl, alkenyl and alkynyl groups, respectively, in which one or more of the carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatomic groups.
- Heteroaryl by itself or as part of another substituent, refers to a monovalent
- heteroaromatic radical derived by the removal of one hydrogen atom from a single atom of a heteroaromatic ring system.
- Typical heteroaryl groups include, but are not limited to, groups derived from acridine, arsindole, carbazole, b-carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine,
- the heteroaryl group is from 5-20 membered heteroaryl. In certain embodiments, the heteroaryl group is from 5-10 membered heteroaryl. In certain embodiments, heteroaryl groups are those derived from thiophene, pyrrole,
- benzothiophene benzofuran, indole, pyridine, quinoline, imidazole, oxazole and pyrazine.
- Heteroarylalkyl by itself or as part of another substituent, refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with a heteroaryl group. Where specific alkyl moieties are intended, the nomenclature heteroarylalkanyl, heteroarylalkenyl and/or heterorylalkynyl is used. In certain embodiments, the heteroarylalkyl group is a 6-30 membered heteroarylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the
- heteroarylalkyl is 1-10 membered and the heteroaryl moiety is a 5-20-membered heteroaryl.
- the heteroarylalkyl group is 6-20 membered heteroarylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the heteroarylalkyl is 1-8 membered and the heteroaryl moiety is a 5-l2-membered heteroaryl.
- aromatic ring system fused ring systems in which one or more of the rings are aromatic and one or more of the rings are saturated or unsaturated, such as, for example, fluorene, indane, indene, phenalene, etc.
- Typical aromatic ring systems include, but are not limited to, aceanthrylene,
- acenaphthylene acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2, 4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene and the like.
- Heteroaromatic Ring System by itself or as part of another substituent, refers to an aromatic ring system in which one or more carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatom.
- Typical heteroatoms to replace the carbon atoms include, but are not limited to, N, P, O, S, Si, etc.
- fused ring systems in which one or more of the rings are aromatic and one or more of the rings are saturated or unsaturated, such as, for example, arsindole, benzodioxan, benzofuran, chromane, chromene, indole, indoline, xanthene, etc.
- fused ring systems in which one or more of the rings are aromatic and one or more of the rings are saturated or unsaturated, such as, for example, arsindole, benzodioxan, benzofuran, chromane, chromene, indole, indoline, xanthene, etc.
- heteroaromatic ring systems include, but are not limited to, arsindole, carbazole, b- carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine,
- phenanthroline phenazine, phthalazine, pteridine
- purine pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene and the like.
- Substituted refers to a group in which one or more hydrogen atoms are independently replaced with the same or different substituent(s).
- R 60 , R 61 , R 62 and R 63 are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R 60 and R 61 together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring; and R 64 and R 65 are independently hydrogen, alkyl, substituted alkyl, aryl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R 64 and
- a substituted group may bear a methylenedioxy substituent or one, two, or three substituents selected from a halogen atom, a (l-4C)alkyl group and a (l-4C)alkoxy group.
- the compounds described herein can contain one or more chiral centers and/or double bonds and therefore, can exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers or diastereomers.
- enantiomers and stereoisomers of the compounds including the stereoisomerically pure form (e.g., geometrically pure, enantiomerically pure or diastereomerically pure) and enantiomeric and stereoisomeric mixtures are included in the description of the compounds herein.
- Enantiomeric and stereoisomeric mixtures can be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the skilled artisan.
- the compounds can also exist in several tautomeric forms including the enol form, the keto form and mixtures thereof. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated compounds.
- the compounds described also include isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass conventionally found in nature.
- isotopes that can be incorporated into the compounds disclosed herein include, but are not limited to, 2 H, 3 ⁇ 4, U C, 13 C, 14 C, 15 N, 1 8 0, 17 0, etc.
- Compounds can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, compounds can be hydrated or solvated. Certain compounds can exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of the present disclosure.
- iPSC induced pluripotent stem cell
- a network-based drug screen was performed to identify small molecules that corrected the gene network dysregulated by Nl haploinsufficiency in human iPSC-derived endothelial cells (ECs) from patients affected by CAVD.
- the present disclosure provides methods of treating cardiac valve disease, e.g., CAVD, by administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Formulae I-X or a pharmaceutically acceptable salt, solvate or prodrug thereof. Also provided are methods of identifying a candidate compound for treatment of cardiac valve disease, e.g., CAVD.
- the present disclosure provides methods for treating cardiac valve disease, e.g., CAVD, by administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Formulas I-X or a pharmaceutically acceptable salt, solvate or prodrug thereof.
- compositions which find use in the methods of the present disclosure can include
- the disclosed methods include administration of a compound of Formula I:
- n is an integer from 1 to 8;
- X is O or S
- Y is O or S
- n is 1. In other embodiments, n is 2. In other embodiments, n is 3. In other embodiments, n is 4. In other embodiments, n is 5. In other embodiments, n is 6. In other embodiments, n is 7. In other embodiments, n is 8.
- X is O. In other embodiments, X is S. In some embodiments, Y is O. In other embodiments, Y is S. In some instances, X is O and Y is O. In other instances, X is O and Y is S. In other embodiments, X is S and Y is O. In other embodiments, X is S and Y is S.
- R 1 is cyano. In some embodiments, R 1 is hydrogen. In other embodiments, R 1 is alkyl or substituted alkyl. In other embodiments, R 1 is aryl or substituted aryl. In other embodiments, R 1 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 1 is heteroaryl or substituted heteroaryl. In other embodiments, R 1 is hydroxyl, alkoxyl or substituted alkoxyl. In other
- R 1 is acyloxy or substituted acyloxy. In other embodiments, R 1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 1 is acyl or substituted acyl. In other embodiments, R 1 is thiol. In other embodiments, R 1 is amino or substituted amino. In other embodiments, R 1 is aminoacyl or substituted aminoacyl. In other embodiments, R 1 is azido. In other embodiments, R 1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 1 is nitro. In certain embodiments, R 1 is naphthyl.
- R 2 is hydrogen. In other embodiments, R 2 is alkyl or substituted alkyl. In other embodiments, R 2 is aryl or substituted aryl. In other embodiments, R 2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 2 is heteroaryl or substituted heteroaryl. In other embodiments, R 2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 2 is acyloxy or substituted acyloxy. In other embodiments, R 2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 2 is acyl or substituted acyl. In other embodiments, R 2 is thiol. In other embodiments, R 2 is amino or substituted amino. In other embodiments, R 2 is aminoacyl or substituted aminoacyl. In other embodiments, R 2 is azido. In other embodiments, R 2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 2 is cyano. In other embodiments, R 2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 2 is nitro.
- R 3 is hydrogen. In other embodiments, R 3 is alkyl or substituted alkyl. In other embodiments, R 3 is aryl or substituted aryl. In other embodiments, R 3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 3 is heteroaryl or substituted heteroaryl. In other embodiments, R 3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 3 is acyloxy or substituted acyloxy. In other embodiments, R 3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 3 is acyl or substituted acyl. In other embodiments, R 3 is thiol. In other embodiments, R 3 is amino or substituted amino. In other embodiments, R 3 is aminoacyl or substituted aminoacyl. In other embodiments, R 3 is azido. In other embodiments, R 3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 3 is cyano. In other embodiments, R 3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 3 is chloro.
- R 4 is hydrogen. In other embodiments, R 4 is alkyl or substituted alkyl. In other embodiments, R 4 is aryl or substituted aryl. In other embodiments, R 4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 4 is heteroaryl or substituted heteroaryl. In other embodiments, R 4 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 4 is acyloxy or substituted acyloxy. In other embodiments, R 4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 4 is acyl or substituted acyl. In other embodiments, R 4 is thiol. In other embodiments, R 4 is amino or substituted amino. In other embodiments, R 4 is aminoacyl or substituted aminoacyl. In other embodiments, R 4 is azido. In other embodiments, R 4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 4 is cyano. In other embodiments, R 4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 4 is nitro.
- R 5 is hydrogen. In other embodiments, R 5 is alkyl or substituted alkyl. In other embodiments, R 5 is aryl or substituted aryl. In other embodiments, R 5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 5 is heteroaryl or substituted heteroaryl. In other embodiments, R 5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 5 is acyloxy or substituted acyloxy. In other embodiments, R 5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 5 is acyl or substituted acyl. In other embodiments, R 5 is thiol. In other embodiments, R 5 is amino or substituted amino. In other embodiments, R 5 is aminoacyl or substituted aminoacyl. In other embodiments, R 5 is azido. In other embodiments, R 5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 5 is cyano. In other embodiments, R 5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 5 is nitro.
- R 6 is alkoxy, such as methoxy or ethoxy. In other embodiments, R 6 is hydrogen. In other embodiments, R 6 is alkyl or substituted alkyl. In other embodiments, R 6 is aryl or substituted aryl. In other embodiments, R 6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 6 is heteroaryl or substituted heteroaryl. In other embodiments, R 6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 6 is acyloxy or substituted acyloxy. In other embodiments, R 6 is alkoxylcarbonyl or substituted alkoxycarbonyl.
- R 6 is acyl or substituted acyl. In other embodiments, R 6 is thiol. In other embodiments, R 6 is amino or substituted amino. In other embodiments, R 6 is aminoacyl or substituted aminoacyl. In other embodiments, R 6 is azido. In other embodiments, R 6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 6 is cyano. In other embodiments, R 6 is a halogen, such as -F, -Cl, -Br and -I. In other
- R 6 is nitro. In certain embodiments, R 6 is alkoxylcarbonyl, such as ethoxycarbonyl.
- R 7 is hydrogen. In other embodiments, R 7 is alkyl or substituted alkyl. In other embodiments, R 7 is aryl or substituted aryl. In other embodiments, R 7 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 7 is heteroaryl or substituted heteroaryl. In other embodiments, R 7 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 7 is acyloxy or substituted acyloxy. In other embodiments, R 7 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 7 is acyl or substituted acyl. In other embodiments, R 7 is thiol. In other embodiments, R 7 is amino or substituted amino. In other embodiments, R 7 is aminoacyl or substituted aminoacyl. In other embodiments, R 7 is azido. In other embodiments, R 7 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 7 is cyano. In other embodiments, R 7 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 7 is nitro. In certain embodiments, R 7 is amino.
- R 8 is hydrogen. In other embodiments, R 8 is alkyl or substituted alkyl. In other embodiments, R 8 is aryl or substituted aryl. In other embodiments, R 8 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 8 is heteroaryl or substituted heteroaryl. In other embodiments, R 8 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 8 is acyloxy or substituted acyloxy. In other embodiments, R 8 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 8 is acyl or substituted acyl. In other embodiments, R 8 is thiol. In other embodiments, R 8 is amino or substituted amino. In other embodiments, R 8 is aminoacyl or substituted aminoacyl. In other embodiments, R 8 is azido. In other embodiments, R 8 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 8 is cyano. In other embodiments, R 8 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 8 is nitro. In certain embodiments, R 8 is amino.
- R 9 is hydrogen. In other embodiments, R 9 is alkyl or substituted alkyl. In other embodiments, R 9 is aryl or substituted aryl. In other embodiments, R 9 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 9 is heteroaryl or substituted heteroaryl. In other embodiments, R 9 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 9 is acyloxy or substituted acyloxy. In other embodiments, R 9 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 9 is acyl or substituted acyl. In other embodiments, R 9 is thiol. In other embodiments, R 9 is amino or substituted amino. In other embodiments, R 9 is aminoacyl or substituted aminoacyl. In other embodiments, R 9 is azido. In other embodiments, R 9 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 9 is cyano. In other embodiments, R 9 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 9 is nitro. In certain embodiments, R 7 is amino.
- R 10 is hydrogen. In other embodiments, R 10 is alkyl or substituted alkyl. In other embodiments, R 10 is aryl or substituted aryl. In other embodiments, R 10 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 10 is heteroaryl or substituted heteroaryl. In other embodiments, R 10 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 10 is acyloxy or substituted acyloxy. In other embodiments, R 10 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 10 is acyl or substituted acyl. In other embodiments, R 10 is thiol.
- R 10 is amino or substituted amino. In other embodiments, R 10 is aminoacyl or substituted aminoacyl. In other embodiments, R 10 is azido. In other embodiments, R 10 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 10 is cyano. In other embodiments, R 10 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 10 is nitro. In certain embodiments, R 10 is amino.
- R 11 is hydrogen. In other embodiments, R 11 is alkyl or substituted alkyl. In other embodiments, R 11 is aryl or substituted aryl. In other embodiments, R 11 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 11 is heteroaryl or substituted heteroaryl. In other embodiments, R 11 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 11 is acyloxy or substituted acyloxy. In other embodiments, R 11 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 11 is acyl or substituted acyl. In other embodiments, R 11 is thiol.
- R 11 is amino or substituted amino. In other embodiments, R 11 is aminoacyl or substituted aminoacyl. In other embodiments, R 11 is azido. In other embodiments, R 11 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 11 is cyano. In other embodiments, R 11 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 11 is nitro. In certain embodiments, R 11 is amino.
- a compound of interest and salts or solvates or
- stereoisomers thereof include:
- compositions which find use in the methods of the present disclosure can include compounds of Formula II, shown below, which formula encompasses TG-003 ((Z)-l-(3- ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene)propan-2-one) and
- the disclosed methods include administration of a compound of Formula II:
- X is O or S
- X is O. In other embodiments, X is S.
- R 1 is hydrogen. In some embodiments, R 1 is cyano. In other embodiments, R 1 is alkyl or substituted alkyl. In other embodiments, R 1 is aryl or substituted aryl. In other embodiments, R 1 is heterocycloalkyl or substituted
- R 1 is heteroaryl or substituted heteroaryl. In other embodiments, R 1 is hydroxyl, alkoxyl or substituted alkoxyl. In other
- R 1 is acyloxy or substituted acyloxy. In other embodiments, R 1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 1 is acyl or substituted acyl. In other embodiments, R 1 is thiol. In other embodiments, R 1 is amino or substituted amino. In other embodiments, R 1 is aminoacyl or substituted aminoacyl. In other embodiments, R 1 is azido. In other embodiments, R 1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 1 is nitro. In certain embodiments, R 1 is naphthyl.
- R 2 is alkoxy, such as methoxy or ethoxy.
- R 2 is hydrogen. In other embodiments, R 2 is alkyl or substituted alkyl. In other embodiments, R 2 is aryl or substituted aryl. In other embodiments, R 2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 2 is heteroaryl or substituted heteroaryl. In other embodiments, R 2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 2 is acyloxy or substituted acyloxy. In other embodiments, R 2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 2 is acyl or substituted acyl. In other embodiments, R 2 is thiol. In other embodiments, R 2 is amino or substituted amino. In other embodiments, R 2 is aminoacyl or substituted aminoacyl. In other embodiments, R 2 is azido. In other embodiments, R 2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 2 is cyano. In other embodiments, R 2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 2 is nitro.
- R 3 is hydrogen. In other embodiments, R 3 is alkyl or substituted alkyl. In other embodiments, R 3 is aryl or substituted aryl. In other embodiments, R 3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 3 is heteroaryl or substituted heteroaryl. In other embodiments, R 3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 3 is acyloxy or substituted acyloxy. In other embodiments, R 3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 3 is acyl or substituted acyl. In other embodiments, R 3 is thiol.
- R 3 is amino or substituted amino. In other embodiments, R 3 is aminoacyl or substituted aminoacyl. In other embodiments, R 3 is azido. In other embodiments, R 3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 3 is cyano. In other embodiments, R 3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 3 is chloro.
- R 4 is hydrogen. In other embodiments, R 4 is alkyl or
- R 4 is aryl or substituted aryl. In other embodiments, R 4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 4 is heteroaryl or substituted heteroaryl. In other embodiments, R 4 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 4 is acyloxy or substituted acyloxy. In other embodiments, R 4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 4 is acyl or substituted acyl. In other embodiments, R 4 is thiol. In other embodiments, R 4 is amino or substituted amino.
- R 4 is aminoacyl or substituted aminoacyl. In other embodiments, R 4 is azido. In other embodiments, R 4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 4 is cyano. In other embodiments, R 4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 4 is nitro.
- R 5 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R 5 is ethyl. In other embodiments, R 5 is hydrogen. In other embodiments, In other embodiments, R 5 is aryl or substituted aryl. In other
- R 5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 5 is heteroaryl or substituted heteroaryl. In other embodiments, R 5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 5 is acyloxy or substituted acyloxy. In other embodiments, R 5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 5 is acyl or substituted acyl. In other embodiments, R 5 is thiol. In other embodiments, R 5 is amino or substituted amino. In other embodiments, R 5 is aminoacyl or substituted aminoacyl. In other embodiments, R 5 is azido.
- R 5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 5 is cyano. In other embodiments, R 5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 5 is nitro.
- R 6 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R 6 is methyl. In other embodiments, R 6 is hydrogen. In other embodiments, R 6 is aryl or substituted aryl. In other embodiments, R 6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 6 is heteroaryl or substituted heteroaryl. In other embodiments, R 6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 6 is acyloxy or substituted acyloxy. In other embodiments, R 6 is alkoxylcarbonyl or substituted alkoxycarbonyl.
- R 6 is acyl or substituted acyl. In other embodiments, R 6 is thiol. In other embodiments, R 6 is amino or substituted amino. In other embodiments, R 6 is aminoacyl or substituted aminoacyl. In other embodiments, R 6 is azido. In other embodiments, R 6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 6 is cyano. In other embodiments, R 6 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 6 is nitro.
- stereoisomers thereof include:
- compositions which find use in the methods of the present disclosure can include compounds of Formula III, shown below, which formula encompasses GSK-837149A (4,4’-(carbonyldiimino)bis[N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide) and pharmaceutically acceptable salts and derivatives thereof.
- the disclosed methods include administration of a compound of Formula III:
- R 1 is hydrogen. In other embodiments, R 1 is alkyl or substituted alkyl. In other embodiments, R 1 is aryl or substituted aryl. In other embodiments, R 1 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 1 is heteroaryl or substituted heteroaryl. In other embodiments, R 1 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 1 is acyloxy or substituted acyloxy. In other embodiments, R 1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 1 is acyl or substituted acyl. In other embodiments, R 1 is thiol.
- R 1 is amino or substituted amino. In other embodiments, R 1 is aminoacyl or substituted aminoacyl. In other embodiments, R 1 is azido. In other embodiments, R 1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 1 is nitro. In certain embodiments, R 1 is naphthyl.
- R 2 is hydrogen. In other embodiments, R 2 is alkyl or
- R 2 is aryl or substituted aryl. In other embodiments, R 2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 2 is heteroaryl or substituted heteroaryl. In other embodiments, R 2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 2 is acyloxy or substituted acyloxy. In other embodiments, R 2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 2 is acyl or substituted acyl. In other embodiments, R 2 is thiol. In other embodiments, R 2 is amino or substituted amino.
- R 2 is aminoacyl or substituted aminoacyl. In other embodiments, R 2 is azido. In other embodiments, R 2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 2 is cyano. In other embodiments, R 2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 2 is nitro.
- R 3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R 3 is methyl. In other embodiments, R 3 is hydrogen. In other embodiments, R 3 is aryl or substituted aryl. In other embodiments, R 3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 3 is heteroaryl or substituted heteroaryl. In other embodiments, R 3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 3 is acyloxy or substituted acyloxy. In other embodiments, R 3 is alkoxylcarbonyl or substituted alkoxycarbonyl.
- R 3 is acyl or substituted acyl. In other embodiments, R 3 is thiol. In other embodiments, R 3 is amino or substituted amino. In other embodiments, R 3 is aminoacyl or substituted aminoacyl. In other embodiments, R 3 is azido. In other embodiments, R 3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 3 is cyano. In other embodiments, R 3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 3 is chloro.
- R 4 is hydrogen. In other embodiments, R 4 is alkyl or
- R 4 is aryl or substituted aryl. In other embodiments, R 4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 4 is heteroaryl or substituted heteroaryl. In other embodiments, R 4 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 4 is acyloxy or substituted acyloxy. In other embodiments, R 4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 4 is acyl or substituted acyl. In other embodiments, R 4 is thiol. In other embodiments, R 4 is amino or substituted amino.
- R 4 is aminoacyl or substituted aminoacyl. In other embodiments, R 4 is azido. In other embodiments, R 4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 4 is cyano. In other embodiments, R 4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 4 is nitro.
- R 5 is hydrogen. In other embodiments, R 5 is alkyl or substituted alkyl. In other embodiments, R 5 is aryl or substituted aryl. In other embodiments, R 5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 5 is heteroaryl or substituted heteroaryl. In other embodiments, R 5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 5 is acyloxy or substituted acyloxy. In other embodiments, R 5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 5 is acyl or substituted acyl. In other embodiments, R 5 is thiol.
- R 5 is amino or substituted amino. In other embodiments, R 5 is aminoacyl or substituted aminoacyl. In other embodiments, R 5 is azido. In other embodiments, R 5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 5 is cyano. In other embodiments, R 5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 5 is nitro. [00120] In some embodiments, R 6 is alkoxy, such as methoxy or ethoxy. In other embodiments, R 6 is hydrogen. In other embodiments, R 6 is alkyl or substituted alkyl.
- R 6 is aryl or substituted aryl. In other embodiments, R 6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 6 is heteroaryl or substituted heteroaryl. In other embodiments, R 6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 6 is acyloxy or substituted acyloxy. In other embodiments, R 6 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 6 is acyl or substituted acyl. In other embodiments, R 6 is thiol. In other embodiments, R 6 is amino or substituted amino. In other embodiments, R 6 is aminoacyl or substituted aminoacyl. In other embodiments, R 6 is azido. In other embodiments, R 6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 6 is cyano. In other embodiments, R 6 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 6 is nitro. In certain embodiments, R 6 is
- alkoxylcarbonyl such as ethoxycarbonyl
- R 7 is hydrogen. In other embodiments, R 7 is alkyl or substituted alkyl. In other embodiments, R 7 is aryl or substituted aryl. In other embodiments, R 7 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 7 is heteroaryl or substituted heteroaryl. In other embodiments, R 7 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 7 is acyloxy or substituted acyloxy. In other embodiments, R 7 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 7 is acyl or substituted acyl. In other embodiments, R 7 is thiol.
- R 7 is amino or substituted amino. In other embodiments, R 7 is aminoacyl or substituted aminoacyl. In other embodiments, R 7 is azido. In other embodiments, R 7 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 7 is cyano. In other embodiments, R 7 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 7 is nitro. In certain embodiments, R 7 is amino.
- R 8 is hydrogen. In other embodiments, R 8 is alkyl or substituted alkyl. In other embodiments, R 8 is aryl or substituted aryl. In other embodiments, R 8 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 8 is heteroaryl or substituted heteroaryl. In other embodiments, R 8 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 8 is acyloxy or substituted acyloxy. In other embodiments, R 8 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 8 is acyl or substituted acyl. In other embodiments, R 8 is thiol.
- R 8 is amino or substituted amino. In other embodiments, R 8 is aminoacyl or substituted aminoacyl. In other embodiments, R 8 is azido. In other embodiments, R 8 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 8 is cyano. In other embodiments, R 8 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 8 is nitro. In certain embodiments, R 8 is amino.
- R 9 is hydrogen. In other embodiments, R 9 is alkyl or substituted alkyl. In other embodiments, R 9 is aryl or substituted aryl. In other embodiments, R 9 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 9 is heteroaryl or substituted heteroaryl. In other embodiments, R 9 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 9 is acyloxy or substituted acyloxy. In other embodiments, R 9 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 9 is acyl or substituted acyl. In other embodiments, R 9 is thiol.
- R 9 is amino or substituted amino. In other embodiments, R 9 is aminoacyl or substituted aminoacyl. In other embodiments, R 9 is azido. In other embodiments, R 9 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 9 is cyano. In other embodiments, R 9 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 9 is nitro. In certain embodiments, R 7 is amino.
- R 10 is hydrogen. In other embodiments, R 10 is alkyl or substituted alkyl. In other embodiments, R 10 is aryl or substituted aryl. In other embodiments, R 10 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 10 is heteroaryl or substituted heteroaryl. In other embodiments, R 10 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 10 is acyloxy or substituted acyloxy. In other embodiments, R 10 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 10 is acyl or substituted acyl. In other embodiments, R 10 is thiol.
- R 10 is amino or substituted amino. In other embodiments, R 10 is aminoacyl or substituted aminoacyl. In other embodiments, R 10 is azido. In other embodiments, R 10 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 10 is cyano. In other embodiments, R 10 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 10 is nitro. In certain embodiments, R 10 is amino.
- R 11 is hydrogen. In other embodiments, R 11 is alkyl or substituted alkyl. In other embodiments, R 11 is aryl or substituted aryl. In other embodiments, R 11 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 11 is heteroaryl or substituted heteroaryl. In other embodiments, R 11 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 11 is acyloxy or substituted acyloxy. In other embodiments, R 11 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 11 is acyl or substituted acyl. In other embodiments, R 11 is thiol.
- R 11 is amino or substituted amino. In other embodiments, R 11 is aminoacyl or substituted aminoacyl. In other embodiments, R 11 is azido. In other embodiments, R 11 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 11 is cyano. In other embodiments, R 11 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 11 is nitro. In certain embodiments, R 11 is amino.
- R 12 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R 12 is methyl. In other embodiments, R 12 is hydrogen. In other embodiments, R 12 is aryl or substituted aryl. In other embodiments, R 12 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 12 is heteroaryl or substituted heteroaryl. In other embodiments, R 12 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 12 is acyloxy or substituted acyloxy. In other embodiments, R 12 is alkoxylcarbonyl or substituted alkoxycarbonyl.
- R 12 is acyl or substituted acyl. In other embodiments, R 12 is thiol. In other embodiments, R 12 is amino or substituted amino. In other embodiments, R 12 is aminoacyl or substituted aminoacyl. In other embodiments, R 12 is azido. In other embodiments, R 12 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 12 is cyano. In other embodiments, R 12 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 12 is chloro. [00127] In some embodiments, R 13 is hydrogen.
- R 13 is alkyl or substituted alkyl. In other embodiments, R 13 is aryl or substituted aryl. In other embodiments, R 13 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 13 is heteroaryl or substituted heteroaryl. In other embodiments, R 13 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 13 is acyloxy or substituted acyloxy. In other embodiments, R 13 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 13 is acyl or substituted acyl. In other embodiments, R 13 is thiol. In other embodiments, R 13 is amino or substituted amino.
- R 13 is aminoacyl or substituted aminoacyl. In other embodiments, R 13 is azido. In other embodiments, R 13 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 13 is cyano. In other embodiments, R 13 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 13 is nitro. In certain embodiments, R 13 is amino.
- R 14 is hydrogen. In other embodiments, R 14 is alkyl or substituted alkyl. In other embodiments, R 14 is aryl or substituted aryl. In other embodiments, R 14 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 14 is heteroaryl or substituted heteroaryl. In other embodiments, R 14 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 14 is acyloxy or substituted acyloxy. In other embodiments, R 14 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 14 is acyl or substituted acyl. In other embodiments, R 14 is thiol.
- R 14 is amino or substituted amino. In other embodiments, R 14 is aminoacyl or substituted aminoacyl. In other embodiments, R 14 is azido. In other embodiments, R 14 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 14 is cyano. In other embodiments, R 14 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 14 is nitro. In certain embodiments, R 14 is amino.
- a compound of interest and salts or solvates or
- stereoisomers thereof include:
- compositions which find use in the methods of the present disclosure can include compounds of Formula IV, shown below, which formula encompasses Naloxone ((4R,4aS,7aR,l2bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,l3-hexahydro-lH-4, l2- methanobenzofuro[3,2-e]isoquinoline-7-one) and pharmaceutically acceptable salts and derivatives thereof.
- Formula IV shown below, which formula encompasses Naloxone ((4R,4aS,7aR,l2bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,l3-hexahydro-lH-4, l2- methanobenzofuro[3,2-e]isoquinoline-7-one
- the disclosed methods include administration of a compound of Formula IV:
- R 1 is hydroxyl. In other embodiments, R 1 is hydrogen. In other embodiments, R 1 is alkyl or substituted alkyl. In other embodiments, R 1 is aryl or substituted aryl. In other embodiments, R 1 is heterocycloalkyl or substituted
- R 1 is heterocycloalkyl.
- R 1 is heteroaryl or substituted heteroaryl.
- R 1 is alkoxyl or substituted alkoxyl.
- R 1 is acyloxy or substituted acyloxy.
- R 1 is alkoxylcarbonyl or substituted alkoxycarbonyl.
- R 1 is acyl or substituted acyl.
- R 1 is thiol.
- R 1 is amino or substituted amino.
- R 1 is aminoacyl or substituted aminoacyl.
- R 1 is azido.
- R 1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl.
- R 1 is a halogen, such as -F, -Cl, -Br and -I.
- R 1 is nitro.
- R 1 is naphthyl.
- R 2 is hydrogen. In other embodiments, R 2 is alkyl or substituted alkyl. In other embodiments, R 2 is aryl or substituted aryl. In other embodiments, R 2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 2 is heteroaryl or substituted heteroaryl. In other embodiments, R 2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 2 is acyloxy or substituted acyloxy. In other embodiments, R 2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 2 is acyl or substituted acyl. In other embodiments, R 2 is thiol.
- R 2 is amino or substituted amino. In other embodiments, R 2 is aminoacyl or substituted aminoacyl. In other embodiments, R 2 is azido. In other embodiments, R 2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 2 is cyano. In other embodiments, R 2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 2 is nitro.
- R 3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R 3 is methyl. In other embodiments, R 3 is hydrogen. In other embodiments, R 3 is aryl or substituted aryl. In other embodiments, R 3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 3 is heteroaryl or substituted heteroaryl. In other embodiments, R 3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 3 is acyloxy or substituted acyloxy. In other embodiments, R 3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 3 is acyl or substituted acyl. In other embodiments, R 3 is thiol. In other embodiments, R 3 is amino or substituted amino. In other embodiments, R 3 is aminoacyl or substituted aminoacyl. In other embodiments, R 3 is azido. In other embodiments, R 3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 3 is cyano. In other embodiments, R 3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 3 is chloro.
- R 4 is hydrogen. In other embodiments, R 4 is hydroxyl. In other embodiments, R 4 is alkyl or substituted alkyl. In other embodiments, R 4 is aryl or substituted aryl. In other embodiments, R 4 is heterocycloalkyl or substituted
- R 4 is heterocycloalkyl.
- R 4 is heteroaryl or substituted heteroaryl.
- R 4 is alkoxyl or substituted alkoxyl.
- R 4 is acyloxy or substituted acyloxy.
- R 4 is alkoxylcarbonyl or substituted alkoxycarbonyl.
- R 4 is acyl or substituted acyl.
- R 4 is thiol.
- R 4 is amino or substituted amino.
- R 4 is aminoacyl or substituted aminoacyl.
- R 4 is azido.
- R 4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 4 is cyano. In other embodiments, R 4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 4 is nitro.
- R 5 is hydrogen. In other embodiments, R 5 is alkyl or substituted alkyl. In other embodiments, R 5 is allyl. In other embodiments, R 5 is aryl or substituted aryl. In other embodiments, R 5 is heterocycloalkyl or substituted
- R 5 is heteroaryl or substituted heteroaryl. In other embodiments, R 5 is hydroxyl, alkoxyl or substituted alkoxyl. In other
- R 5 is acyloxy or substituted acyloxy. In other embodiments, R 5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 5 is acyl or substituted acyl. In other embodiments, R 5 is thiol. In other embodiments, R 5 is amino or substituted amino. In other embodiments, R 5 is aminoacyl or substituted aminoacyl. In other embodiments, R 5 is azido. In other embodiments, R 5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 5 is cyano. In other embodiments, R 5 is a halogen, such as -F, -Cl, -Br and -I. In other
- R 5 is nitro
- a compound of interest and salts or solvates or
- stereoisomers thereof include:
- compositions which find use in the methods of the present disclosure can include compounds of Formula V, shown below, which formula encompasses Cytochalasin and pharmaceutically acceptable salts and derivatives thereof.
- the disclosed methods include administration of a compound of Formula V:
- R 1 is hydrogen. In other embodiments, R 1 is alkyl or
- R 1 is substituted alkyl.
- R 1 is aryl or substituted aryl.
- R 1 is heterocycloalkyl or substituted heterocycloalkyl.
- R 1 is heteroaryl or substituted heteroaryl.
- R 1 is hydroxyl, alkoxyl or substituted alkoxyl.
- R 1 is acyloxy or substituted acyloxy.
- R 1 is alkoxylcarbonyl or substituted alkoxycarbonyl.
- R 1 is acyl or substituted acyl.
- R 1 is thiol.
- R 1 is amino or substituted amino.
- R 1 is aminoacyl or substituted aminoacyl. In other embodiments, R 1 is azido. In other embodiments, R 1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 1 is nitro. In certain embodiments, R 1 is naphthyl.
- R 2 is hydrogen. In other embodiments, R 2 is alkyl or
- R 2 is aryl or substituted aryl. In other embodiments, R 2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 2 is heteroaryl or substituted heteroaryl. In other embodiments, R 2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 2 is acyloxy or substituted acyloxy. In other embodiments, R 2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 2 is acyl or substituted acyl. In other embodiments, R 2 is thiol. In other embodiments, R 2 is amino or substituted amino.
- R 2 is aminoacyl or substituted aminoacyl. In other embodiments, R 2 is azido. In other embodiments, R 2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 2 is cyano. In other embodiments, R 2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 2 is nitro.
- R 3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R 3 is methyl. In other embodiments, R 3 is hydrogen. In other embodiments, R 3 is aryl or substituted aryl. In other embodiments, R 3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 3 is heteroaryl or substituted heteroaryl. In other embodiments, R 3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 3 is acyloxy or substituted acyloxy. In other embodiments, R 3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 3 is acyl or substituted acyl. In other embodiments, R 3 is thiol. In other embodiments, R 3 is amino or substituted amino. In other embodiments, R 3 is aminoacyl or substituted aminoacyl. In other embodiments, R 3 is azido. In other embodiments, R 3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 3 is cyano. In other embodiments, R 3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 3 is chloro.
- R 4 is hydrogen. In other embodiments, R 4 is alkyl or
- R 4 is aryl or substituted aryl. In other embodiments, R 4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 4 is heteroaryl or substituted heteroaryl. In other embodiments, R 4 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 4 is acyloxy or substituted acyloxy. In other embodiments, R 4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 4 is acyl or substituted acyl. In other embodiments, R 4 is thiol. In other embodiments, R 4 is amino or substituted amino.
- R 4 is aminoacyl or substituted aminoacyl. In other embodiments, R 4 is azido. In other embodiments, R 4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 4 is cyano. In other embodiments, R 4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 4 is nitro.
- R 5 is hydrogen. In other embodiments, R 5 is alkyl or substituted alkyl. In other embodiments, R 5 is aryl or substituted aryl. In other embodiments, R 5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 5 is heteroaryl or substituted heteroaryl. In other embodiments, R 5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 5 is acyloxy or substituted acyloxy. In other embodiments, R 5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 5 is acyl or substituted acyl. In other embodiments, R 5 is thiol.
- R 5 is amino or substituted amino. In other embodiments, R 5 is aminoacyl or substituted aminoacyl. In other embodiments, R 5 is azido. In other embodiments, R 5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 5 is cyano. In other embodiments, R 5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 5 is nitro.
- R 6 is hydrogen. In other embodiments, R 6 is alkoxy, such as methoxy or ethoxy. In other embodiments, R 6 is alkyl or substituted alkyl. In other embodiments, R 6 is aryl or substituted aryl. In other embodiments, R 6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 6 is heteroaryl or substituted heteroaryl. In other embodiments, R 6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 6 is acyloxy or substituted acyloxy. In other embodiments, R 6 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 6 is acyl or substituted acyl. In other embodiments, R 6 is thiol. In other embodiments, R 6 is amino or substituted amino. In other embodiments, R 6 is aminoacyl or substituted aminoacyl.
- R 6 is azido. In other embodiments, R 6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 6 is cyano. In other embodiments, R 6 is a halogen, such as -F, -Cl, -Br and -I. In other
- R 6 is nitro. In certain embodiments, R 6 is alkoxylcarbonyl, such as ethoxycarbonyl.
- R 7 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R 7 is methyl. In other embodiments, R 7 is hydrogen. In other embodiments, R 7 is aryl or substituted aryl. In other embodiments, R 7 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 7 is heteroaryl or substituted heteroaryl. In other embodiments, R 7 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 7 is acyloxy or substituted acyloxy. In other embodiments, R 7 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 7 is acyl or substituted acyl. In other embodiments, R 7 is thiol. In other embodiments, R 7 is amino or substituted amino. In other embodiments, R 7 is aminoacyl or substituted aminoacyl. In other embodiments, R 7 is azido. In other embodiments, R 7 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 7 is cyano. In other embodiments, R 7 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 7 is nitro. In certain embodiments, R 7 is amino. [00147] In some embodiments, R 8 is hydrogen.
- R 8 is alkyl or substituted alkyl. In other embodiments, R 8 is aryl or substituted aryl. In other embodiments, R 8 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 8 is heteroaryl or substituted heteroaryl. In other embodiments, R 8 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 8 is acyloxy or substituted acyloxy. In other embodiments, R 8 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 8 is acyl or substituted acyl. In other embodiments, R 8 is thiol. In other embodiments, R 8 is amino or substituted amino.
- R 8 is aminoacyl or substituted aminoacyl. In other embodiments, R 8 is azido. In other embodiments, R 8 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 8 is cyano. In other embodiments, R 8 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 8 is nitro. In certain embodiments, R 8 is amino.
- R 9 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R 9 is methyl. In other embodiments, R 9 is hydrogen. In other embodiments, R 9 is aryl or substituted aryl. In other embodiments, R 9 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 9 is heteroaryl or substituted heteroaryl. In other embodiments, R 9 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 9 is acyloxy or substituted acyloxy. In other embodiments, R 9 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 9 is acyl or substituted acyl. In other embodiments, R 9 is thiol. In other embodiments, R 9 is amino or substituted amino. In other embodiments, R 9 is aminoacyl or substituted aminoacyl. In other embodiments, R 9 is azido. In other embodiments, R 9 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 9 is cyano. In other embodiments, R 9 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 9 is nitro. In certain embodiments, R 7 is amino.
- a compound of interest and salts or solvates or
- stereoisomers thereof include:
- compositions which find use in the methods of the present disclosure can include compounds of Formula VI, shown below, which formula encompasses Putrescine (butane-l, 4-diamine) and pharmaceutically acceptable salts and derivatives thereof.
- the disclosed methods include administration of a compound of Formula VI:
- each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted
- R 1 is hydrogen. In other embodiments, R 1 is alkyl or substituted alkyl. In other embodiments, R 1 is aryl or substituted aryl. In other embodiments, R 1 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 1 is heteroaryl or substituted heteroaryl. In other embodiments, R 1 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 1 is acyloxy or substituted acyloxy. In other embodiments, R 1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 1 is acyl or substituted acyl. In other embodiments, R 1 is thiol.
- R 1 is amino or substituted amino. In other embodiments, R 1 is aminoacyl or substituted aminoacyl. In other embodiments, R 1 is azido. In other embodiments, R 1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 1 is nitro. In certain embodiments, R 1 is naphthyl.
- R 2 is hydrogen. In other embodiments, R 2 is alkyl or
- R 2 is aryl or substituted aryl. In other embodiments, R 2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 2 is heteroaryl or substituted heteroaryl. In other embodiments, R 2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 2 is acyloxy or substituted acyloxy. In other embodiments, R 2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 2 is acyl or substituted acyl. In other embodiments, R 2 is thiol. In other embodiments, R 2 is amino or substituted amino.
- R 2 is aminoacyl or substituted aminoacyl. In other embodiments, R 2 is azido. In other embodiments, R 2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 2 is cyano. In other embodiments, R 2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 2 is nitro.
- R 3 is hydrogen. In certain instances, R 3 is methyl. In other embodiments, R 3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In other embodiments, R 3 is aryl or substituted aryl. In other embodiments, R 3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 3 is heteroaryl or substituted heteroaryl. In other embodiments, R 3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 3 is acyloxy or substituted acyloxy. In other embodiments, R 3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 3 is acyl or substituted acyl. In other embodiments, R 3 is thiol. In other embodiments, R 3 is amino or substituted amino. In other embodiments, R 3 is aminoacyl or substituted aminoacyl. In other embodiments, R 3 is azido. In other embodiments, R 3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 3 is cyano. In other embodiments, R 3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 3 is chloro.
- R 4 is hydrogen. In other embodiments, R 4 is alkyl or
- R 4 is aryl or substituted aryl. In other embodiments, R 4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 4 is heteroaryl or substituted heteroaryl. In other embodiments, R 4 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 4 is acyloxy or substituted acyloxy. In other embodiments, R 4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 4 is acyl or substituted acyl. In other embodiments, R 4 is thiol. In other embodiments, R 4 is amino or substituted amino.
- R 4 is aminoacyl or substituted aminoacyl. In other embodiments, R 4 is azido. In other embodiments, R 4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 4 is cyano. In other embodiments, R 4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 4 is nitro.
- R 5 is hydrogen. In other embodiments, R 5 is alkyl or
- R 5 is aryl or substituted aryl. In other embodiments, R 5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 5 is heteroaryl or substituted heteroaryl. In other embodiments, R 5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 5 is acyloxy or substituted acyloxy. In other embodiments, R 5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 5 is acyl or substituted acyl. In other embodiments, R 5 is thiol. In other embodiments, R 5 is amino or substituted amino.
- R 5 is aminoacyl or substituted aminoacyl. In other embodiments, R 5 is azido. In other embodiments, R 5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 5 is cyano. In other embodiments, R 5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 5 is nitro.
- R 6 is hydrogen. In other embodiments, R 6 is alkoxy, such as methoxy or ethoxy. In other embodiments, R 6 is alkyl or substituted alkyl. In other embodiments, R 6 is aryl or substituted aryl. In other embodiments, R 6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 6 is heteroaryl or substituted heteroaryl. In other embodiments, R 6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 6 is acyloxy or substituted acyloxy. In other embodiments, R 6 is alkoxylcarbonyl or substituted alkoxycarbonyl.
- R 6 is acyl or substituted acyl. In other embodiments, R 6 is thiol. In other embodiments, R 6 is amino or substituted amino. In other embodiments, R 6 is aminoacyl or substituted aminoacyl. In other embodiments, R 6 is azido. In other embodiments, R 6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 6 is cyano. In other embodiments, R 6 is a halogen, such as -F, -Cl, -Br and -I. In other
- R 6 is nitro. In certain embodiments, R 6 is alkoxylcarbonyl, such as ethoxycarbonyl.
- R 7 is hydrogen. In other embodiments, R 7 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R 7 is methyl. In other embodiments, R 7 is aryl or substituted aryl. In other embodiments, R 7 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 7 is heteroaryl or substituted heteroaryl. In other embodiments, R 7 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 7 is acyloxy or substituted acyloxy. In other embodiments, R 7 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 7 is acyl or substituted acyl. In other embodiments, R 7 is thiol. In other embodiments, R 7 is amino or substituted amino. In other embodiments, R 7 is aminoacyl or substituted aminoacyl. In other embodiments, R 7 is azido. In other embodiments, R 7 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 7 is cyano. In other embodiments, R 7 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 7 is nitro. In certain embodiments, R 7 is amino.
- R 8 is hydrogen. In other embodiments, R 8 is alkyl or substituted alkyl. In other embodiments, R 8 is aryl or substituted aryl. In other embodiments, R 8 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 8 is heteroaryl or substituted heteroaryl. In other embodiments, R 8 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 8 is acyloxy or substituted acyloxy. In other embodiments, R 8 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 8 is acyl or substituted acyl. In other embodiments, R 8 is thiol.
- R 8 is amino or substituted amino. In other embodiments, R 8 is aminoacyl or substituted aminoacyl. In other embodiments, R 8 is azido. In other embodiments, R 8 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 8 is cyano. In other embodiments, R 8 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 8 is nitro. In certain embodiments, R 8 is amino.
- a compound of interest and salts or solvates or
- stereoisomers thereof include:
- compositions which find use in the methods of the present disclosure can include compounds of Formula VII, shown below, which formula encompasses CB-1954 (5-(l- aziridinyl)-2,4-dinitrobenzamide) and pharmaceutically acceptable salts and derivatives thereof.
- the disclosed methods include administration of a compound of Formula VII:
- R 1 is hydrogen. In other embodiments, R 1 is alkyl or
- R 1 is substituted alkyl.
- R 1 is aryl or substituted aryl.
- R 1 is heterocycloalkyl or substituted heterocycloalkyl.
- R 1 is heteroaryl or substituted heteroaryl.
- R 1 is hydroxyl, alkoxyl or substituted alkoxyl.
- R 1 is acyloxy or substituted acyloxy.
- R 1 is alkoxylcarbonyl or substituted alkoxycarbonyl.
- R 1 is acyl or substituted acyl.
- R 1 is thiol.
- R 1 is amino or substituted amino.
- R 1 is aminoacyl or substituted aminoacyl. In other embodiments, R 1 is azido. In other embodiments, R 1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 1 is nitro. In certain embodiments, R 1 is naphthyl.
- R 2 is hydrogen. In other embodiments, R 2 is alkyl or
- R 2 is aryl or substituted aryl. In other embodiments, R 2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 2 is heteroaryl or substituted heteroaryl. In other embodiments, R 2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 2 is acyloxy or substituted acyloxy. In other embodiments, R 2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 2 is acyl or substituted acyl. In other embodiments, R 2 is thiol. In other embodiments, R 2 is amino or substituted amino.
- R 2 is aminoacyl or substituted aminoacyl. In other embodiments, R 2 is azido. In other embodiments, R 2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 2 is cyano. In other embodiments, R 2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 2 is nitro.
- R 3 is hydrogen. In certain instances, R 3 is methyl. In other embodiments, R 3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In other embodiments, R 3 is aryl or substituted aryl. In other embodiments, R 3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 3 is heteroaryl or substituted heteroaryl. In other embodiments, R 3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 3 is acyloxy or substituted acyloxy. In other embodiments, R 3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 3 is acyl or substituted acyl. In other embodiments, R 3 is thiol. In other embodiments, R 3 is amino or substituted amino. In other embodiments, R 3 is aminoacyl or substituted aminoacyl. In other embodiments, R 3 is azido. In other embodiments, R 3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 3 is cyano. In other embodiments, R 3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 3 is chloro.
- a compound of interest and salts or solvates or
- stereoisomers thereof include:
- compositions which find use in the methods of the present disclosure can include compounds of Formula VIII, shown below, which formula encompasses biperiden ((lRS,2SR,4RS)-l-(bicyclo[2.2. l]hept-5-en-2-yl)-l-phenyl-3-(piperidin- l -yl)propan-l- ol) and pharmaceutically acceptable salts and derivatives thereof.
- Pharmaceutical compositions and methods of the present disclosure also contemplate compounds of Formula VIII.
- the disclosed methods include administration of a compound of Formula VIIII:
- each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted
- R 1 is hydroxyl. In other embodiments, R 1 is hydrogen. In other embodiments, R 1 is alkyl or substituted alkyl. In other embodiments, R 1 is aryl or substituted aryl. In other embodiments, R 1 is heterocycloalkyl or substituted
- R 1 is heterocycloalkyl.
- R 1 is heteroaryl or substituted heteroaryl.
- R 1 is alkoxyl or substituted alkoxyl.
- R 1 is acyloxy or substituted acyloxy.
- R 1 is alkoxylcarbonyl or substituted alkoxycarbonyl.
- R 1 is acyl or substituted acyl.
- R 1 is thiol.
- R 1 is amino or substituted amino.
- R 1 is aminoacyl or substituted aminoacyl.
- R 1 is azido.
- R 1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl.
- R 1 is a halogen, such as -F, -Cl, -Br and -I.
- R 1 is nitro.
- R 1 is naphthyl.
- R 2 is hydrogen.
- R 2 is alkyl or substituted alkyl.
- R 2 is aryl or substituted aryl.
- R 2 is heterocycloalkyl or substituted heterocycloalkyl.
- R 2 is heteroaryl or substituted heteroaryl.
- R 2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 2 is acyloxy or substituted acyloxy. In other embodiments, R 2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 2 is acyl or substituted acyl. In other embodiments, R 2 is thiol. In other embodiments, R 2 is amino or substituted amino. In other embodiments, R 2 is aminoacyl or substituted aminoacyl. In other embodiments, R 2 is azido. In other embodiments, R 2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 2 is cyano. In other embodiments, R 2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 2 is nitro.
- R 3 is hydrogen. In certain instances, R 3 is methyl. In other embodiments, R 3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In other embodiments, R 3 is aryl or substituted aryl. In other embodiments, R 3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 3 is heteroaryl or substituted heteroaryl. In other embodiments, R 3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 3 is acyloxy or substituted acyloxy. In other embodiments, R 3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 3 is acyl or substituted acyl. In other embodiments, R 3 is thiol. In other embodiments, R 3 is amino or substituted amino. In other embodiments, R 3 is aminoacyl or substituted aminoacyl. In other embodiments, R 3 is azido. In other embodiments, R 3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 3 is cyano. In other embodiments, R 3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 3 is chloro.
- R 4 is hydrogen. In other embodiments, R 4 is alkyl or
- R 4 is aryl or substituted aryl. In other embodiments, R 4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 4 is heteroaryl or substituted heteroaryl. In other embodiments, R 4 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 4 is acyloxy or substituted acyloxy. In other embodiments, R 4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 4 is acyl or substituted acyl. In other embodiments, R 4 is thiol. In other embodiments, R 4 is amino or substituted amino.
- R 4 is aminoacyl or substituted aminoacyl. In other embodiments, R 4 is azido. In other embodiments, R 4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 4 is cyano. In other embodiments, R 4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 4 is nitro.
- R 5 is hydrogen. In other embodiments, R 5 is alkyl or
- R 5 is aryl or substituted aryl. In other embodiments, R 5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 5 is heteroaryl or substituted heteroaryl. In other embodiments, R 5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 5 is acyloxy or substituted acyloxy. In other embodiments, R 5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 5 is acyl or substituted acyl. In other embodiments, R 5 is thiol. In other embodiments, R 5 is amino or substituted amino.
- R 5 is aminoacyl or substituted aminoacyl. In other embodiments, R 5 is azido. In other embodiments, R 5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 5 is cyano. In other embodiments, R 5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 5 is nitro.
- R 6 is hydrogen. In other embodiments, R 6 is alkoxy, such as methoxy or ethoxy. In other embodiments, R 6 is alkyl or substituted alkyl. In other embodiments, R 6 is aryl or substituted aryl. In other embodiments, R 6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 6 is heteroaryl or substituted heteroaryl. In other embodiments, R 6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 6 is acyloxy or substituted acyloxy. In other embodiments, R 6 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 6 is acyl or substituted acyl. In other embodiments, R 6 is thiol. In other embodiments, R 6 is amino or substituted amino. In other embodiments, R 6 is aminoacyl or substituted aminoacyl.
- R 6 is azido. In other embodiments, R 6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 6 is cyano. In other embodiments, R 6 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 6 is nitro. In certain embodiments, R 6 is alkoxylcarbonyl, such as ethoxycarbonyl.
- R 7 is hydrogen. In other embodiments, R 7 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R 7 is methyl. In other embodiments, R 7 is aryl or substituted aryl. In other embodiments, R 7 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 7 is heteroaryl or substituted heteroaryl. In other embodiments, R 7 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 7 is acyloxy or substituted acyloxy. In other embodiments, R 7 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 7 is acyl or substituted acyl. In other embodiments, R 7 is thiol. In other embodiments, R 7 is amino or substituted amino. In other embodiments, R 7 is aminoacyl or substituted aminoacyl. In other embodiments, R 7 is azido. In other embodiments, R 7 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 7 is cyano. In other embodiments, R 7 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 7 is nitro. In certain embodiments, R 7 is amino.
- a compound of interest and salts or solvates or
- stereoisomers thereof include:
- compositions which find use in the methods of the present disclosure can include compounds of Formula IX, shown below, which formula encompasses RO-4929097 (2,2-dimethyl-N-[(l0S)-9-oxo-8-azatricyclo[9.4.0.02,7]pentadeca-l,2,4,6,l 1,13- hexaene-lO-yl]-N’-(2,2,3,3,3-pentafluoropropyl)propanediamide) and pharmaceutically acceptable salts and derivatives thereof.
- the disclosed methods include administration of a compound of Formula IX, shown below, which formula encompasses RO-4929097 (2,2-dimethyl-N-[(l0S)-9-oxo-8-azatricyclo[9.4.0.02,7]pentadeca-l,2,4,6,l 1,13- hexaene-lO-yl]-N’-(2,2,3,3,3-pentafluoropropyl)propanediamide) and pharmaceutically
- R 1 is hydrogen. In other embodiments, R 1 is alkyl or substituted alkyl. In other embodiments, R 1 is aryl or substituted aryl. In other embodiments, R 1 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 1 is heteroaryl or substituted heteroaryl. In other embodiments, R 1 is hyrdoxyl alkoxyl or substituted alkoxyl. In other embodiments, R 1 is acyloxy or substituted acyloxy. In other embodiments, R 1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 1 is acyl or substituted acyl.
- R 1 is thiol. In other embodiments, R 1 is amino or substituted amino. In other embodiments, R 1 is aminoacyl or substituted aminoacyl. In other embodiments, R 1 is azido. In other embodiments, R 1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 1 is nitro. In certain embodiments, R 1 is naphthyl.
- R 2 is hydrogen. In other embodiments, R 2 is alkyl or substituted alkyl. In other embodiments, R 2 is aryl or substituted aryl. In other embodiments, R 2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 2 is heteroaryl or substituted heteroaryl. In other embodiments, R 2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 2 is acyloxy or substituted acyloxy. In other embodiments, R 2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 2 is acyl or substituted acyl. In other embodiments, R 2 is thiol.
- R 2 is amino or substituted amino. In other embodiments, R 2 is aminoacyl or substituted aminoacyl. In other embodiments, R 2 is azido. In other embodiments, R 2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 2 is cyano. In other embodiments, R 2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 2 is nitro.
- R 3 is hydrogen. In certain instances, R 3 is methyl. In other embodiments, R 3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In other embodiments, R 3 is aryl or substituted aryl. In other embodiments, R 3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 3 is heteroaryl or substituted heteroaryl. In other embodiments, R 3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 3 is acyloxy or substituted acyloxy. In other embodiments, R 3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 3 is acyl or substituted acyl. In other embodiments, R 3 is thiol. In other embodiments, R 3 is amino or substituted amino. In other embodiments, R 3 is aminoacyl or substituted aminoacyl. In other embodiments, R 3 is azido. In other embodiments, R 3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 3 is cyano. In other embodiments, R 3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 3 is chloro.
- R 4 is hydrogen. In other embodiments, R 4 is alkyl or
- R 4 is aryl or substituted aryl. In other embodiments, R 4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 4 is heteroaryl or substituted heteroaryl. In other embodiments, R 4 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 4 is acyloxy or substituted acyloxy. In other embodiments, R 4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 4 is acyl or substituted acyl. In other embodiments, R 4 is thiol. In other embodiments, R 4 is amino or substituted amino.
- R 4 is aminoacyl or substituted aminoacyl. In other embodiments, R 4 is azido. In other embodiments, R 4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 4 is cyano. In other embodiments, R 4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 4 is nitro.
- R 5 is hydrogen. In other embodiments, R 5 is alkyl or
- R 5 is aryl or substituted aryl. In other embodiments, R 5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 5 is heteroaryl or substituted heteroaryl. In other embodiments, R 5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 5 is acyloxy or substituted acyloxy. In other embodiments, R 5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 5 is acyl or substituted acyl. In other embodiments, R 5 is thiol. In other embodiments, R 5 is amino or substituted amino.
- R 5 is aminoacyl or substituted aminoacyl. In other embodiments, R 5 is azido. In other embodiments, R 5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 5 is cyano. In other embodiments, R 5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 5 is nitro.
- R 6 is hydrogen. In other embodiments, R 6 is alkoxy, such as methoxy or ethoxy. In other embodiments, R 6 is alkyl or substituted alkyl. In other embodiments, R 6 is aryl or substituted aryl. In other embodiments, R 6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 6 is heteroaryl or substituted heteroaryl. In other embodiments, R 6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 6 is acyloxy or substituted acyloxy. In other embodiments, R 6 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 6 is acyl or substituted acyl. In other embodiments, R 6 is thiol. In other embodiments, R 6 is amino or substituted amino. In other embodiments, R 6 is aminoacyl or substituted aminoacyl.
- R 6 is azido. In other embodiments, R 6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 6 is cyano. In other embodiments, R 6 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 6 is nitro. In certain embodiments, R 6 is alkoxylcarbonyl, such as ethoxycarbonyl.
- R 7 is hydrogen. In other embodiments, R 7 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R 7 is methyl. In other embodiments, R 7 is aryl or substituted aryl. In other embodiments, R 7 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 7 is heteroaryl or substituted heteroaryl. In other embodiments, R 7 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 7 is acyloxy or substituted acyloxy. In other embodiments, R 7 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
- R 7 is acyl or substituted acyl. In other embodiments, R 7 is thiol. In other embodiments, R 7 is amino or substituted amino. In other embodiments, R 7 is aminoacyl or substituted aminoacyl. In other embodiments, R 7 is azido. In other embodiments, R 7 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 7 is cyano. In other embodiments, R 7 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 7 is nitro. In certain embodiments, R 7 is amino.
- R 9 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R 9 is pentalfuoro ethyl. In other embodiments, R 9 is hydrogen. In other embodiments, R 9 is aryl or substituted aryl. In other embodiments, R 9 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 9 is heteroaryl or substituted heteroaryl. In other embodiments, R 9 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 9 is acyloxy or substituted acyloxy.
- R 9 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 9 is acyl or substituted acyl. In other embodiments, R 9 is thiol. In other embodiments, R 9 is amino or substituted amino. In other embodiments, R 9 is aminoacyl or substituted aminoacyl. In other embodiments, R 9 is azido. In other embodiments, R 9 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 9 is cyano. In other embodiments, R 9 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 9 is nitro. In certain embodiments, R 7 is amino.
- R 10 is hydrogen. In other embodiments, R 10 is alkyl or substituted alkyl. In other embodiments, R 10 is aryl or substituted aryl. In other embodiments, R 10 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 10 is heteroaryl or substituted heteroaryl. In other embodiments, R 10 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 10 is acyloxy or substituted acyloxy. In other embodiments, R 10 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 10 is acyl or substituted acyl. In other embodiments, R 10 is thiol.
- R 10 is amino or substituted amino. In other embodiments, R 10 is aminoacyl or substituted aminoacyl. In other embodiments, R 10 is azido. In other embodiments, R 10 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 10 is cyano. In other embodiments, R 10 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 10 is nitro. In certain embodiments, R 10 is amino.
- R 11 is hydrogen. In other embodiments, R 11 is alkyl or substituted alkyl. In other embodiments, R 11 is aryl or substituted aryl. In other embodiments, R 11 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R 11 is heteroaryl or substituted heteroaryl. In other embodiments, R 11 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R 11 is acyloxy or substituted acyloxy. In other embodiments, R 11 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R 11 is acyl or substituted acyl. In other embodiments, R 11 is thiol.
- R 11 is amino or substituted amino. In other embodiments, R 11 is aminoacyl or substituted aminoacyl. In other embodiments, R 11 is azido. In other embodiments, R 11 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R 11 is cyano. In other embodiments, R 11 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R 11 is nitro. In certain embodiments, R 11 is amino.
- a compound of interest and salts or solvates or
- stereoisomers thereof include:
- RO-4929097 ((2,2-dimethyl-N-[(l0S)-9-oxo-8-azatricyclo[9.4.0.02,7]pentadeca- l,2,4,6,l l,l3-hexaene-l0-yl]-N’-(2,2,3,3,3-pentafluoropropyl)propanediamide)
- compositions which find use in the methods of the present disclosure can include compounds of Formula X, shown below, which formula encompasses Fmoc-leucine and pharmaceutically acceptable salts and derivatives thereof.
- the disclosed methods include administration of a compound of Formula X:
- a compound of interest and salts or solvates or
- an active agent e.g., a compound of Formulae I-X, or a
- pharmaceutically acceptable salt or derivative thereof is prepared in a pharmaceutically acceptable composition(s) for delivery to a host.
- Pharmaceutically acceptable carriers preferred for use with active agents may include sterile aqueous or non- aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, and microparticles, including saline and buffered media.
- Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like.
- a composition comprising an active agent (and optionally one or more additional therapeutic agent) may also be lyophilized using means well known in the art, for subsequent reconstitution and use according to the invention.
- An active agent is generally administered to an individual in need thereof in a formulation with a pharmaceutically acceptable excipient(s).
- a pharmaceutically acceptable excipient(s) A wide variety of pharmaceutically acceptable excipients is known in the art and need not be discussed in detail herein.
- Pharmaceutically acceptable excipients have been amply described in a variety of publications, including, for example, A. Gennaro (2000)“Remington: The Science and Practice of Pharmacy”, 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems (1999) H. C. Ansel et ak, eds 7 th ed., Lippincott, Williams, & Wilkins; and Handbook of Pharmaceutical Excipients (2000) A. H.
- “active agent” includes an active agent as described above, and optionally one or more additional therapeutic agent.
- an active agent may be administered to the host using any convenient means capable of resulting in treatment of cardiac valve disease, e.g., CAVD.
- CAVD cardiac valve disease
- an active agent can be incorporated into a variety of formulations for therapeutic administration.
- an active agent can be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable carriers or diluents, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosols.
- an active agent is formulated as a gel, as a solution, or in some other form suitable for intravaginal administration.
- an active agent is formulated as a gel, as a solution, or in some other form suitable for rectal (e.g., intrarectal)
- an active agent may be administered in the form of its pharmaceutically acceptable salts, or it may also be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds.
- the following methods and excipients are merely exemplary and are in no way limiting.
- an active agent is formulated in an aqueous buffer.
- Suitable aqueous buffers include, but are not limited to, acetate, succinate, citrate, and phosphate buffers varying in strengths from about 5 mM to about 100 mM.
- the aqueous buffer includes reagents that provide for an isotonic solution. Such reagents include, but are not limited to, sodium chloride; and sugars e.g., mannitol, dextrose, sucrose, and the like.
- the aqueous buffer further includes a non-ionic surfactant such as polysorbate 20 or 80.
- the formulations may further include a preservative.
- Suitable preservatives include, but are not limited to, a benzyl alcohol, phenol, chlorobutanol, benzalkonium chloride, and the like. In many cases, the formulation is stored at about 4°C. Formulations may also be lyophilized, in which case they generally include cryoprotectants such as sucrose, trehalose, lactose, maltose, mannitol, and the like. Lyophilized formulations can be stored over extended periods of time, even at ambient temperatures.
- an active agent can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules, for example, with conventional additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators, such as com starch, potato starch or sodium
- carboxymethylcellulose carboxymethylcellulose
- lubricants such as talc or magnesium stearate
- diluents such as talc or magnesium stearate
- An active agent can be formulated into preparations for injection by dissolving, suspending or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.
- an aqueous or nonaqueous solvent such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol
- solubilizers such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.
- An active agent can be utilized in aerosol formulation to be administered via inhalation.
- An active agent can be formulated into pressurized acceptable propellants such as dichlorodifluoromethane, propane, nitrogen and the like.
- an active agent can be made into suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases.
- bases such as emulsifying bases or water-soluble bases.
- An active agent can be administered rectally via a suppository.
- the suppository can include vehicles such as cocoa butter, carbowaxes and polyethylene glycols, which melt at body temperature, yet are solidified at room temperature.
- Unit dosage forms for oral or rectal administration such as syrups, elixirs, and suspensions may be provided wherein each dosage unit, for example, teaspoonful, tablespoonful, tablet or suppository, contains a predetermined amount of the
- compositions containing one or more active agents may comprise the active agent(s) in a
- composition as a solution in sterile water, normal saline or another pharmaceutically acceptable carrier.
- Unit dosage forms for intravaginal or intrarectal administration such as syrups, elixirs, gels, and suspensions may be provided wherein each dosage unit, for example, teaspoonful, tablespoonful, tablet, unit gel volume, or suppository, contains a predetermined amount of the composition containing one or more active agents.
- unit dosage form refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of an active agent, calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier or vehicle.
- the specifications for a given active agent will depend in part on the particular compound employed and the effect to be achieved, and the pharmacodynamics associated with each compound in the host.
- an active agent can be formulated in suppositories and, in some cases, aerosol and intranasal compositions.
- the vehicle composition will include traditional binders and carriers such as, polyalkylene glycols, or triglycerides.
- suppositories may be formed from mixtures containing the active ingredient in the range of about 0.5% to about 10% (w/w), e.g. about 1% to about 2%.
- An active agent can be administered as an injectable.
- injectable Typically, injectable
- compositions are prepared as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.
- the preparation may also be emulsified or the active ingredient encapsulated in liposome vehicles.
- An active agent will in some embodiments be formulated for vaginal delivery.
- a subject formulation for intravaginal administration comprises an active agent formulated as an intravaginal bioadhesive tablet, intravaginal bioadhesive microparticle, intravaginal cream, intravaginal lotion, intravaginal foam, intravaginal ointment, intravaginal paste, intravaginal solution, or intravaginal gel.
- An active agent will in some embodiments be formulated for rectal delivery.
- a subject formulation for intrarectal administration comprises an active agent formulated as an intrarectal bioadhesive tablet, intrarectal bioadhesive microparticle, intrarectal cream, intrarectal lotion, intrarectal foam, intrarectal ointment, intrarectal paste, intrarectal solution, or intrarectal gel.
- a subject formulation comprising an active agent includes one or more of an excipient (e.g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate or calcium carbonate), a binder (e.g., cellulose, methylcellulose, hydroxymethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, poly(ethylene glycol), sucrose or starch), a disintegrator (e.g., starch, carboxymethylcellulose, hydroxypropyl starch, low substituted hydroxypropylcellulose, sodium bicarbonate, calcium phosphate or calcium citrate), a lubricant (e.g., magnesium stearate, light anhydrous silicic acid, talc or sodium lauryl sulfate), a flavoring agent (e.g., citric acid, menthol, glycine or orange powder), a preservative (e.g.
- hydroxypropylmethylcellulose hydroxypropylmethylcellulose
- a diluent e.g., water
- base wax e.g., cocoa butter, white petrolatum or polyethylene glycol
- Tablets comprising an active agent may be coated with a suitable film-forming agent, e.g., hydroxypropylmethyl cellulose, hydroxypropyl cellulose or ethyl cellulose, to which a suitable excipient may optionally be added, e.g., a softener such as glycerol, propylene glycol, di ethyl phthal ate, or glycerol triacetate; a filler such as sucrose, sorbitol, xylitol, glucose, or lactose; a colorant such as titanium hydroxide; and the like.
- a suitable film-forming agent e.g., hydroxypropylmethyl cellulose, hydroxypropyl cellulose or ethyl cellulose
- a suitable excipient e.g., a softener such as glycerol, propylene glycol, di ethyl phthal ate, or glycerol triacetate
- a filler such
- Suitable excipient vehicles are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof.
- the vehicle may contain minor amounts of auxiliary substances such as wetting or emulsifying agents or pH buffering agents.
- auxiliary substances such as wetting or emulsifying agents or pH buffering agents.
- Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., l7th edition, 1985.
- the composition or formulation to be administered will, in any event, contain a quantity of the agent adequate to achieve the desired state in the subject being treated.
- the pharmaceutically acceptable excipients such as vehicles, adjuvants, carriers or diluents, are readily available to the public.
- pharmaceutically acceptable auxiliary substances such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are readily available to the public.
- a suitable dosage range of an active agent is one which provides up to about 1 mg to about 5000 mg, e.g., from about 1 mg to about 25 mg, from about 25 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 200 mg, from about 200 mg to about 250 mg, from about 250 mg to about 500 mg, from about 500 mg to about 1000 mg, or from about 1000 mg to about 5000 mg of an active agent, which can be administered in a single dose.
- dose levels can vary as a function of the specific compound, the severity of the symptoms and the susceptibility of the subject to side effects. Preferred dosages for a given compound are readily determinable by those of skill in the art by a variety of means.
- pharmaceutically acceptable salt or derivative thereof is in the range of from about 1 mg/kg body weight to about 500 mg/kg body weight, e.g., from about 5 mg/kg body weight to about 500 mg/kg body weight, from about 10 mg/kg body weight to about 500 mg/kg body weight, from about 20 mg/kg body weight to about 500 mg/kg body weight, from about 30 mg/kg body weight to about 500 mg/kg body weight, from about 40 mg/kg body weight to about 500 mg/kg body weight, from about 50 mg/kg body weight to about 500 mg/kg body weight, from about 60 mg/kg body weight to about 500 mg/kg body weight, from about 70 mg/kg body weight to about 500 mg/kg body weight, from about 80 mg/kg body weight to about 500 mg/kg body weight, from about 90 mg/kg body weight to about 500 mg/kg body weight, from about 100 mg/kg body weight to about 500 mg/kg body weight, from about 200 mg/kg body weight to about 500mg/kg body weight, from about 300 mg/kg body weight to about 500mg/
- pharmaceutically acceptable salt or derivative thereof is in the range of from about 1 mg/kg body weight to about 5 mg/kg body weight, from about 5 mg/kg body weight to about 10 mg/kg body weight, from about 10 mg/kg body weight to about 20 mg/kg body weight, from about 20 mg/kg body weight to about 30 mg/kg body weight, from about 30 mg/kg body weight to about 40 mg/kg body weight, from about 40 mg/kg body weight to about 50 mg/kg body weight, from about 50 mg/kg body weight to about 100 mg/kg body weight, or from about 100 mg/kg body weight to about 500 mg/kg body weight.
- a single dose of an active agent is administered.
- multiple doses of an active agent are administered.
- an active agent is administered, e.g., twice daily (qid), daily (qd), every other day (qod), every third day, three times per week (tiw), or twice per week (biw) over a period of time.
- an active agent is administered qid, qd, qod, tiw, or biw over a period of from one day to about 2 years or more.
- an active agent is administered at any of the aforementioned frequencies for one week, two weeks, one month, two months, six months, one year, or two years, or more, depending on various factors.
- a first active agent and a second active agent can be administered in separate formulations.
- a first active agent and a second active agent can be administered substantially simultaneously, or within about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 8 hours, about 16 hours, about 24 hours, about 36 hours, about 72 hours, about 4 days, about 7 days, or about 2 weeks of one another.
- the separate pharmaceutical compositions comprising the different agents may be administered using the same or different routes of administration in accordance with any medically acceptable method known in the art.
- a compound of Formula I is administered in combination with a compound of Formula III.
- XCT-790 (2E-3-(4- ⁇ [2,4- bis(trifluoromethyl)benzyl]oxy ⁇ -3-methoxyphenyl)-2-cyano-N-[5-(trifluoromethyl)- l,3,4-thiadiazol-2-yl]acrylamide) is administered in combination with GSK-837149A (4,4’-(carbonyldiimino)bis[N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide).
- a compound of Formula I is administered in combination with a compound of Formula II and a compound of Formula II.
- XCT-790 (2E-3-(4- ⁇ [2,4-bis(trifluoromethyl)benzyl]oxy ⁇ -3-methoxyphenyl)- 2-cyano-N-[5-(trifluoromethyl)-l,3,4-thiadiazol-2-yl]acrylamide) is administered in combination with TG-003 ((Z)-l-(3-ethyl-5-methoxy-2,3-dihydrobenzothiazol-2- ylidene)propan-2-one) and GSK-837149A (4,4’-(carbonyldiimino)bis[N-(4-methyl-2- pyrimidinyl)-benzenesulfonamide).
- the compound of Formula I (e.g., XCT-790) can be administered prior to,
- the compound of Formula III e.g., GSK-837149A
- the compound of Formula II e.g., TG-003
- the compound of Formula I e.g., XCT-790
- the three agents, or two of the three agents can be presented to the individual by way of concurrent therapy.
- concurrent therapy is intended administration to a human subject such that the therapeutic effect of the combination of the substances is caused in the subject undergoing therapy.
- concurrent therapy may be achieved by administering at least one therapeutically effective dose of a pharmaceutical composition comprising a compound of Formula I (e.g., XCT-790) and at least one therapeutically effective dose of a pharmaceutical composition comprising a compound of Formula III (e.g., GSK-837149A) and, optionally, at least one therapeutically effective dose of a composition comprising a compound of Formula II (e.g., TG-003) according to a particular dosing regimen.
- a pharmaceutical composition comprising a compound of Formula I (e.g., XCT-790) and at least one therapeutically effective dose of a pharmaceutical composition comprising a compound of Formula III (e.g., GSK-837149A) and, optionally, at least one therapeutically effective dose of a composition comprising a compound of Formula II (e.g., TG-003) according to a particular dosing regimen.
- a pharmaceutical composition comprising a compound of Formula I (e.g., XCT-790) and at least one
- Administration of the separate pharmaceutical compositions can be at the same time (i.e., simultaneously) or at different times (i.e., sequentially, in either order, on the same day, or on different days), as long as the therapeutic effect of the combination of these compounds is caused in the subject undergoing therapy.
- An active agent is administered to an individual using any available method and route suitable for drug delivery, including in vivo and ex vivo methods, as well as systemic and localized routes of administration.
- Conventional and pharmaceutically acceptable routes of administration include intranasal, intramuscular, intratracheal, transdermal, subcutaneous, intradermal, topical application, intravenous, vaginal, nasal, and other parenteral routes of administration.
- an active agent is administered via an intravaginal route of administration.
- an active agent is administered via an intrarectal route of administration. Routes of administration may be combined, if desired, or adjusted depending upon the agent and/or the desired effect.
- the composition can be administered in a single dose or in multiple doses.
- An active agent can be administered to a host using any available conventional methods and routes suitable for delivery of conventional drugs, including systemic or localized routes.
- routes of administration contemplated by the invention include, but are not necessarily limited to, enteral, parenteral, or inhalational routes.
- Parenteral routes of administration other than inhalation administration include, but are not necessarily limited to, topical, vaginal, transdermal, subcutaneous, intramuscular, and intravenous routes, i.e., any route of administration other than through the alimentary canal.
- Parenteral administration can be carried to effect systemic or local delivery of the agent. Where systemic delivery is desired, administration typically involves invasive or systemically absorbed topical or mucosal administration of pharmaceutical preparations.
- An active agent can also be delivered to the subject by enteral administration.
- Enteral routes of administration include, but are not necessarily limited to, oral and rectal (e.g., using a suppository) delivery.
- treatment is meant at least an amelioration of the symptoms associated with the pathological condition afflicting the host, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g. symptom, associated with the pathological condition being treated, such as the degree of calcification of an aortic valve.
- amelioration also includes situations where the pathological condition, or at least symptoms associated therewith, are completely inhibited, e.g.
- hosts are“mammals” or“mammalian,” where these terms are used broadly to describe organisms which are within the class mammalia, and primates (e.g., humans, chimpanzees, and monkeys). In many embodiments, the hosts will be humans.
- a suitable subject may be a subject that has been identified as at risk of or diagnosed with a cardiac valve disease, e.g., CAVD, including aortic sclerosis, and/or calcific aortic stenosis.
- Total cholesterol, increased low-density lipoprotein (LDL) cholesterol, increased lipoprotein(a), increased triglycerides, decreased high-density lipoprotein cholesterol, male sex, cigarette smoking, hypertension, and diabetes mellitus have been reported to increase the incidence of aortic stenosis, and may contribute to endothelial dysfunction and leaflet damage.
- LDL low-density lipoprotein
- lipoprotein(a) increased lipoprotein(a)
- increased triglycerides decreased high-density lipoprotein cholesterol
- male sex sex
- hypertension cigarette smoking
- diabetes mellitus have been reported to increase the incidence of aortic stenosis, and may contribute to endothelial dysfunction and leaflet damage.
- oxLDL Oxidised LDL
- Elevated blood levels of oxLDL correlate with aortic valve calcification and fibrosis, and oxLDL accumulation in calcific, stenotic aortic valves has been described.
- Metabolic bone diseases e.g., Paget’s disease, secondary hyperparathyroidism and renal disease, as well as increased serum creatinine and calcium are also linked to progression of valve calcification.
- Patients with valve malformations, e.g. bicuspid aortic valve are also at risk for valve calcification.
- patients identified as having a mutation in one of the multiple genes found to be associated with valve calcification may be identified as at-risk patients where preventative treatment is recommended, e.g., patients identified as having a mutation in one or more of NOTCH1, SMAD6, and GATA5.
- a suitable subject may also be a subject that has a NOTCH1 haploinsufficiency. Accordingly, a suitable subject may be a subject having one or more of the above clinical and/or genetic risk factors.
- Kits with unit doses of the active agent e.g. in oral, vaginal, rectal, transdermal, or injectable doses (e.g., for intramuscular, intravenous, or subcutaneous injection), are provided.
- injectable doses e.g., for intramuscular, intravenous, or subcutaneous injection
- kits in addition to the containers containing the unit doses will be an informational package insert describing the use and attendant benefits of the drugs in treating or preventing cardiac valve disease.
- Suitable active agents and unit doses are those described herein above.
- a subject kit will further include instructions for
- a website URL directing the user to a webpage which provides the instructions
- these instructions are typically printed on a substrate, which substrate may be one or more of: a package insert, the packaging, formulation containers, and the like.
- a subject kit includes one or more components or features that increase patient compliance, e.g., a component or system to aid the patient in remembering to take the active agent at the appropriate time or interval.
- a component or system to aid the patient in remembering to take the active agent at the appropriate time or interval.
- Such components include, but are not limited to, a calendaring system to aid the patient in remembering to take the active agent at the appropriate time or interval.
- the present invention provides a delivery system comprising a compound of Formulae I-X, or a pharmaceutically acceptable salt or derivative thereof.
- the delivery system is a delivery system that provides for injection of a formulation comprising an active agent subcutaneously, intravenously, or
- the delivery system is a vaginal or rectal delivery system.
- an active agent is packaged for oral administration.
- the present invention provides a packaging unit comprising daily dosage units of an active agent.
- the packaging unit is in some embodiments a conventional blister pack or any other form that includes tablets, pills, and the like.
- the blister pack will contain the appropriate number of unit dosage forms, in a sealed blister pack with a cardboard, paperboard, foil, or plastic backing, and enclosed in a suitable cover.
- Each blister container may be numbered or otherwise labeled, e.g., starting with day 1.
- a subject delivery system comprises an injection device.
- Exemplary, non-limiting drug delivery devices include injections devices, such as pen injectors, and needle/syringe devices.
- the invention provides an injection delivery device that is pre-loaded with a formulation comprising an effective amount of a compound of Formulae I-X or a pharmaceutically acceptable salt or derivative thereof.
- a subject delivery device comprises an injection device pre-loaded with a single dose of a compound of Formulae I-X or a pharmaceutically acceptable salt or derivative thereof.
- a subject injection device can be re-usable or disposable.
- Pen injectors are well known in the art. Exemplary devices which can be adapted for use in the present methods are any of a variety of pen injectors from Becton
- the medication delivery pen can be disposable, or reusable and refillable.
- the present invention provides a delivery system for vaginal or rectal delivery of an active agent to the vagina or rectum of an individual.
- the delivery system comprises a device for insertion into the vagina or rectum.
- the delivery system comprises an applicator for delivery of a formulation into the vagina or rectum; and a container that contains a formulation comprising an active agent.
- the container e.g., a tube
- the delivery system comprises a device that is inserted into the vagina or rectum, which device includes an active agent.
- the device is coated with, impregnated with, or otherwise contains a formulation comprising the active agent.
- the vaginal or rectal delivery system is a tampon or
- Drug delivery tampons are known in the art, and any such tampon can be used in conjunction with a subject drug delivery system. Drug delivery tampons are described in, e.g., U.S. Pat. No. 6,086,909.
- the drug can be incorporated into a gel-like bioadhesive reservoir in the tip of the device.
- the drug can be in the form of a powdered material positioned at the tip of the tampon.
- the drug can also be absorbed into fibers at the tip of the tampon, for example, by dissolving the drug in a pharmaceutically acceptable carrier and absorbing the drug solution into the tampon fibers.
- the drug can also be dissolved in a coating material which is applied to the tip of the tampon.
- the drug can be incorporated into an insertable suppository which is placed in association with the tip of the tampon.
- the drug delivery device is a vaginal or rectal ring.
- Vaginal or rectal rings usually consist of an inert elastomer ring coated by another layer of elastomer containing an active agent to be delivered.
- the rings can be easily inserted, left in place for the desired period of time (e.g., up to 7 days), then removed by the user.
- the ring can optionally include a third, outer, rate-controlling elastomer layer which contains no drug.
- the third ring can contain a second drug for a dual release ring.
- the drug can be incorporated into polyethylene glycol throughout the silicone elastomer ring to act as a reservoir for drug to be delivered.
- a subject vaginal or rectal delivery system is a vaginal or rectal sponge.
- the active agent is incorporated into a silicone matrix which is coated onto a cylindrical drug-free polyurethane sponge, as described in the literature.
- Pessaries, tablets, and suppositories are other examples of drug delivery systems which can be used, e.g., in carrying out a method of the present disclosure. These systems have been described extensively in the literature.
- Bioadhesive microparticles constitute still another drug delivery system suitable for use in the present invention.
- This system is a multi-phase liquid or semi-solid preparation which does not seep from the vagina or rectum as do many suppository formulations. The substances cling to the wall of the vagina or rectum and release the drug over a period of time. Many of these systems were designed for nasal use but can be used in the vagina or rectum as well (e.g. U.S. Pat. No. 4,756,907).
- the system may comprise microspheres with an active agent; and a surfactant for enhancing uptake of the drug.
- the microparticles have a diameter of 10-100 pm and can be prepared from starch, gelatin, albumin, collagen, or dextran.
- Another system is a container comprising a subject formulation (e.g., a tube) that is adapted for use with an applicator.
- the active agent is incorporated into creams, lotions, foams, paste, ointments, and gels which can be applied to the vagina or rectum using an applicator. Processes for preparing pharmaceuticals in cream, lotion, foam, paste, ointment and gel formats can be found throughout the literature.
- a suitable system is a standard fragrance free lotion formulation containing glycerol, ceramides, mineral oil, petrolatum, parabens, fragrance and water such as the product sold under the trademark JERGENSTM (Andrew Jergens Co., Cincinnati, Ohio).
- JERGENSTM Andrew Jergens Co., Cincinnati, Ohio.
- Suitable nontoxic pharmaceutically acceptable systems for use in the compositions of the present invention will be apparent to those skilled in the art of pharmaceutical formulations and examples are described in Remington's Pharmaceutical Sciences, l9th Edition, A. R. Gennaro, ed., 1995.
- suitable carriers will depend on the exact nature of the particular vaginal or rectal dosage form desired, e.g., whether the active ingredient(s) is/are to be formulated into a cream, lotion, foam, ointment, paste, solution, or gel, as well as on the identity of the active ingredient(s).
- suitable delivery devices are those described in ET.S. Pat. No. 6,476,079.
- kits e.g., any two or more compounds selected from compounds of Formulae I-X.
- the kit may comprise a compound of Formula I and a compound of Formula III, or a compound of Formula I, a compound of Formula II, and a compound of Formula III.
- the kit comprises XCT-790, and GSK-837149A.
- the kit comprises XCT-790, TG-003, and GSK-837149A.
- the present disclosure provides screening methods for identifying a candidate compound for treatment of cardiac valve disease.
- the methods include contacting human NOTCHl +/ endothelial cells with a compound; performing targeted RNA sequencing (RNA-seq) to provide an expression profile for the human NOTCHl +/ endothelial cells resulting from the contacting, wherein the targeted RNA- seq comprises sequencing RNA transcripts for a plurality of the genes listed in Table 1; comparing the expression profile resulting from the contacting with an isogenic WT expression profile for the plurality of genes listed in Table 1; and identifying the compound as a candidate compound for treatment of cardiac valve disease when the expression profile resulting from the contacting is corrected to the isogenic WT expression profile.
- RNA-seq targeted RNA sequencing
- the plurality includes one or more or all of the following genes: NOTCH1, SOX7, TCF4, and SMAD1.
- the plurality includes NOTCH1, SOX7, TCF4, and SMAD1 and at least 1, e.g., 2, 3, 4, 5, 6, 7, 8, 9,
- the plurality includes at least one housekeeping gene.
- the at least one housekeeping gene is selected from CHMP2A, Clorf43, and REEP5.
- one, two or all of the housekeeping genes CHMP2A, Clorf43, and REEP5 are excluded from the expression profile.
- the targeted RNA-seq does not include sequencing RNA transcripts for one, two or all of the housekeeping genes CHMP2A, Clorf43, and REEP5.
- the human NOTCHl +/ endothelial cells are derived from human induced pluripotent stem cells (iPSC) derived from a subject having CAVD, e.g., iPSC derived from fibroblasts of a subject having CAVD.
- iPSC human induced pluripotent stem cells
- wild type cells e.g., wild type human endothelial cells, genetically engineered to have the Nl mutation, are used in place of human NOTCHl +/ endothelial cells derived from human induced pluripotent stem cells (iPSC) derived from a subject having CAVD.
- endothelial cells are derived from human induced pluripotent stem cells (iPSC) e.g., iPSC derived from fibroblasts, wherein the endothelial cells are genetically engineered to have the Nl mutation.
- iPSC human induced pluripotent stem cells
- KNN K-nearest neighbors
- a suitable isogenic WT expression profile can be obtained, e.g., by deriving isogenic control lines, wherein the Nl mutation is corrected using an appropriate gene editing tool, e.g., Meganuclease, TALEN, ZFN, or CRISPR/Cas system.
- n is an integer from 1 to 8;
- X is O or S
- Y is O or S
- heterocyclyl substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
- X is O or S
- each of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR 12 , -C(0)0R 12 , -
- cardiac valve disease is a calcific aortic valve disease.
- the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
- each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR 9 , -C(0)0R 9 , -
- each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR 12 , -
- N CR 12 R 13 , wherein t is 0, 1, 2 or 3 and R 12 and R 13 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted
- heterocyclyl substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
- cardiac valve disease is a calcific aortic valve disease.
- R 1 is selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl,
- PG is a hydroxyl protecting group selected from the group consisting of a benzyl ether, methyl ester, benzoic acid ester, t-butyl ester, t-butyl ether (TBDMS, TBDPS), methoxymethyl ether (MOM), allyl ether, tetrahydropyranyl ether (THP), a fluorenylmethyloxycarbonyl (Fmoc).
- a method of identifying a candidate compound for treatment of cardiac valve disease comprising:
- RNA-seq targeted RNA sequencing
- the plurality of genes further comprises one or more or all of ITGA5, CD34, ETS1, CSDA, IGFBP3, SDPR, CDH5, LXN, CXCR4, TNFSF4, GJA4, NRP1, CD24P4, HMGA2, THSD1, RASSF2, HHIP, TERF1, NID2, ALDH1A1, HEY1, ETS2, ITGA9, NRCAM, HOXB5, HOXB6, PRDM1, ClOorflO, ALDH2, COL12A1, SNCA, SFRP1, NPPB, CA8, GNA14, VCAN, HOXB7, ITGA8, ACP5, TMEM178, HOXB3, PLAGL1, NR5A2, VLDLR, BICD1, MAML3, NRG3, FOXF1, CXCL12, HLX, MEIS2, HOXB4, TCF7L1, FGF2, ALX1, CARHSP1, DNER, TGFBR3, TO
- the plurality of genes further comprises one or more or all of F2R, F2RL2, THBS1, FAM124B, PLOD2, COX6A1, KIAA0494, RNF19A, CLEC14A, DIAPH2, NDUFA12, FAM89A, NNMT, MLF1, Clorf54, HAPLN1, IL1RL1, ITPKB, and CD97.
- identifying comprises applying a machine learning algorithm to determine when the expression profile resulting from the contacting is corrected to the isogenic WT expression profile.
- a composition comprising at least one compound of any one of Formulae I-X for use in the treatment of cardiac valve disease.
- Standard abbreviations may be used, e.g., bp, base pair(s); kb, kilobase(s); pi, picoliter(s); s or sec, second(s); min, minute(s); h or hr, hour(s); aa, amino acid(s); kb, kilobase(s); bp, base pair(s); nt, nucleotide(s); i.m., intramuscular(ly); i.p.,
- TALEN-engineered isogenic human iPSCs that were either WT (wild-type) or Nl +/ ⁇ were derived and characterized as detailed in Theodoris et ah, Cell. 2015;160: 1072-1086.
- Isogenic iPSCs induced pluripotent stem cells
- ECs were differentiated into ECs as previously described (Theodoris et al., 2015; White et al., Stem Cells. 2012;31 :92-103).
- ECs were greater than 90% double-positive for CD31 (BD #558068) and CD144 (#FAB938lP) by FACS (fluorescence-activated cell sorting) analysis (Figures 9G-H). Small molecule experiments (described below) were conducted at day 15 of differentiation.
- ECs were lysed and RNA was isolated using the Qiagen RNeasy 96-well
- the selected 119 target genes included 3 low-expressing housekeeping genes for normalization (CHMP2A, Clorf43, REEP5 ) and either predicted central regulatory nodes or peripheral genes positioned within varied regions of the Nl network to permit identification of small molecules that affected central nodes as well as those that may have a synergistic effect in combination due to regulating different aspects of the network.
- RNA was added to the Precise Encoding Plate containing indexed dT primer, dNTPs, and Spike-in mRNA controls and incubated at 65°C for 3 minutes followed by cooling on ice.
- a master-mix of RT enzyme, RNase inhibitor, and buffer was then added to the samples, and they were incubated at 42°C for 30 minutes followed by 80°C for 5 minutes.
- Each plate of samples was combined into a single 2ml tube and purified with AMPureXP beads.
- Nl PCR master-mix was added and samples were incubated for 94°C for 2 minutes, followed by 15 cycles of 94°C for 30 seconds, 55°C for 3 minutes, and 68°C for 1 minute, followed by 68°C for 7 minutes. Samples were purified with
- AMPureXP beads and N2 PCR master-mix was added. Samples were incubated with the same thermal cycler program as above for 12 cycles. These final libraries were then purified with AMPureXP beads and analyzed for quality and concentration by Agilent Bioanalyzer and Illumina Library Quantification Kit (KAPA Biosystems), respectively. Libraries were normalized to equivalent concentration and pooled for paired-end 100 bp sequencing on an Illumina HiSeq 2500 instrument.
- Sequencing data was analyzed using Cellular Research Precise Analysis Pipeline on the SevenBridges platform, which included analyzing sequencing quality with FASTQC, trimming adapters and filtering reads, demultiplexing based on sample barcodes, aligning reads with Bowtie 2, and determining the number of unique molecular indices per gene.
- Network inference was based on mutual information of gene expression from all DMSO- and small molecule-exposed samples as described in Margolin et ak, BMC Bioinformatics . 2006;7 Suppl l :S7.
- Network diagram was generated using NetworkX (Hagberg et ak, Exploring Network Structure, Dynamics, and Function using NetworkX. SciPy. 2008) based on network connections inferred from the small molecule screen data as described above with colors based on whole transcriptome RNA-seq gene expression of isogenic Nl +/ ⁇ compared to WT ECs.
- RNA-seq of 119 genes was performed in isogenic wild-type ( WT) or Nl +/ iPSC-derived ECs exposed to either DMSO or one of 1595 small molecules.
- the selected 119 target genes were either predicted central regulatory nodes or peripheral genes positioned within varied regions of the Nl network to facilitate identification of small molecules that affected central nodes as well as those that may have a synergistic effect in combination due to regulating different aspects of the network.
- haploinsufficiency and serves as an anti-inflammatory repressor of the GM-CSF promoter.
- KNN hierarchical clustering algorithms
- the KNN algorithm was then applied to the small molecule-exposed ECs to identify small molecules that sufficiently corrected the network gene expression such that treated Nl +/ ⁇ ECs were classified as WT.
- Hierarchical clustering was applied using a complete agglomeration method to identify small molecules that promoted Nl +/ ⁇ ECs to cluster with WT ECs and separately from DMSO- ex posed N I ECs.
- KNN K-nearest neighbors
- Nl +/ ⁇ ECs exposed to one of 1595 small molecules, with the vast majority remaining classified as Nl +/ ⁇ , but eleven molecules sufficiently corrected the network gene expression such that the treated N I ECs were classified as WT ( Figures 1C and 10A-C).
- These network-correcting molecules were Cytochalasin; Fmoc-leu; GSK837149A; RO-4929097; Alprostadil; Norfloxacin; YC-l; CB_l954; L-74l,626; Naloxone benzoylhydrazone; and
- CAVD cardiac aortic valve disease
- additional network-correcting molecules were anti -proliferative, including CB1954 and cytochalasin.
- the network-correcting molecules also included two vasodilating compounds, prostaglandin El (alprostadil) and beta-adrenoreceptor agonist tulobuterol hydrochloride.
- ECs were lysed and RNA was isolated using the Qiagen RNeasy Micro
- RNA-seq libraries were constructed using the Clontech SMRTer Stranded RNA-seq Library Prep Kit for Illumina per kit protocol. Libraries were analyzed by Agilent Bioanalyzer, normalized to equivalent concentration, pooled, gel purified, and sequenced 75 bp paired-end on an Illumina NextSeq instrument with 10% PhiX. [00266] Sequencing quality was assessed with FASTQC (located on the web by placing “www.” in front of“bioinformatics.babraham.ac.uk/projects/fastqc/”).
- GO analyses were completed using GO-Elite and ToppGene (Chen et al., Nucleic Acids Research. 2009;37:W305-W3 l l; Zambon et al., Bioinformatics. 2012;28:2209-2210).
- Network diagrams were generated using NetworkX (Hagberg et al., SciPy. 2008) based on network connections inferred from mRNA-seq gene expression of isogenic N I compared to WT ECs with colors based on whole transcriptome RNA-seq gene expression of DMSO- vs small molecule-treated WT and N I ECs.
- RNA-seq was performed to determine the effect of the identified network- correcting small molecules on the transcriptional landscape as a whole ( Figure 2A).
- XCT790 was the most effective at repressing genes aberrantly activated in Nl-haploinsufficient ECs, including those genes involved in extracellular matrix for elasticity, cell motility, arterial thrombosis, T cell signaling, and peroxisomes.
- TG003 was also broadly effective at repressing these genes, albeit to a lesser degree, with less effect specifically on peroxisome-related genes.
- Cytochalasin was effective at downregulating arterial thrombosis and T cell signal genes, but worsened the dysregulation of cell motility genes.
- XCT790, TG003, and cytochalasin had the strongest repressive effect on cadherin-l 1, repression of which prevents CAVD in Nl +/ mice exposed to high fat diet (Figure 9A).
- XCT790 also effectively restored the transcription of mesoderm and cell cycle checkpoint genes, and GSK837149A restored transcription of a complementary group of genes involved in angiogenesis and cardiovascular development.
- XCT790 was most effective at restoring both aberrantly activated and repressed genes, and XCT790-treated ECs correlated most strongly with the transcriptional profile of WT ECs ( Figure 2B).
- XCT790 Conversely, GSK837149A restored more complementary genes to XCT790 including inflammatory regulator CEACAM1 and INK signaling factor NRK.
- mice were treated with XCT790 (5mg/kg/day), TG003 (0.3mg/kg/day or 2mg/kg/day, results pooled for analysis), Fmoc-leu (0.6mg/kg/day), GSK837149A (4.5 mg/kg/day), biperiden (10 mg/kg/day), CB1954 (15 mg/kg/day), putrescine (0.26 mg/kg/day), naloxone
- RO4929097 60 mg/kg/day
- oral gavage or equivalent volume of solvent (DMSO or saline) for four weeks starting at the fourth postnatal week.
- Echocardiography was performed under isofluorane anesthesia with standard measurement techniques using the Vevo 770 Imaging System (VisualSonics) equipped with an RMV-707B transducer with central frequency of 30 MHz. Peak blood flow velocity through AVs and PVs was obtained by pulsed wave Doppler in the modified parasternal long and short axis views. The average of three cardiac cycles was used for each measurement.
- VisualSonics Vevo 770 Imaging System
- Hearts were fixed by perfusion fixation under anesthesia using isofluorane by ventricular KC1 injection followed by PBS wash and fixation with 4%
- Nl +/ ⁇ mice with shortened telomeres develop age-dependent AV and pulmonary valve (PV) stenosis, mimicking the range of human disease caused by Nl
- mice with shortened telomeres generation 2 (G2) mice lacking telomerase activity due to mutations in the telomerase RNA component Terc ( mTR )
- G2 mice with shortened telomeres generation 2 mice
- XCT790 significantly prevented PV stenosis
- both XCT790 and TG003 showed a trend of reducing AV calcification in Nl +/ /mTR G2 mice.
- the network-based drug screen thus effectively identified network- correcting molecules promising for preventing cardiac valve disease in vivo.
- ARACNE an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics. 2006;7 Suppl 1 :S7.
- NESK a Member of the Germinal Center Kinase Family That Activates the c-Jun N-terminal Kinase Pathway and Is Expressed during the Late Stages of Embry ogenesis. JBiol Chem. 2000;275:20533- 20539. Foffa I, Ait Ali L, Panesi P, Mariani M, Festa P, Botto N, Vecoli C, Andreassi MG. Sequencing of NOTCH1, GATA5, TGFBR1 and TGFBR2 genes in familial cases of bicuspid aortic valve. BMC Med Genet. 2013; 14:44. 27.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present disclosure provides methods of treating cardiac valve disease, e.g., calcific aortic valve disease (CAVD), by administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Formulae I-X or a pharmaceutically acceptable salt, solvate or prodrug thereof. Also provided are methods of identifying a candidate compound for treatment of cardiac valve disease, e.g., CAVD.
Description
METHODS FOR TREATING CARDIAC VALVE DISEASE
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims benefit under 35 U.S.C. § 119(e) of provisional application
62/721,389, filed August 22, 2018, which application is hereby incorporated by reference in its entirety.
INTRODUCTION
[0002] Determining the gene regulatory networks driving human disease allows the design of therapies targeting the underlying disease mechanism rather than mere symptomatic management. Mapping the architecture of the dysregulated network enables screening for molecules that correct the network’s core regulatory elements as opposed to peripheral downstream effectors that will likely have only limited influence on the disease process. Identifying molecules that target key regulatory nodes focuses efforts on molecules that will ultimately have the broadest corrective effects on the entire network and therefore the largest impact on the disease as a whole.
[0003] Small molecules are traditionally screened for their effects on one to several outputs at most, from which their predicted efficacy on the disease as a whole is extrapolated. Whole transcriptome RNA sequencing (RNA-seq) would provide the most complete information about the effect of each small molecule on the transcriptome of the cells of interest, but its costliness prohibits its use for high-throughput drug screening. By contrast, the advent of targeted RNA-seq methods, which are significantly less costly as they focus sequencing on select transcripts of interest, permits high-throughput screening for network-correcting molecules by determining their effect on 100-200 transcripts within the disease network.
[0004] Calcific aortic valve disease (CAVD), the third leading cause of adult heart disease, is a progressive disorder that ranges from mild valve thickening without obstruction of blood flow, termed aortic sclerosis, to severe calcification with impaired leaflet motion, termed aortic stenosis. Neurogenic locus notch homolog protein 1 (NOTCH1) (Nl) is a human membrane-bound transcription factor, and Nl haploinsufficiency (Nl+/ ), in which a
single functional copy of the Nl gene is present, has been identified as a cause of CAVD. The only current treatment for CAVD is valve transplant, necessitating over 100,000 valve transplants annually in the United States alone. Given that valve calcification progresses over time, there is an opportunity to intervene with a
preventative medical therapy if one were elucidated. The present disclosure addresses the above issues and provides related advantages.
SUMMARY OF THE INVENTION
[0005] The present disclosure provides methods of treating cardiac valve disease, e.g., calcific aortic valve disease (CAVD), by administering to a subject in need thereof a
therapeutically effective amount of a compound of any one of Formulae I-X or a pharmaceutically acceptable salt, solvate or prodrug thereof. Also provided are methods of identifying a candidate compound for treatment of cardiac valve disease, e.g., CAVD.
BRIEF DESCRIPTION OF THE DRAWINGS
[0006] Figure 1A depicts a map of gene network dysregulation by Nl haploinsufficiency (from targeted RNA-seq).
[0007] Figure IB depicts a principle components analysis (PC A) plot of gene expression in WT or Nl+/ ECs (from targeted RNA-seq). The line through the graph divides WT+DMSO data points on the right and Nl+/ +DMSO data points on the left.
[0008] Figure 1C depicts a PCA plot of gene expression in Nl+/~ ECs treated with one of 1595 small molecules compared to Nl+/~ or WT ECs exposed to DMSO (from targeted RNA- seq). Squares indicate molecule-treated Nl+/~ whose network transcription was corrected sufficiently to classify as WT by the KNN algorithm.
[0009] Figure ID depicts a hierarchical clustering of transcriptional profiles of Nl+/~ ECs
treated with each of the small molecules (from LOP AC library plate 9 of 16) compared to Nl+/~ or WT ECs exposed to DMSO (from targeted RNA-seq).
[0010] Figure IE depicts percent of targeted RNA-seq validation replicates that classified as WT with true identities of DMSO-exposed WT, DMSO-exposed Nl , or small molecule-treated Nl (from targeted RNA-seq).
[0011] Figure 2A depicts the effect of network-correcting molecules on genes dysregulated in Nl+/~ ECs (from whole transcriptome RNA-seq). Gene ontology (GO) pathways enriched in each gene cluster are indicated to the right.
[0012] Figure 2B depicts correlation of gene expression in WT ECs with gene expression in Nl+/~ ECs exposed to DMSO or network-correcting molecules (from whole
transcriptome RNA-seq).
[0013] Figure 2C depicts correlation of Nl -dependent gene expression by siRNA repression of SOX7 and TCF4 regulatory nodes, which are upregulated by Nl haploinsufficiency (from whole transcriptome RNA-seq).
[0014] Figure 2D depicts the repression of SOX7 and TCF4 regulatory nodes by network- correcting molecules (from whole transcriptome RNA-seq).
[0015] Figure 2E depicts the extent of Nl -dependent network restoration in Nl+/~ ECs treated with network-correcting molecules or siRNA targeting SOX7 and TCF4 (from whole transcriptome RNA-seq). Positive values indicate correction towards or past WT expression level. Negative values indicate worsened dysregulation.
[0016] Figure 3A depicts the percent correction of nodes within the Nl -dependent network to WT expression levels in N I ECs treated with network-correcting molecules or siRNA targeting SOX7 and TCF4.
[0017] Figure 3B depicts the number of N l+/ YmTR02 mice with calcified AVs by Alizarin red staining after treatment with TG003 (2 of 38) or DMSO (14 of 86) (p=0.09, X2 test).
[0018] Figure 3C depicts the percentage of the AV calcified by Alizarin red staining in
Nl+/ /mTRG2 mice treated with TG003 (n=2) or DMSO (n=l4) (p=0.09, one-sided t- test). Error bars represent standard error.
[0019] Figure 3D depicts AV peak velocity by echocardiography in Nl+/ lmTRG2 mice treated with XCT790 (n=l7) or DMSO (n=86) (p=0.17, one-sided t-test). Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
[0020] Figure 3E depicts PV peak velocity by echocardiography in Nl+/ lmTRG2 mice treated with XCT790 (n=l7) or DMSO (n=86) (p=0.00l, one-sided t-test). Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
[0021] Figure 4A depicts a histogram of the number of network connections of each node within the Nl -dependent gene network as mapped by network inference based on targeted RNA-seq data.
[0022] Figure 4B depicts the top 20 most connected nodes in the Nl -dependent gene network ordered from greatest to least valent.
[0023] Figure 5 A depicts a hierarchical clustering of transcriptional profiles of Nl+/~ ECs
treated with each of the small molecules (from LOP AC library plate 1 of 16) compared to Nl+/~ or WT ECs exposed to DMSO.
[0024] Figure 5B depicts a hierarchical clustering of transcriptional profiles of Nl+/~ ECs
treated with each of the small molecules (from LOP AC library plate 4 of 16) compared to Nl+/~ or WT ECs exposed to DMSO.
[0025] Figure 6 A depicts a hierarchical clustering of transcriptional profiles of Nl+/~ ECs
treated with each of the small molecules (from LOP AC library plate 7 of 16) compared to Nl+/~ or WT ECs exposed to DMSO.
[0026] Figure 6B depicts a hierarchical clustering of transcriptional profiles of Nl+/~ ECs
treated with each of the small molecules (from LOP AC library plate 8 of 16) compared to Nl+/~ or WT ECs exposed to DMSO.
[0027] Figure 7 A depicts a hierarchical clustering of transcriptional profiles of Nl+/~ ECs
treated with each of the small molecules (from LOP AC library plate 12 of 16) compared to Nl+/~ or WT ECs exposed to DMSO.
[0028] Figure 7B depicts a hierarchical clustering of transcriptional profiles of Nl+/~ ECs
treated with each of the small molecules (from LOP AC library plate 13 of 16) compared to Nl+/~ or WT ECs exposed to DMSO.
[0029] Figure 8 A depicts a hierarchical clustering of transcriptional profiles of Nl+/~ ECs
treated with each of the small molecules (from LOP AC library plate 14 of 16) compared to Nl+/~ or WT ECs exposed to DMSO.
[0030] Figure 8B depicts a hierarchical clustering of transcriptional profiles of Nl+/~ ECs
treated with each of the small molecules (from LOP AC library plate 3 of 16) compared to Nl+/~ or WT ECs exposed to DMSO. No small molecules from LOP AC library plate 3 sufficiently restored the transcriptional profile of Nl+/~ ECs such that they clustered with WT ECs.
[0031] Figure 9A depicts Cadherin 11 mRNA expression by whole transcriptome RNA-seq in Nl+/~ ECs treated with each network-correcting small molecule compared to N I
or WT ECs exposed to DMSO. Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median.
[0032] Figure 9B depicts SOX7 or TCF4 mRNA expression by whole transcriptome RNA-seq in A'7 ECs treated with siRNA targeting SOX7 and TCF4 compared to N 1
or WT ECs treated with control siRNA. Error bars represent standard error.
[0033] Figure 9C depicts AV peak velocity by echocardiography in Nl+/ lmTRG2 mice treated with TG003 (n=38) or DMSO (n=86) (p=0.22, one-sided t-test). Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
[0034] Figure 9D depicts PV peak velocity by echocardiography in Nl+/ lmTRG2 mice treated with TG003 (n=38) or DMSO (n=86) (p=0.83, one-sided t-test). Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
[0035] Figure 9E depicts the number of N l+/ 7mTRG2 mice with calcified AVs by Alizarin red staining after treatment with XCT790 (1 of 17) or DMSO (14 of 86) (p=0.27, X2 test).
[0036] Figure 9F depicts the percentage of the AV calcified by Alizarin red staining in
Nl+/ /mTRG2 mice treated with XCT790 (n=l) or DMSO (n=l4). Error bars represent standard error.
[0037] Figure 9G depicts representative FACS analysis of unstained CD31/CD144 double positive iPSC-derived ECs on day 13 of differentiation.
[0038] Figure 9H depicts representative FACS analysis of stained CD31/CD144 double
positive iPSC-derived ECs on day 13 of differentiation.
[0039] Figure 10A depicts 37 network-correcting molecule candidates identified by KNN and hierarchical clustering algorithms.
[0040] Figure 10B depicts the activity of 15 of 37 network-correcting molecule candidates identified by KNN and hierarchical clustering algorithms.
[0041] Figure 10C depicts the activity of 22 of 37 network-correcting molecule candidates identified by KNN and hierarchical clustering algorithms.
[0042] Figure 11 A depicts AV peak velocity and PV peak velocity by echocardiography in a small initial cohort of Nl+/ lmTRG2 mice treated with Fmoc-leu or DMSO. Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
[0043] Figure 11B depicts AV max thickness and PV max thickness in a small initial cohort of Nl+/ 1mTRG2 mice treated with Fmoc-leu or DMSO.
[0044] Figure 11C (left/top) depicts the number of N1
m l'Rr’2 mice with calcified AVs by Alizarin red staining after treatment with Fmoc-leu or DMSO for a small initial cohort. Figure 11C (right/bottom) depicts the percentage of the AV calcified by Alizarin red staining in Nl+/ /mTRG2 mice treated with Fmoc-leu or DMSO for a small initial cohort.
[0045] Figure 12A depicts AV peak velocity and PV peak velocity by echocardiography in a small initial cohort of Nl+/ lmTRG2 mice treated with naloxone or saline. Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
[0046] Figure 12B depicts AV max thickness and PV max thickness in a small initial cohort of Nl+/ lmTRG2 mice treated with naloxone or saline.
[0047] Figure 12C depicts the number of Nl+/ /mTRG2 mice with calcified AVs by Alizarin red staining after treatment with naloxone or saline for a small initial cohort.
[0048] Figure 13 depicts AV peak velocity and PV peak velocity by echocardiography in a small initial cohort of Nl+/ lmTRG2 mice treated with putrescine + CB1954 or DMSO. Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
[0049] Figure 14 depicts AV peak velocity and PV peak velocity by echocardiography in a small initial cohort of Nl+/ hnTRG2 mice treated with RO4929097 or DMSO. Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
[0050] Figures 15A and 15B depict AV peak velocity and PV peak velocity by echocardiography in a small initial cohort of Nl+/ lmTRG2 mice treated with
GSK837149A or DMSO. Boxes represent the interquartile range, whiskers represent the range, and the solid horizontal line represents the median. Circular dots represent females and diamonds represent males.
DEFINITIONS
[0051] As used herein, the terms“treatment,”“treating,” and the like, refer to obtaining a
desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse affect attributable to the disease.“Treatment,” as used herein, covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease.
[0052] The terms“individual,”“subject,”“host,” and“patient,” used interchangeably herein, refer to a mammal, including, but not limited to, murines (rats, mice), non-human primates, humans, canines, felines, ungulates (e.g., equines, bovines, ovines, porcines, caprines), etc.
[0053] A“therapeutically effective amount” or“efficacious amount” means the amount of a compound that, when administered to a mammal or other subject for treating a disease, is sufficient to effect such treatment for the disease. The“therapeutically effective amount” may vary depending on the compound, the disease and its severity and the age, weight, etc., of the subject to be treated.
[0054] As used herein, the term“stem cell” refers to an undifferentiated cell that can be induced to proliferate. The stem cell is capable of self-maintenance, meaning that with each cell division, one daughter cell will also be a stem cell. Stem cells can be obtained from embryonic, post-natal, juvenile or adult tissue. The term“progenitor cell”, as used herein, refers to an undifferentiated cell derived from a stem cell, and is not itself a stem
cell. Some progenitor cells can produce progeny that are capable of differentiating into more than one cell type.
[0055] The term“induced pluripotent stem cell” (or“iPS cell”), as used herein, refers to a
pluripotent stem cell induced from a somatic cell, e.g., a differentiated somatic cell. iPS cells are capable of self-renewal and differentiation into cell fate-committed stem cells, including neural stem cells, as well as various types of mature cells.
DEFINITION OF SELECT CHEMICAL TERMINOLOGY
[0056] The nomenclature of certain compounds or substituents are used in their conventional sense, such as described in chemistry literature including but not limited to Loudon, Organic Chemistry, Fourth Edition, New York: Oxford University Press, 2002, pp. 360- 361, 1084-1085; Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-Interscience, 2001.
[0057] As used herein, the term“alkyl” by itself or as part of another substituent refers to a saturated branched or straight-chain monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane. Typical alkyl groups include, but are not limited to, methyl; ethyl, propyls such as propan- l-yl or propan-2-yl; and butyls such as butan-l-yl, butan-2-yl, 2-methyl-propan- l-yl or
2-methyl-propan-2-yl. In some embodiments, an alkyl group comprises from 1 to 20 carbon atoms. In other embodiments, an alkyl group comprises from 1 to 10 carbon atoms. In still other embodiments, an alkyl group comprises from 1 to 6 carbon atoms, such as from 1 to 4 carbon atoms.
[0058]“Alkanyl” by itself or as part of another substituent refers to a saturated branched,
straight-chain or cyclic alkyl radical derived by the removal of one hydrogen atom from a single carbon atom of an alkane. Typical alkanyl groups include, but are not limited to, methanyl; ethanyl; propanyls such as propan-l-yl, propan-2-yl (isopropyl), cyclopropan- l-yl, etc.; butanyls such as butan-l-yl, butan-2-yl (sec-butyl), 2-methyl-propan- l-yl (isobutyl), 2-methyl-propan -2-yl (t-butyl), cyclobutan-l-yl, etc.; and the like.
[0059]“Alkylene” refers to a branched or unbranched saturated hydrocarbon chain, usually having from 1 to 40 carbon atoms, more usually 1 to 10 carbon atoms and even more usually 1 to 6 carbon atoms. This term is exemplified by groups such as methylene (-
CH2-), ethylene (-CH2CH2-), the propylene isomers (e.g., -CH2CH2CH2- and
-CH(CH3)CH2-) and the like.
[0060]“Alkenyl” by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom of an alkene. The group may be in either the cis or trans conformation about the double bond(s).
Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-l- en-l-yl, prop-l-en-2-yl, prop-2-en-l-yl (allyl), prop-2-en-2-yl, cycloprop-l-en-l-yl; cycloprop-2-en-l-yl; butenyls such as but-l-en-l-yl, but-l-en-2-yl, 2-methyl -prop- l-en- l-yl, but-2-en-l-yl, but-2-en-l-yl, but-2-en-2-yl, buta-l,3-dien-l-yl, buta-l,3-dien-2-yl, cyclobut-l-en-l-yl, cyclobut-l-en-3-yl, cyclobuta-l,3-dien-l-yl, etc.; and the like.
[0061]“Alkynyl” by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of an alkyne. Typical alkynyl groups include, but are not limited to, ethynyl; propynyls such as prop- l-yn-l-yl, prop-2-yn-l-yl, etc.; butynyls such as but-l-yn-l-yl, but-l-yn-3-yl, but-3-yn- l-yl, etc.; and the like.
[0062]“Acyl” by itself or as part of another substituent refers to a radical -C(0)R30, where R30 is hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroaryl alkyl as defined herein and substituted versions thereof. Representative examples include, but are not limited to formyl, acetyl, cyclohexyl carbonyl,
cyclohexylmethylcarbonyl, benzoyl, benzylcarbonyl, piperonyl, succinyl, and malonyl, and the like.
[0063] The term“aminoacyl” refers to the group -C(0)NR21R22, wherein R21 and R22
independently are selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic and where R21 and R22 are optionally joined together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl,
substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
[0064]“Alkoxy” by itself or as part of another substituent refers to a radical -OR31 where R31 represents an alkyl or cycloalkyl group as defined herein. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclohexyloxy and the like.
[0065]“Alkoxycarbonyl” by itself or as part of another substituent refers to a radical -C(0)OR31 where R31 represents an alkyl or cycloalkyl group as defined herein. Representative examples include, but are not limited to, methoxycarbonyl, ethoxycarbonyl,
propoxycarbonyl, butoxycarbonyl, cyclohexyloxycarbonyl and the like.
[0066]“Aryl” by itself or as part of another substituent refers to a monovalent aromatic
hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of an aromatic ring system. Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2, 4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene and the like. In certain embodiments, an aryl group comprises from 6 to 20 carbon atoms. In certain embodiments, an aryl group comprises from 6 to 12 carbon atoms. Examples of an aryl group are phenyl and naphthyl.
[0067]“Arylalkyl” by itself or as part of another substituent refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with an aryl group. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-l-yl, 2-phenylethen-l-yl, naphthylmethyl, 2- naphthylethan-l-yl, 2-naphthylethen-l-yl, naphthobenzyl, 2-naphthophenylethan-l-yl and the like. Where specific alkyl moieties are intended, the nomenclature arylalkanyl, arylalkenyl and/or arylalkynyl is used. In certain embodiments, an arylalkyl group is (C7-C30) arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C1-C10) and the aryl moiety is (C6-C20). In certain embodiments, an arylalkyl group is
(C7-C20) arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (Ci-C8) and the aryl moiety is (C6-Ci2).
[0068]“Arylaryl” by itself or as part of another substituent, refers to a monovalent hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a ring system in which two or more identical or non-identical aromatic ring systems are joined directly together by a single bond, where the number of such direct ring junctions is one less than the number of aromatic ring systems involved. Typical arylaryl groups include, but are not limited to, biphenyl, triphenyl, phenyl-napthyl, binaphthyl, biphenyl-napthyl, and the like. When the number of carbon atoms in an arylaryl group are specified, the numbers refer to the carbon atoms comprising each aromatic ring. For example, (C5-C14) arylaryl is an arylaryl group in which each aromatic ring comprises from 5 to 14
carbons, e.g., biphenyl, triphenyl, binaphthyl, phenylnapthyl, etc. In certain
embodiments, each aromatic ring system of an arylaryl group is independently a (C5-C14) aromatic. In certain embodiments, each aromatic ring system of an arylaryl group is independently a (C5-C10) aromatic. In certain embodiments, each aromatic ring system is identical, e.g., biphenyl, triphenyl, binaphthyl, trinaphthyl, etc.
[0069]“Cycloalkyl” by itself or as part of another substituent refers to a saturated or
unsaturated cyclic alkyl radical. Where a specific level of saturation is intended, the nomenclature“cycloalkanyl” or“cycloalkenyl” is used. Typical cycloalkyl groups include, but are not limited to, groups derived from cyclopropane, cyclobutane, cyclopentane, cyclohexane and the like. In certain embodiments, the cycloalkyl group is (C3-C10) cycloalkyl. In certain embodiments, the cycloalkyl group is (C3-C7) cycloalkyl.
[0070]“Cycloheteroalkyl” or“heterocyclyl” by itself or as part of another substituent, refers to a saturated or unsaturated cyclic alkyl radical in which one or more carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatom. Typical heteroatoms to replace the carbon atom(s) include, but are not limited to, N, P, O, S, Si, etc. Where a specific level of saturation is intended, the nomenclature“cycloheteroalkanyl” or“cycloheteroalkenyl” is used. Typical
cycloheteroalkyl groups include, but are not limited to, groups derived from epoxides, azirines, thiiranes, imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine and the like.
[0071]“Heteroalkyl, Heteroalkanyl, Heteroalkenyl and Heteroalkynyl” by themselves or as part of another substituent refer to alkyl, alkanyl, alkenyl and alkynyl groups, respectively, in which one or more of the carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatomic groups. Typical heteroatomic groups which can be included in these groups include, but are not limited to, -0-, -S-, -S-S-, -0-S-, -NR37R38-, =N-N=, -N=N-, -N=N-NR39R40, -PR41-, -P(0)2-, - POR42-, -0-P(0)2-, -S-0-, -S-(O)-, -S02-, -SnR43R44- and the like, where R37, R38, R39, R40, R41, R42, R43 and R44 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroaryl alkyl or substituted heteroarylalkyl.
[0072]“Heteroaryl” by itself or as part of another substituent, refers to a monovalent
heteroaromatic radical derived by the removal of one hydrogen atom from a single atom of a heteroaromatic ring system. Typical heteroaryl groups include, but are not limited to, groups derived from acridine, arsindole, carbazole, b-carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, benzodioxole and the like. In certain
embodiments, the heteroaryl group is from 5-20 membered heteroaryl. In certain embodiments, the heteroaryl group is from 5-10 membered heteroaryl. In certain embodiments, heteroaryl groups are those derived from thiophene, pyrrole,
benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole, oxazole and pyrazine.
[0073]“Heteroarylalkyl” by itself or as part of another substituent, refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with a heteroaryl group. Where specific alkyl moieties are intended, the nomenclature heteroarylalkanyl, heteroarylalkenyl and/or heterorylalkynyl is used. In certain embodiments, the heteroarylalkyl group is a 6-30
membered heteroarylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the
heteroarylalkyl is 1-10 membered and the heteroaryl moiety is a 5-20-membered heteroaryl. In certain embodiments, the heteroarylalkyl group is 6-20 membered heteroarylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the heteroarylalkyl is 1-8 membered and the heteroaryl moiety is a 5-l2-membered heteroaryl.
[0074]“Aromatic Ring System” by itself or as part of another substituent, refers to an
unsaturated cyclic or polycyclic ring system having a conjugated p electron system. Specifically included within the definition of“aromatic ring system” are fused ring systems in which one or more of the rings are aromatic and one or more of the rings are saturated or unsaturated, such as, for example, fluorene, indane, indene, phenalene, etc. Typical aromatic ring systems include, but are not limited to, aceanthrylene,
acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2, 4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene and the like.
[0075]“Heteroaromatic Ring System” by itself or as part of another substituent, refers to an aromatic ring system in which one or more carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatom. Typical heteroatoms to replace the carbon atoms include, but are not limited to, N, P, O, S, Si, etc. Specifically included within the definition of“heteroaromatic ring systems” are fused ring systems in which one or more of the rings are aromatic and one or more of the rings are saturated or unsaturated, such as, for example, arsindole, benzodioxan, benzofuran, chromane, chromene, indole, indoline, xanthene, etc. Typical
heteroaromatic ring systems include, but are not limited to, arsindole, carbazole, b- carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine,
phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline,
quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene and the like.
[0076]“ Substituted” refers to a group in which one or more hydrogen atoms are independently replaced with the same or different substituent(s). Typical substituents include, but are not limited to, alkylenedioxy (such as methylenedioxy), -M, -R60, -O , =0, -OR60, -SR60,
-C(NR62)NR60R61 where M is halogen; R60, R61, R62 and R63 are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R60 and R61 together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring; and R64 and R65 are independently hydrogen, alkyl, substituted alkyl, aryl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R64 and R65 together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring. In certain embodiments, substituents include -M, -R60, =0, -OR60, -SR60, -S , =S, -NR60R61, =NR60, -CF3, -CN, -OCN, -SCN, -NO, -N02,=N2, -Ns,
)(OR61),
In certain embodiments, substituents include -M, -R60, =0, -OR60, -SR60, -NR60R61, -CF3, -CN, -N02, -S(0)2R60, -P(O)(OR60)(O ), -OP(O)(OR60)(OR61), -C(0)R60, -C(0)OR60,
-C(O)NR60R61,-C(O)O . In certain embodiments, substituents include -M, -R60,=O, -OR60, -SR60, -NR60R61, -CFS, -CN, -N02, -S(0)2R6°, -OP(O)(OR60)(OR61), -C(0)R60, -C(0)OR60 ,-C(0)0 , where R60, R61 and R62 are as defined above. For example, a substituted group may bear a methylenedioxy substituent or one, two, or three substituents selected from a halogen atom, a (l-4C)alkyl group and a (l-4C)alkoxy group.
[0077] The compounds described herein can contain one or more chiral centers and/or double bonds and therefore, can exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers or diastereomers. Accordingly, all possible enantiomers and stereoisomers of the compounds including the stereoisomerically pure form (e.g., geometrically pure, enantiomerically pure or diastereomerically pure) and enantiomeric and stereoisomeric mixtures are included in the description of the compounds herein. Enantiomeric and stereoisomeric mixtures can be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the skilled artisan. The compounds can also exist in several tautomeric forms including the enol form, the keto form and mixtures thereof. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated compounds. The compounds described also include isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass conventionally found in nature. Examples of isotopes that can be incorporated into the compounds disclosed herein include, but are not limited to, 2H, ¾, UC, 13C, 14C, 15N, 180, 170, etc. Compounds can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, compounds can be hydrated or solvated. Certain compounds can exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of the present disclosure.
[0078] Before aspects of the present disclosure are further described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
[0079] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also
encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
[0080] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.
[0081] It must be noted that as used herein and in the appended claims, the singular forms“a,” “an,” and“the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any recited element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as“solely,”“only” and the like in connection with the recitation of claim elements, or use of a“negative” limitation.
[0082] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
DETAILED DESCRIPTION
[0083] Whereas molecules discovered in animal models do not always translate to humans, induced pluripotent stem cell (iPSC) technology allows drug discovery in human iPSC- derived cells generated directly from patients affected by the disease.
[0084] A network-based drug screen was performed to identify small molecules that corrected the gene network dysregulated by Nl haploinsufficiency in human iPSC-derived endothelial cells (ECs) from patients affected by CAVD. Molecules targeting
atherosclerotic and osteogenic pathways had the largest corrective impact on the network. Their effects mimicked that of siRNA inhibition of SOX7 and TCF4, two key
regulatory nodes upregulated in Nl haploinsufficient ECs. Select compounds reduced Nl -dependent cardiac valve disease in vivo in mice. In sum, network-based screening distinguishes molecules with broadly restorative effects on gene networks dysregulated in human disease that may thus represent promising candidates for treating the disease as a whole.
[0085] The present disclosure provides methods of treating cardiac valve disease, e.g., CAVD, by administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Formulae I-X or a pharmaceutically acceptable salt, solvate or prodrug thereof. Also provided are methods of identifying a candidate compound for treatment of cardiac valve disease, e.g., CAVD.
METHODS OF TREATING CARDIAC VALVE DISEASE
[0086] The present disclosure provides methods for treating cardiac valve disease, e.g., CAVD, by administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Formulas I-X or a pharmaceutically acceptable salt, solvate or prodrug thereof. Methods for treating cardiac valve disease, e.g., CAVD, by
administering a combination of compounds selected from Formulas I-X are also contemplated.
Compounds for Treating Cardiac Valve Disease and Pharmaceutically Acceptable Salts and Derivatives Thereof
Compounds of Formula I
[0087] Compositions which find use in the methods of the present disclosure can include
compounds of Formula I, shown below, which formula encompasses XCT-790 (2E-3-(4- {[2,4-bis(trifluoromethyl)benzyl]oxy}-3-methoxyphenyl)-2-cyano-N-[5- (trifluoromethyl)-l,3,4-thiadiazol-2-yl]acrylamide) and pharmaceutically acceptable salts and derivatives thereof.
[0088] In one aspect, the disclosed methods include administration of a compound of Formula I:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
n is an integer from 1 to 8;
X is O or S;
Y is O or S; and
each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR12, -C(0)0R12, -C(0)NR12R13, -C=NR12, - OR12, -0C(0)R12, -S(0)t-R7, -NR12R13, -NR12C(0)R13, -N=CR12R13, wherein t is 0, 1, 2 or 3 and R12 and R13 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
[0089] In some embodiments, n is 1. In other embodiments, n is 2. In other embodiments, n is 3. In other embodiments, n is 4. In other embodiments, n is 5. In other embodiments, n is 6. In other embodiments, n is 7. In other embodiments, n is 8.
[0090] In some embodiments, X is O. In other embodiments, X is S. In some embodiments, Y is O. In other embodiments, Y is S. In some instances, X is O and Y is O. In other instances, X is O and Y is S. In other embodiments, X is S and Y is O. In other embodiments, X is S and Y is S.
[0091] In some embodiments, R1 is cyano. In some embodiments, R1 is hydrogen. In other embodiments, R1 is alkyl or substituted alkyl. In other embodiments, R1 is aryl or substituted aryl. In other embodiments, R1 is heterocycloalkyl or substituted
heterocycloalkyl. In other embodiments, R1 is heteroaryl or substituted heteroaryl. In other embodiments, R1 is hydroxyl, alkoxyl or substituted alkoxyl. In other
embodiments, R1 is acyloxy or substituted acyloxy. In other embodiments, R1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R1 is acyl or substituted acyl. In other embodiments, R1 is thiol. In other embodiments, R1 is amino or substituted amino. In other embodiments, R1 is aminoacyl or substituted aminoacyl. In other embodiments, R1 is azido. In other embodiments, R1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R1 is nitro. In certain embodiments, R1 is naphthyl.
[0092] In some embodiments, R2 is hydrogen. In other embodiments, R2 is alkyl or substituted alkyl. In other embodiments, R2 is aryl or substituted aryl. In other embodiments, R2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R2 is heteroaryl or substituted heteroaryl. In other embodiments, R2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R2 is acyloxy or substituted acyloxy. In other embodiments, R2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R2 is acyl or substituted acyl. In other embodiments, R2 is thiol. In other embodiments, R2 is amino or substituted amino. In other embodiments, R2 is aminoacyl or substituted aminoacyl. In other embodiments, R2 is azido. In other embodiments, R2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R2 is cyano. In other embodiments, R2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R2 is nitro.
[0093] In some embodiments, R3 is hydrogen. In other embodiments, R3 is alkyl or substituted alkyl. In other embodiments, R3 is aryl or substituted aryl. In other embodiments, R3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R3 is heteroaryl or substituted heteroaryl. In other embodiments, R3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R3 is acyloxy or substituted acyloxy. In other embodiments, R3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R3 is acyl or substituted acyl. In other embodiments, R3 is thiol. In other embodiments, R3 is amino or substituted amino. In other embodiments, R3 is aminoacyl or substituted aminoacyl. In other embodiments, R3 is azido. In other embodiments, R3
is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R3 is cyano. In other embodiments, R3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R3 is chloro.
[0094] In some embodiments, R4 is hydrogen. In other embodiments, R4 is alkyl or substituted alkyl. In other embodiments, R4 is aryl or substituted aryl. In other embodiments, R4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R4 is heteroaryl or substituted heteroaryl. In other embodiments, R4 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R4 is acyloxy or substituted acyloxy. In other embodiments, R4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R4 is acyl or substituted acyl. In other embodiments, R4 is thiol. In other embodiments, R4 is amino or substituted amino. In other embodiments, R4 is aminoacyl or substituted aminoacyl. In other embodiments, R4 is azido. In other embodiments, R4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R4 is cyano. In other embodiments, R4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R4 is nitro.
[0095] In some embodiments, R5 is hydrogen. In other embodiments, R5 is alkyl or substituted alkyl. In other embodiments, R5 is aryl or substituted aryl. In other embodiments, R5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R5 is heteroaryl or substituted heteroaryl. In other embodiments, R5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R5 is acyloxy or substituted acyloxy. In other embodiments, R5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R5 is acyl or substituted acyl. In other embodiments, R5 is thiol. In other embodiments, R5 is amino or substituted amino. In other embodiments, R5 is aminoacyl or substituted aminoacyl. In other embodiments, R5 is azido. In other embodiments, R5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R5 is cyano. In other embodiments, R5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R5 is nitro.
[0096] In some embodiments, R6 is alkoxy, such as methoxy or ethoxy. In other embodiments, R6 is hydrogen. In other embodiments, R6 is alkyl or substituted alkyl. In other embodiments, R6 is aryl or substituted aryl. In other embodiments, R6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R6 is heteroaryl or substituted
heteroaryl. In other embodiments, R6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R6 is acyloxy or substituted acyloxy. In other embodiments, R6 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R6 is acyl or substituted acyl. In other embodiments, R6 is thiol. In other embodiments, R6 is amino or substituted amino. In other embodiments, R6 is aminoacyl or substituted aminoacyl. In other embodiments, R6 is azido. In other embodiments, R6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R6 is cyano. In other embodiments, R6 is a halogen, such as -F, -Cl, -Br and -I. In other
embodiments, R6 is nitro. In certain embodiments, R6 is alkoxylcarbonyl, such as ethoxycarbonyl.
[0097] In some embodiments, R7 is hydrogen. In other embodiments, R7 is alkyl or substituted alkyl. In other embodiments, R7 is aryl or substituted aryl. In other embodiments, R7 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R7 is heteroaryl or substituted heteroaryl. In other embodiments, R7 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R7 is acyloxy or substituted acyloxy. In other embodiments, R7 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R7 is acyl or substituted acyl. In other embodiments, R7 is thiol. In other embodiments, R7 is amino or substituted amino. In other embodiments, R7 is aminoacyl or substituted aminoacyl. In other embodiments, R7 is azido. In other embodiments, R7 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R7 is cyano. In other embodiments, R7 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R7 is nitro. In certain embodiments, R7 is amino.
[0098] In some embodiments, R8 is hydrogen. In other embodiments, R8 is alkyl or substituted alkyl. In other embodiments, R8 is aryl or substituted aryl. In other embodiments, R8 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R8 is heteroaryl or substituted heteroaryl. In other embodiments, R8 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R8 is acyloxy or substituted acyloxy. In other embodiments, R8 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R8 is acyl or substituted acyl. In other embodiments, R8 is thiol. In other embodiments, R8 is amino or substituted amino. In other embodiments, R8 is aminoacyl or substituted aminoacyl. In other embodiments, R8 is azido. In other embodiments, R8
is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R8 is cyano. In other embodiments, R8 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R8 is nitro. In certain embodiments, R8 is amino.
[0099] In some embodiments, R9 is hydrogen. In other embodiments, R9 is alkyl or substituted alkyl. In other embodiments, R9 is aryl or substituted aryl. In other embodiments, R9 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R9 is heteroaryl or substituted heteroaryl. In other embodiments, R9 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R9 is acyloxy or substituted acyloxy. In other embodiments, R9 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R9 is acyl or substituted acyl. In other embodiments, R9 is thiol. In other embodiments, R9 is amino or substituted amino. In other embodiments, R9 is aminoacyl or substituted aminoacyl. In other embodiments, R9 is azido. In other embodiments, R9 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R9 is cyano. In other embodiments, R9 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R9 is nitro. In certain embodiments, R7 is amino.
[00100] In some embodiments, R10 is hydrogen. In other embodiments, R10 is alkyl or substituted alkyl. In other embodiments, R10 is aryl or substituted aryl. In other embodiments, R10 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R10 is heteroaryl or substituted heteroaryl. In other embodiments, R10 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R10 is acyloxy or substituted acyloxy. In other embodiments, R10 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R10 is acyl or substituted acyl. In other embodiments, R10 is thiol. In other embodiments, R10 is amino or substituted amino. In other embodiments, R10 is aminoacyl or substituted aminoacyl. In other embodiments, R10 is azido. In other embodiments, R10 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R10 is cyano. In other embodiments, R10 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R10 is nitro. In certain embodiments, R10 is amino.
[00101] In some embodiments, R11 is hydrogen. In other embodiments, R11 is alkyl or substituted alkyl. In other embodiments, R11 is aryl or substituted aryl. In other embodiments, R11 is heterocycloalkyl or substituted heterocycloalkyl. In other
embodiments, R11 is heteroaryl or substituted heteroaryl. In other embodiments, R11 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R11 is acyloxy or substituted acyloxy. In other embodiments, R11 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R11 is acyl or substituted acyl. In other embodiments, R11 is thiol. In other embodiments, R11 is amino or substituted amino. In other embodiments, R11 is aminoacyl or substituted aminoacyl. In other embodiments, R11 is azido. In other embodiments, R11 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R11 is cyano. In other embodiments, R11 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R11 is nitro. In certain embodiments, R11 is amino.
[00102] In certain embodiments, a compound of interest and salts or solvates or
stereoisomers thereof, include:
(“XCT -790”) (2E-3 -(4- { [2,4-bi s(trifluorom ethyl )benzyl] oxy } -3 -methoxyphenyl)-2-cyano-N - [5-(trifluoromethyl)-l,3,4-thiadiazol-2-yl]acrylamide).
Compounds of Formula II
[00103] Compositions which find use in the methods of the present disclosure can include compounds of Formula II, shown below, which formula encompasses TG-003 ((Z)-l-(3- ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene)propan-2-one) and
pharmaceutically acceptable salts and derivatives thereof.
[00104] In one aspect, the disclosed methods include administration of a compound of Formula II:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
X is O or S;
each of R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, - COR12, -C(0)0R12, -C(0)NR12R13, -C=NR12, -OR12, -0C(0)R12, -S(0)t-R7, -NR12R13, - NR12C(0)R13, -N=CR12R13, wherein t is 0, 1, 2 or 3 and R12 and R13 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
[00105] In some embodiments, X is O. In other embodiments, X is S.
[00106] In some embodiments, R1 is hydrogen. In some embodiments, R1 is cyano. In other embodiments, R1 is alkyl or substituted alkyl. In other embodiments, R1 is aryl or substituted aryl. In other embodiments, R1 is heterocycloalkyl or substituted
heterocycloalkyl. In other embodiments, R1 is heteroaryl or substituted heteroaryl. In other embodiments, R1 is hydroxyl, alkoxyl or substituted alkoxyl. In other
embodiments, R1 is acyloxy or substituted acyloxy. In other embodiments, R1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R1 is acyl or substituted acyl. In other embodiments, R1 is thiol. In other embodiments, R1 is amino or substituted amino. In other embodiments, R1 is aminoacyl or substituted aminoacyl. In other embodiments, R1 is azido. In other embodiments, R1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R1 is nitro. In certain embodiments, R1 is naphthyl.
[00107] In some embodiments, R2 is alkoxy, such as methoxy or ethoxy. In other
embodiments, R2 is hydrogen. In other embodiments, R2 is alkyl or substituted alkyl. In other embodiments, R2 is aryl or substituted aryl. In other embodiments, R2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R2 is heteroaryl
or substituted heteroaryl. In other embodiments, R2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R2 is acyloxy or substituted acyloxy. In other embodiments, R2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R2 is acyl or substituted acyl. In other embodiments, R2 is thiol. In other embodiments, R2 is amino or substituted amino. In other embodiments, R2 is aminoacyl or substituted aminoacyl. In other embodiments, R2 is azido. In other embodiments, R2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R2 is cyano. In other embodiments, R2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R2 is nitro.
[00108] In some embodiments, R3 is hydrogen. In other embodiments, R3 is alkyl or substituted alkyl. In other embodiments, R3 is aryl or substituted aryl. In other embodiments, R3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R3 is heteroaryl or substituted heteroaryl. In other embodiments, R3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R3 is acyloxy or substituted acyloxy. In other embodiments, R3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R3 is acyl or substituted acyl. In other embodiments, R3 is thiol. In other embodiments, R3 is amino or substituted amino. In other embodiments, R3 is aminoacyl or substituted aminoacyl. In other embodiments, R3 is azido. In other embodiments, R3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R3 is cyano. In other embodiments, R3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R3 is chloro.
[00109] In some embodiments, R4 is hydrogen. In other embodiments, R4 is alkyl or
substituted alkyl. In other embodiments, R4 is aryl or substituted aryl. In other embodiments, R4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R4 is heteroaryl or substituted heteroaryl. In other embodiments, R4 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R4 is acyloxy or substituted acyloxy. In other embodiments, R4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R4 is acyl or substituted acyl. In other embodiments, R4 is thiol. In other embodiments, R4 is amino or substituted amino. In other embodiments, R4 is aminoacyl or substituted aminoacyl. In other embodiments, R4 is azido. In other embodiments, R4 is carboxyl, substituted carboxyl, carboxyalkyl or
substituted carboxyalkyl. In other embodiments, R4 is cyano. In other embodiments, R4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R4 is nitro.
[00110] In some embodiments, R5 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R5 is ethyl. In other embodiments, R5 is hydrogen. In other embodiments, In other embodiments, R5 is aryl or substituted aryl. In other
embodiments, R5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R5 is heteroaryl or substituted heteroaryl. In other embodiments, R5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R5 is acyloxy or substituted acyloxy. In other embodiments, R5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R5 is acyl or substituted acyl. In other embodiments, R5 is thiol. In other embodiments, R5 is amino or substituted amino. In other embodiments, R5 is aminoacyl or substituted aminoacyl. In other embodiments, R5 is azido. In other embodiments, R5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R5 is cyano. In other embodiments, R5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R5 is nitro.
[00111] In some embodiments, R6 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R6 is methyl. In other embodiments, R6 is hydrogen. In other embodiments, In other embodiments, R6 is aryl or substituted aryl. In other embodiments, R6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R6 is heteroaryl or substituted heteroaryl. In other embodiments, R6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R6 is acyloxy or substituted acyloxy. In other embodiments, R6 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R6 is acyl or substituted acyl. In other embodiments, R6 is thiol. In other embodiments, R6 is amino or substituted amino. In other embodiments, R6 is aminoacyl or substituted aminoacyl. In other embodiments, R6 is azido. In other embodiments, R6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R6 is cyano. In other embodiments, R6 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R6 is nitro.
[00112] In certain embodiments, a compound of interest and salts or solvates or
(“TG-003”) ((Z)-l-(3-ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene)propan-2-one)
Compounds of Formula III
[00113] Compositions which find use in the methods of the present disclosure can include compounds of Formula III, shown below, which formula encompasses GSK-837149A (4,4’-(carbonyldiimino)bis[N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide) and pharmaceutically acceptable salts and derivatives thereof.
[00114] In one aspect, the disclosed methods include administration of a compound of Formula III:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR15, -C(0)OR15, -C(0)NR15R16, -C=NR15, - OR15, -OC(0)R15, -S(0)t-R15, -NR15R16, -NR15C(0)R16, -N=CR15R16, wherein t is 0, 1, 2 or 3 and R15 and R15 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
[00115] In some embodiments, R1 is hydrogen. In other embodiments, R1 is alkyl or substituted alkyl. In other embodiments, R1 is aryl or substituted aryl. In other embodiments, R1 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R1 is heteroaryl or substituted heteroaryl. In other embodiments, R1 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R1 is acyloxy or substituted acyloxy. In other embodiments, R1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R1 is acyl or substituted acyl. In other embodiments, R1 is thiol. In other embodiments, R1 is amino or substituted amino. In other embodiments, R1 is aminoacyl or substituted aminoacyl. In other embodiments, R1 is azido. In other embodiments, R1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R1 is nitro. In certain embodiments, R1 is naphthyl.
[00116] In some embodiments, R2 is hydrogen. In other embodiments, R2 is alkyl or
substituted alkyl. In other embodiments, R2 is aryl or substituted aryl. In other embodiments, R2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R2 is heteroaryl or substituted heteroaryl. In other embodiments, R2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R2 is acyloxy or substituted acyloxy. In other embodiments, R2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R2 is acyl or substituted acyl. In other embodiments, R2 is thiol. In other embodiments, R2 is amino or substituted amino. In other embodiments, R2 is aminoacyl or substituted aminoacyl. In other embodiments, R2 is azido. In other embodiments, R2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R2 is cyano. In other embodiments, R2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R2 is nitro.
[00117] In some embodiments, R3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R3 is methyl. In other embodiments, R3 is hydrogen. In other embodiments, R3 is aryl or substituted aryl. In other embodiments, R3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R3 is heteroaryl or substituted heteroaryl. In other embodiments, R3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R3 is acyloxy or substituted acyloxy. In other embodiments, R3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R3 is acyl or substituted acyl. In other embodiments, R3 is thiol. In other embodiments, R3 is amino or substituted amino. In other embodiments, R3 is aminoacyl or substituted aminoacyl. In other embodiments, R3 is azido. In other embodiments, R3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R3 is cyano. In other embodiments, R3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R3 is chloro.
[00118] In some embodiments, R4 is hydrogen. In other embodiments, R4 is alkyl or
substituted alkyl. In other embodiments, R4 is aryl or substituted aryl. In other embodiments, R4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R4 is heteroaryl or substituted heteroaryl. In other embodiments, R4 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R4 is acyloxy or substituted acyloxy. In other embodiments, R4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R4 is acyl or substituted acyl. In other embodiments, R4 is thiol. In other embodiments, R4 is amino or substituted amino. In other embodiments, R4 is aminoacyl or substituted aminoacyl. In other embodiments, R4 is azido. In other embodiments, R4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R4 is cyano. In other embodiments, R4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R4 is nitro.
[00119] In some embodiments, R5 is hydrogen. In other embodiments, R5 is alkyl or substituted alkyl. In other embodiments, R5 is aryl or substituted aryl. In other embodiments, R5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R5 is heteroaryl or substituted heteroaryl. In other embodiments, R5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R5 is acyloxy or substituted acyloxy. In other embodiments, R5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R5 is acyl or substituted acyl. In other embodiments, R5 is thiol. In other embodiments, R5 is amino or substituted amino. In other embodiments, R5 is aminoacyl or substituted aminoacyl. In other embodiments, R5 is azido. In other embodiments, R5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R5 is cyano. In other embodiments, R5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R5 is nitro.
[00120] In some embodiments, R6 is alkoxy, such as methoxy or ethoxy. In other embodiments, R6 is hydrogen. In other embodiments, R6 is alkyl or substituted alkyl. In other embodiments, R6 is aryl or substituted aryl. In other embodiments, R6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R6 is heteroaryl or substituted heteroaryl. In other embodiments, R6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R6 is acyloxy or substituted acyloxy. In other embodiments, R6 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R6 is acyl or substituted acyl. In other embodiments, R6 is thiol. In other embodiments, R6 is amino or substituted amino. In other embodiments, R6 is aminoacyl or substituted aminoacyl. In other embodiments, R6 is azido. In other embodiments, R6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R6 is cyano. In other embodiments, R6 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R6 is nitro. In certain embodiments, R6 is
alkoxylcarbonyl, such as ethoxycarbonyl.
[00121] In some embodiments, R7 is hydrogen. In other embodiments, R7 is alkyl or substituted alkyl. In other embodiments, R7 is aryl or substituted aryl. In other embodiments, R7 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R7 is heteroaryl or substituted heteroaryl. In other embodiments, R7 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R7 is acyloxy or substituted acyloxy. In other embodiments, R7 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R7 is acyl or substituted acyl. In other embodiments, R7 is thiol. In other embodiments, R7 is amino or substituted amino. In other embodiments, R7 is aminoacyl or substituted aminoacyl. In other embodiments, R7 is azido. In other embodiments, R7 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R7 is cyano. In other embodiments, R7 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R7 is nitro. In certain embodiments, R7 is amino.
[00122] In some embodiments, R8 is hydrogen. In other embodiments, R8 is alkyl or substituted alkyl. In other embodiments, R8 is aryl or substituted aryl. In other embodiments, R8 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R8 is heteroaryl or substituted heteroaryl. In other embodiments, R8 is
hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R8 is acyloxy or substituted acyloxy. In other embodiments, R8 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R8 is acyl or substituted acyl. In other embodiments, R8 is thiol. In other embodiments, R8 is amino or substituted amino. In other embodiments, R8 is aminoacyl or substituted aminoacyl. In other embodiments, R8 is azido. In other embodiments, R8 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R8 is cyano. In other embodiments, R8 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R8 is nitro. In certain embodiments, R8 is amino.
[00123] In some embodiments, R9 is hydrogen. In other embodiments, R9 is alkyl or substituted alkyl. In other embodiments, R9 is aryl or substituted aryl. In other embodiments, R9 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R9 is heteroaryl or substituted heteroaryl. In other embodiments, R9 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R9 is acyloxy or substituted acyloxy. In other embodiments, R9 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R9 is acyl or substituted acyl. In other embodiments, R9 is thiol. In other embodiments, R9 is amino or substituted amino. In other embodiments, R9 is aminoacyl or substituted aminoacyl. In other embodiments, R9 is azido. In other embodiments, R9 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R9 is cyano. In other embodiments, R9 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R9 is nitro. In certain embodiments, R7 is amino.
[00124] In some embodiments, R10 is hydrogen. In other embodiments, R10 is alkyl or substituted alkyl. In other embodiments, R10 is aryl or substituted aryl. In other embodiments, R10 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R10 is heteroaryl or substituted heteroaryl. In other embodiments, R10 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R10 is acyloxy or substituted acyloxy. In other embodiments, R10 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R10 is acyl or substituted acyl. In other embodiments, R10 is thiol. In other embodiments, R10 is amino or substituted amino. In other embodiments, R10 is aminoacyl or substituted aminoacyl. In other embodiments,
R10 is azido. In other embodiments, R10 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R10 is cyano. In other embodiments, R10 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R10 is nitro. In certain embodiments, R10 is amino.
[00125] In some embodiments, R11 is hydrogen. In other embodiments, R11 is alkyl or substituted alkyl. In other embodiments, R11 is aryl or substituted aryl. In other embodiments, R11 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R11 is heteroaryl or substituted heteroaryl. In other embodiments, R11 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R11 is acyloxy or substituted acyloxy. In other embodiments, R11 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R11 is acyl or substituted acyl. In other embodiments, R11 is thiol. In other embodiments, R11 is amino or substituted amino. In other embodiments, R11 is aminoacyl or substituted aminoacyl. In other embodiments, R11 is azido. In other embodiments, R11 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R11 is cyano. In other embodiments, R11 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R11 is nitro. In certain embodiments, R11 is amino.
[00126] In some embodiments, R12 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R12 is methyl. In other embodiments, R12 is hydrogen. In other embodiments, R12 is aryl or substituted aryl. In other embodiments, R12 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R12 is heteroaryl or substituted heteroaryl. In other embodiments, R12 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R12 is acyloxy or substituted acyloxy. In other embodiments, R12 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R12 is acyl or substituted acyl. In other embodiments, R12 is thiol. In other embodiments, R12 is amino or substituted amino. In other embodiments, R12 is aminoacyl or substituted aminoacyl. In other embodiments, R12 is azido. In other embodiments, R12 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R12 is cyano. In other embodiments, R12 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R12 is chloro.
[00127] In some embodiments, R13 is hydrogen. In other embodiments, R13 is alkyl or substituted alkyl. In other embodiments, R13 is aryl or substituted aryl. In other embodiments, R13 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R13 is heteroaryl or substituted heteroaryl. In other embodiments, R13 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R13 is acyloxy or substituted acyloxy. In other embodiments, R13 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R13 is acyl or substituted acyl. In other embodiments, R13 is thiol. In other embodiments, R13 is amino or substituted amino. In other embodiments, R13 is aminoacyl or substituted aminoacyl. In other embodiments, R13 is azido. In other embodiments, R13 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R13 is cyano. In other embodiments, R13 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R13 is nitro. In certain embodiments, R13 is amino.
[00128] In some embodiments, R14 is hydrogen. In other embodiments, R14 is alkyl or substituted alkyl. In other embodiments, R14 is aryl or substituted aryl. In other embodiments, R14 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R14 is heteroaryl or substituted heteroaryl. In other embodiments, R14 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R14 is acyloxy or substituted acyloxy. In other embodiments, R14 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R14 is acyl or substituted acyl. In other embodiments, R14 is thiol. In other embodiments, R14 is amino or substituted amino. In other embodiments, R14 is aminoacyl or substituted aminoacyl. In other embodiments, R14 is azido. In other embodiments, R14 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R14 is cyano. In other embodiments, R14 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R14 is nitro. In certain embodiments, R14 is amino.
[00129] In certain embodiments, a compound of interest and salts or solvates or
(“GSK-837149A”) (4,4’ -(carbonyl diimino)bis[N-(4-methyl-2-pyrimidinyl)- benzenesulfonamide)
Compounds of Formula IV
[00130] Compositions which find use in the methods of the present disclosure can include compounds of Formula IV, shown below, which formula encompasses Naloxone ((4R,4aS,7aR,l2bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,l3-hexahydro-lH-4, l2- methanobenzofuro[3,2-e]isoquinoline-7-one) and pharmaceutically acceptable salts and derivatives thereof.
[00131] In one aspect, the disclosed methods include administration of a compound of Formula IV:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4 and R5 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, - COR15, -C(0)OR15, -C(0)NR15R16, -C=NR15, -OR15, -OC(0)R15, -S(0)t-R15, -NR15R16, - NR15C(0)R16, -N=CR15R16, wherein t is 0, 1, 2 or 3 and R15 and R15 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted
cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
[00132] In some embodiments, R1 is hydroxyl. In other embodiments, R1 is hydrogen. In other embodiments, R1 is alkyl or substituted alkyl. In other embodiments, R1 is aryl or substituted aryl. In other embodiments, R1 is heterocycloalkyl or substituted
heterocycloalkyl. In other embodiments, R1 is heteroaryl or substituted heteroaryl. In other embodiments, R1 is alkoxyl or substituted alkoxyl. In other embodiments, R1 is acyloxy or substituted acyloxy. In other embodiments, R1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R1 is acyl or substituted acyl. In other embodiments, R1 is thiol. In other embodiments, R1 is amino or substituted amino. In other embodiments, R1 is aminoacyl or substituted aminoacyl. In other embodiments, R1 is azido. In other embodiments, R1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R1 is nitro. In certain embodiments, R1 is naphthyl.
[00133] In some embodiments, R2 is hydrogen. In other embodiments, R2 is alkyl or substituted alkyl. In other embodiments, R2 is aryl or substituted aryl. In other embodiments, R2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R2 is heteroaryl or substituted heteroaryl. In other embodiments, R2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R2 is acyloxy or substituted acyloxy. In other embodiments, R2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R2 is acyl or substituted acyl. In other embodiments, R2 is thiol. In other embodiments, R2 is amino or substituted amino. In other embodiments, R2 is aminoacyl or substituted aminoacyl. In other embodiments, R2 is azido. In other embodiments, R2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R2 is cyano. In other embodiments, R2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R2 is nitro.
[00134] In some embodiments, R3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R3 is methyl. In other embodiments, R3 is hydrogen. In other embodiments, R3 is aryl or substituted aryl. In other embodiments, R3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R3 is heteroaryl
or substituted heteroaryl. In other embodiments, R3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R3 is acyloxy or substituted acyloxy. In other embodiments, R3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R3 is acyl or substituted acyl. In other embodiments, R3 is thiol. In other embodiments, R3 is amino or substituted amino. In other embodiments, R3 is aminoacyl or substituted aminoacyl. In other embodiments, R3 is azido. In other embodiments, R3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R3 is cyano. In other embodiments, R3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R3 is chloro.
[00135] In some embodiments, R4 is hydrogen. In other embodiments, R4 is hydroxyl. In other embodiments, R4 is alkyl or substituted alkyl. In other embodiments, R4 is aryl or substituted aryl. In other embodiments, R4 is heterocycloalkyl or substituted
heterocycloalkyl. In other embodiments, R4 is heteroaryl or substituted heteroaryl. In other embodiments, R4 is alkoxyl or substituted alkoxyl. In other embodiments, R4 is acyloxy or substituted acyloxy. In other embodiments, R4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R4 is acyl or substituted acyl. In other embodiments, R4 is thiol. In other embodiments, R4 is amino or substituted amino. In other embodiments, R4 is aminoacyl or substituted aminoacyl. In other embodiments, R4 is azido. In other embodiments, R4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R4 is cyano. In other embodiments, R4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R4 is nitro.
[00136] In some embodiments, R5 is hydrogen. In other embodiments, R5 is alkyl or substituted alkyl. In other embodiments, R5 is allyl. In other embodiments, R5 is aryl or substituted aryl. In other embodiments, R5 is heterocycloalkyl or substituted
heterocycloalkyl. In other embodiments, R5 is heteroaryl or substituted heteroaryl. In other embodiments, R5 is hydroxyl, alkoxyl or substituted alkoxyl. In other
embodiments, R5 is acyloxy or substituted acyloxy. In other embodiments, R5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R5 is acyl or substituted acyl. In other embodiments, R5 is thiol. In other embodiments, R5 is amino or substituted amino. In other embodiments, R5 is aminoacyl or substituted aminoacyl. In other embodiments, R5 is azido. In other embodiments, R5 is carboxyl, substituted
carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R5 is cyano. In other embodiments, R5 is a halogen, such as -F, -Cl, -Br and -I. In other
embodiments, R5 is nitro.
[00137] In certain embodiments, a compound of interest and salts or solvates or
stereoisomers thereof, include:
(“Naloxone”) ((4R,4aS,7aR,l2bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,l3-hexahydro-lH- 4,l2-methanobenzofuro[3,2-e]isoquinoline-7-one)
Compounds of Formula V
[00138] Compositions which find use in the methods of the present disclosure can include compounds of Formula V, shown below, which formula encompasses Cytochalasin and pharmaceutically acceptable salts and derivatives thereof.
[00139] In one aspect, the disclosed methods include administration of a compound of Formula V:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6, R7, R8 and R9 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR10, -C(0)OR10, -C(O)NR10Ru, -C=NR10, -OR10, -OC(0)R10, -S(0)t-
R10, -NR10RU, -NR10C(O)Ru, -N=CR10RU, wherein t is 0, 1, 2 or 3 and R10 and R11 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or
unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
[00140] In some embodiments, R1 is hydrogen. In other embodiments, R1 is alkyl or
substituted alkyl. In other embodiments, R1 is aryl or substituted aryl. In other embodiments, R1 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R1 is heteroaryl or substituted heteroaryl. In other embodiments, R1 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R1 is acyloxy or substituted acyloxy. In other embodiments, R1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R1 is acyl or substituted acyl. In other embodiments, R1 is thiol. In other embodiments, R1 is amino or substituted amino. In other embodiments, R1 is aminoacyl or substituted aminoacyl. In other embodiments, R1 is azido. In other embodiments, R1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R1 is nitro. In certain embodiments, R1 is naphthyl.
[00141] In some embodiments, R2 is hydrogen. In other embodiments, R2 is alkyl or
substituted alkyl. In other embodiments, R2 is aryl or substituted aryl. In other embodiments, R2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R2 is heteroaryl or substituted heteroaryl. In other embodiments, R2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R2 is acyloxy or substituted acyloxy. In other embodiments, R2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R2 is acyl or substituted acyl. In other embodiments, R2 is thiol. In other embodiments, R2 is amino or substituted amino. In other embodiments, R2 is aminoacyl or substituted aminoacyl. In other embodiments, R2 is azido. In other embodiments, R2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R2 is cyano. In other embodiments, R2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R2 is nitro.
[00142] In some embodiments, R3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R3 is methyl. In other embodiments, R3 is hydrogen. In
other embodiments, R3 is aryl or substituted aryl. In other embodiments, R3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R3 is heteroaryl or substituted heteroaryl. In other embodiments, R3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R3 is acyloxy or substituted acyloxy. In other embodiments, R3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R3 is acyl or substituted acyl. In other embodiments, R3 is thiol. In other embodiments, R3 is amino or substituted amino. In other embodiments, R3 is aminoacyl or substituted aminoacyl. In other embodiments, R3 is azido. In other embodiments, R3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R3 is cyano. In other embodiments, R3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R3 is chloro.
[00143] In some embodiments, R4 is hydrogen. In other embodiments, R4 is alkyl or
substituted alkyl. In other embodiments, R4 is aryl or substituted aryl. In other embodiments, R4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R4 is heteroaryl or substituted heteroaryl. In other embodiments, R4 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R4 is acyloxy or substituted acyloxy. In other embodiments, R4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R4 is acyl or substituted acyl. In other embodiments, R4 is thiol. In other embodiments, R4 is amino or substituted amino. In other embodiments, R4 is aminoacyl or substituted aminoacyl. In other embodiments, R4 is azido. In other embodiments, R4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R4 is cyano. In other embodiments, R4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R4 is nitro.
[00144] In some embodiments, R5 is hydrogen. In other embodiments, R5 is alkyl or substituted alkyl. In other embodiments, R5 is aryl or substituted aryl. In other embodiments, R5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R5 is heteroaryl or substituted heteroaryl. In other embodiments, R5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R5 is acyloxy or substituted acyloxy. In other embodiments, R5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R5 is acyl or substituted acyl. In other embodiments, R5 is thiol. In other embodiments, R5 is amino or substituted amino. In
other embodiments, R5 is aminoacyl or substituted aminoacyl. In other embodiments, R5 is azido. In other embodiments, R5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R5 is cyano. In other embodiments, R5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R5 is nitro.
[00145] In some embodiments, R6 is hydrogen. In other embodiments, R6 is alkoxy, such as methoxy or ethoxy. In other embodiments, R6 is alkyl or substituted alkyl. In other embodiments, R6 is aryl or substituted aryl. In other embodiments, R6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R6 is heteroaryl or substituted heteroaryl. In other embodiments, R6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R6 is acyloxy or substituted acyloxy. In other embodiments, R6 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R6 is acyl or substituted acyl. In other embodiments, R6 is thiol. In other embodiments, R6 is amino or substituted amino. In other embodiments, R6 is aminoacyl or substituted aminoacyl.
In other embodiments, R6 is azido. In other embodiments, R6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R6 is cyano. In other embodiments, R6 is a halogen, such as -F, -Cl, -Br and -I. In other
embodiments, R6 is nitro. In certain embodiments, R6 is alkoxylcarbonyl, such as ethoxycarbonyl.
[00146] In some embodiments, R7 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R7 is methyl. In other embodiments, R7 is hydrogen. In other embodiments, R7 is aryl or substituted aryl. In other embodiments, R7 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R7 is heteroaryl or substituted heteroaryl. In other embodiments, R7 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R7 is acyloxy or substituted acyloxy. In other embodiments, R7 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R7 is acyl or substituted acyl. In other embodiments, R7 is thiol. In other embodiments, R7 is amino or substituted amino. In other embodiments, R7 is aminoacyl or substituted aminoacyl. In other embodiments, R7 is azido. In other embodiments, R7 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R7 is cyano. In other embodiments, R7 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R7 is nitro. In certain embodiments, R7 is amino.
[00147] In some embodiments, R8 is hydrogen. In other embodiments, R8 is alkyl or substituted alkyl. In other embodiments, R8 is aryl or substituted aryl. In other embodiments, R8 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R8 is heteroaryl or substituted heteroaryl. In other embodiments, R8 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R8 is acyloxy or substituted acyloxy. In other embodiments, R8 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R8 is acyl or substituted acyl. In other embodiments, R8 is thiol. In other embodiments, R8 is amino or substituted amino. In other embodiments, R8 is aminoacyl or substituted aminoacyl. In other embodiments, R8 is azido. In other embodiments, R8 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R8 is cyano. In other embodiments, R8 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R8 is nitro. In certain embodiments, R8 is amino.
[00148] In some embodiments, R9 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R9 is methyl. In other embodiments, R9 is hydrogen. In other embodiments, R9 is aryl or substituted aryl. In other embodiments, R9 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R9 is heteroaryl or substituted heteroaryl. In other embodiments, R9 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R9 is acyloxy or substituted acyloxy. In other embodiments, R9 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R9 is acyl or substituted acyl. In other embodiments, R9 is thiol. In other embodiments, R9 is amino or substituted amino. In other embodiments, R9 is aminoacyl or substituted aminoacyl. In other embodiments, R9 is azido. In other embodiments, R9 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R9 is cyano. In other embodiments, R9 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R9 is nitro. In certain embodiments, R7 is amino.
[00149] In certain embodiments, a compound of interest and salts or solvates or
(“Cytochalasin”)
Compounds of Formula VI
[00150] Compositions which find use in the methods of the present disclosure can include compounds of Formula VI, shown below, which formula encompasses Putrescine (butane-l, 4-diamine) and pharmaceutically acceptable salts and derivatives thereof.
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6, R7 and R8 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted
heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR9, -C(0)OR9, -C(0)NR9R10, -C=NR9, -OR9, -OC(0)R9, -S(0)t-R9, - NR9R10, -NR9C(0)R10, -N=CR9R10, wherein t is 0, 1, 2 or 3 and R9 and R10 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or
unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
[00152] In some embodiments, R1 is hydrogen. In other embodiments, R1 is alkyl or substituted alkyl. In other embodiments, R1 is aryl or substituted aryl. In other embodiments, R1 is heterocycloalkyl or substituted heterocycloalkyl. In other
embodiments, R1 is heteroaryl or substituted heteroaryl. In other embodiments, R1 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R1 is acyloxy or substituted acyloxy. In other embodiments, R1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R1 is acyl or substituted acyl. In other embodiments, R1 is thiol. In other embodiments, R1 is amino or substituted amino. In other embodiments, R1 is aminoacyl or substituted aminoacyl. In other embodiments, R1 is azido. In other embodiments, R1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R1 is nitro. In certain embodiments, R1 is naphthyl.
[00153] In some embodiments, R2 is hydrogen. In other embodiments, R2 is alkyl or
substituted alkyl. In other embodiments, R2 is aryl or substituted aryl. In other embodiments, R2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R2 is heteroaryl or substituted heteroaryl. In other embodiments, R2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R2 is acyloxy or substituted acyloxy. In other embodiments, R2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R2 is acyl or substituted acyl. In other embodiments, R2 is thiol. In other embodiments, R2 is amino or substituted amino. In other embodiments, R2 is aminoacyl or substituted aminoacyl. In other embodiments, R2 is azido. In other embodiments, R2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R2 is cyano. In other embodiments, R2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R2 is nitro.
[00154] In some embodiments, R3 is hydrogen. In certain instances, R3 is methyl. In other embodiments, R3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In other embodiments, R3 is aryl or substituted aryl. In other embodiments, R3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R3 is heteroaryl or substituted heteroaryl. In other embodiments, R3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R3 is acyloxy or substituted acyloxy. In other embodiments, R3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R3 is acyl or substituted acyl. In other embodiments, R3 is thiol. In other embodiments, R3 is amino or substituted amino. In other embodiments, R3 is aminoacyl or substituted aminoacyl. In other embodiments, R3 is azido. In other embodiments, R3
is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R3 is cyano. In other embodiments, R3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R3 is chloro.
[00155] In some embodiments, R4 is hydrogen. In other embodiments, R4 is alkyl or
substituted alkyl. In other embodiments, R4 is aryl or substituted aryl. In other embodiments, R4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R4 is heteroaryl or substituted heteroaryl. In other embodiments, R4 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R4 is acyloxy or substituted acyloxy. In other embodiments, R4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R4 is acyl or substituted acyl. In other embodiments, R4 is thiol. In other embodiments, R4 is amino or substituted amino. In other embodiments, R4 is aminoacyl or substituted aminoacyl. In other embodiments, R4 is azido. In other embodiments, R4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R4 is cyano. In other embodiments, R4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R4 is nitro.
[00156] In some embodiments, R5 is hydrogen. In other embodiments, R5 is alkyl or
substituted alkyl. In other embodiments, R5 is aryl or substituted aryl. In other embodiments, R5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R5 is heteroaryl or substituted heteroaryl. In other embodiments, R5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R5 is acyloxy or substituted acyloxy. In other embodiments, R5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R5 is acyl or substituted acyl. In other embodiments, R5 is thiol. In other embodiments, R5 is amino or substituted amino. In other embodiments, R5 is aminoacyl or substituted aminoacyl. In other embodiments, R5 is azido. In other embodiments, R5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R5 is cyano. In other embodiments, R5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R5 is nitro.
[00157] In some embodiments, R6 is hydrogen. In other embodiments, R6 is alkoxy, such as methoxy or ethoxy. In other embodiments, R6 is alkyl or substituted alkyl. In other embodiments, R6 is aryl or substituted aryl. In other embodiments, R6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R6 is heteroaryl or substituted
heteroaryl. In other embodiments, R6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R6 is acyloxy or substituted acyloxy. In other embodiments, R6 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R6 is acyl or substituted acyl. In other embodiments, R6 is thiol. In other embodiments, R6 is amino or substituted amino. In other embodiments, R6 is aminoacyl or substituted aminoacyl. In other embodiments, R6 is azido. In other embodiments, R6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R6 is cyano. In other embodiments, R6 is a halogen, such as -F, -Cl, -Br and -I. In other
embodiments, R6 is nitro. In certain embodiments, R6 is alkoxylcarbonyl, such as ethoxycarbonyl.
[00158] In some embodiments, R7 is hydrogen. In other embodiments, R7 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R7 is methyl. In other embodiments, R7 is aryl or substituted aryl. In other embodiments, R7 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R7 is heteroaryl or substituted heteroaryl. In other embodiments, R7 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R7 is acyloxy or substituted acyloxy. In other embodiments, R7 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R7 is acyl or substituted acyl. In other embodiments, R7 is thiol. In other embodiments, R7 is amino or substituted amino. In other embodiments, R7 is aminoacyl or substituted aminoacyl. In other embodiments, R7 is azido. In other embodiments, R7 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R7 is cyano. In other embodiments, R7 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R7 is nitro. In certain embodiments, R7 is amino.
[00159] In some embodiments, R8 is hydrogen. In other embodiments, R8 is alkyl or substituted alkyl. In other embodiments, R8 is aryl or substituted aryl. In other embodiments, R8 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R8 is heteroaryl or substituted heteroaryl. In other embodiments, R8 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R8 is acyloxy or substituted acyloxy. In other embodiments, R8 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R8 is acyl or substituted acyl. In other embodiments, R8 is thiol. In other embodiments, R8 is amino or substituted amino. In
other embodiments, R8 is aminoacyl or substituted aminoacyl. In other embodiments, R8 is azido. In other embodiments, R8 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R8 is cyano. In other embodiments, R8 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R8 is nitro. In certain embodiments, R8 is amino.
[00160] In certain embodiments, a compound of interest and salts or solvates or
(“Putrescine”) (“Butane- 1 ,4-diamine”)
Compounds of Formula VII
[00161] Compositions which find use in the methods of the present disclosure can include compounds of Formula VII, shown below, which formula encompasses CB-1954 (5-(l- aziridinyl)-2,4-dinitrobenzamide) and pharmaceutically acceptable salts and derivatives thereof.
[00162] In one aspect, the disclosed methods include administration of a compound of Formula VII:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2 and R3 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxyl alkyl, cyano, halogen, nitro, -COR4, - C(0)OR4, -C(0)NR4R5, -C=NR4, -OR4, -OC(0)R4, -S(0)t-R4, -NR4R5, -NR4C(0)R5, - N=CR4R5, wherein t is 0, 1, 2 or 3 and R4and R5 are independently selected from
hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or
unsubstituted aryloxy or halogen.
[00163] In some embodiments, R1 is hydrogen. In other embodiments, R1 is alkyl or
substituted alkyl. In other embodiments, R1 is aryl or substituted aryl. In other embodiments, R1 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R1 is heteroaryl or substituted heteroaryl. In other embodiments, R1 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R1 is acyloxy or substituted acyloxy. In other embodiments, R1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R1 is acyl or substituted acyl. In other embodiments, R1 is thiol. In other embodiments, R1 is amino or substituted amino. In other embodiments, R1 is aminoacyl or substituted aminoacyl. In other embodiments, R1 is azido. In other embodiments, R1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R1 is nitro. In certain embodiments, R1 is naphthyl.
[00164] In some embodiments, R2 is hydrogen. In other embodiments, R2 is alkyl or
substituted alkyl. In other embodiments, R2 is aryl or substituted aryl. In other embodiments, R2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R2 is heteroaryl or substituted heteroaryl. In other embodiments, R2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R2 is acyloxy or substituted acyloxy. In other embodiments, R2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R2 is acyl or substituted acyl. In other embodiments, R2 is thiol. In other embodiments, R2 is amino or substituted amino. In other embodiments, R2 is aminoacyl or substituted aminoacyl. In other embodiments, R2 is azido. In other embodiments, R2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R2 is cyano. In other embodiments, R2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R2 is nitro.
[00165] In some embodiments, R3 is hydrogen. In certain instances, R3 is methyl. In other embodiments, R3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In other embodiments, R3 is aryl or substituted aryl. In other embodiments, R3 is
heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R3 is heteroaryl or substituted heteroaryl. In other embodiments, R3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R3 is acyloxy or substituted acyloxy. In other embodiments, R3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R3 is acyl or substituted acyl. In other embodiments, R3 is thiol. In other embodiments, R3 is amino or substituted amino. In other embodiments, R3 is aminoacyl or substituted aminoacyl. In other embodiments, R3 is azido. In other embodiments, R3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R3 is cyano. In other embodiments, R3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R3 is chloro.
[00166] In certain embodiments, a compound of interest and salts or solvates or
stereoisomers thereof, include:
(“CB-1954”) (5-(l-aziridinyl)-2,4-dinitrobenzamide)
Compounds of Formula VIII
[00167] Compositions which find use in the methods of the present disclosure can include compounds of Formula VIII, shown below, which formula encompasses biperiden ((lRS,2SR,4RS)-l-(bicyclo[2.2. l]hept-5-en-2-yl)-l-phenyl-3-(piperidin- l -yl)propan-l- ol) and pharmaceutically acceptable salts and derivatives thereof. Pharmaceutical compositions and methods of the present disclosure also contemplate compounds of Formula VIII.
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6 and R7 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted
heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR8, -C(0)0R8, -C(0)NR8R9, -C=NR8, -OR9, -0C(0)R8, -S(0)t-R8, - NR8R9, -NR8C(0)R9, -N=CR8R9, wherein t is 0, 1, 2 or 3 and R8 and R9 are
independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or
unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
[00169] In some embodiments, R1 is hydroxyl. In other embodiments, R1 is hydrogen. In other embodiments, R1 is alkyl or substituted alkyl. In other embodiments, R1 is aryl or substituted aryl. In other embodiments, R1 is heterocycloalkyl or substituted
heterocycloalkyl. In other embodiments, R1 is heteroaryl or substituted heteroaryl. In other embodiments, R1 is alkoxyl or substituted alkoxyl. In other embodiments, R1 is acyloxy or substituted acyloxy. In other embodiments, R1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R1 is acyl or substituted acyl. In other embodiments, R1 is thiol. In other embodiments, R1 is amino or substituted amino. In other embodiments, R1 is aminoacyl or substituted aminoacyl. In other embodiments, R1 is azido. In other embodiments, R1 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R1 is nitro. In certain embodiments, R1 is naphthyl.
[00170] In some embodiments, R2 is hydrogen. In other embodiments, R2 is alkyl or substituted alkyl. In other embodiments, R2 is aryl or substituted aryl. In other embodiments, R2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R2 is heteroaryl or substituted heteroaryl. In other embodiments, R2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R2 is acyloxy or substituted acyloxy. In other embodiments, R2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R2 is acyl or substituted acyl. In other embodiments, R2 is thiol. In other embodiments, R2 is amino or substituted amino. In other embodiments, R2 is aminoacyl or substituted aminoacyl. In other embodiments, R2 is azido. In other embodiments, R2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R2 is cyano. In other embodiments, R2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R2 is nitro.
[00171] In some embodiments, R3 is hydrogen. In certain instances, R3 is methyl. In other embodiments, R3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In other embodiments, R3 is aryl or substituted aryl. In other embodiments, R3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R3 is heteroaryl or substituted heteroaryl. In other embodiments, R3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R3 is acyloxy or substituted acyloxy. In other embodiments, R3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R3 is acyl or substituted acyl. In other embodiments, R3 is thiol. In other embodiments, R3 is amino or substituted amino. In other embodiments, R3 is aminoacyl or substituted aminoacyl. In other embodiments, R3 is azido. In other embodiments, R3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R3 is cyano. In other embodiments, R3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R3 is chloro.
[00172] In some embodiments, R4 is hydrogen. In other embodiments, R4 is alkyl or
substituted alkyl. In other embodiments, R4 is aryl or substituted aryl. In other embodiments, R4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R4 is heteroaryl or substituted heteroaryl. In other embodiments, R4 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R4 is acyloxy or substituted acyloxy. In other embodiments, R4 is alkoxylcarbonyl or substituted
alkoxycarbonyl. In other embodiments, R4 is acyl or substituted acyl. In other embodiments, R4 is thiol. In other embodiments, R4 is amino or substituted amino. In other embodiments, R4 is aminoacyl or substituted aminoacyl. In other embodiments, R4 is azido. In other embodiments, R4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R4 is cyano. In other embodiments, R4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R4 is nitro.
[00173] In some embodiments, R5 is hydrogen. In other embodiments, R5 is alkyl or
substituted alkyl. In other embodiments, R5 is aryl or substituted aryl. In other embodiments, R5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R5 is heteroaryl or substituted heteroaryl. In other embodiments, R5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R5 is acyloxy or substituted acyloxy. In other embodiments, R5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R5 is acyl or substituted acyl. In other embodiments, R5 is thiol. In other embodiments, R5 is amino or substituted amino. In other embodiments, R5 is aminoacyl or substituted aminoacyl. In other embodiments, R5 is azido. In other embodiments, R5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R5 is cyano. In other embodiments, R5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R5 is nitro.
[00174] In some embodiments, R6 is hydrogen. In other embodiments, R6 is alkoxy, such as methoxy or ethoxy. In other embodiments, R6 is alkyl or substituted alkyl. In other embodiments, R6 is aryl or substituted aryl. In other embodiments, R6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R6 is heteroaryl or substituted heteroaryl. In other embodiments, R6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R6 is acyloxy or substituted acyloxy. In other embodiments, R6 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R6 is acyl or substituted acyl. In other embodiments, R6 is thiol. In other embodiments, R6 is amino or substituted amino. In other embodiments, R6 is aminoacyl or substituted aminoacyl.
In other embodiments, R6 is azido. In other embodiments, R6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R6 is cyano. In other embodiments, R6 is a halogen, such as -F, -Cl, -Br and -I. In other
embodiments, R6 is nitro. In certain embodiments, R6 is alkoxylcarbonyl, such as ethoxycarbonyl.
[00175] In some embodiments, R7 is hydrogen. In other embodiments, R7 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R7 is methyl. In other embodiments, R7 is aryl or substituted aryl. In other embodiments, R7 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R7 is heteroaryl or substituted heteroaryl. In other embodiments, R7 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R7 is acyloxy or substituted acyloxy. In other embodiments, R7 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R7 is acyl or substituted acyl. In other embodiments, R7 is thiol. In other embodiments, R7 is amino or substituted amino. In other embodiments, R7 is aminoacyl or substituted aminoacyl. In other embodiments, R7 is azido. In other embodiments, R7 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R7 is cyano. In other embodiments, R7 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R7 is nitro. In certain embodiments, R7 is amino.
[00176] In certain embodiments, a compound of interest and salts or solvates or
stereoisomers thereof, include:
(“biperiden”) ((lRS,2SR,4RS)-l-(bicyclo[2.2.l]hept-5-en-2-yl)-l-phenyl-3-(piperidin- 1- yl)propan-l-ol))
Compounds of Formula IX
[00177] Compositions which find use in the methods of the present disclosure can include compounds of Formula IX, shown below, which formula encompasses RO-4929097 (2,2-dimethyl-N-[(l0S)-9-oxo-8-azatricyclo[9.4.0.02,7]pentadeca-l,2,4,6,l 1,13- hexaene-lO-yl]-N’-(2,2,3,3,3-pentafluoropropyl)propanediamide) and pharmaceutically acceptable salts and derivatives thereof.
[00178] In one aspect, the disclosed methods include administration of a compound of
Formula IX:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR12, -C(0)0R12, -C(0)NR12R13, -C=NR12, - OR12, -0C(0)R12, -S(0)t-R12, -NR12R13, -NR12C(0)R13, -N=CR12R13, wherein t is 0, 1, 2 or 3 and R12 and R13 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
[00179] In some embodiments, R1 is hydrogen. In other embodiments, R1 is alkyl or substituted alkyl. In other embodiments, R1 is aryl or substituted aryl. In other embodiments, R1 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R1 is heteroaryl or substituted heteroaryl. In other embodiments, R1 is hyrdoxyl alkoxyl or substituted alkoxyl. In other embodiments, R1 is acyloxy or substituted acyloxy. In other embodiments, R1 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R1 is acyl or substituted acyl. In other embodiments, R1 is thiol. In other embodiments, R1 is amino or substituted amino. In other embodiments, R1 is aminoacyl or substituted aminoacyl. In other embodiments, R1 is azido. In other embodiments, R1 is carboxyl, substituted carboxyl, carboxyalkyl or
substituted carboxyalkyl. In other embodiments, R1 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R1 is nitro. In certain embodiments, R1 is naphthyl.
[00180] In some embodiments, R2 is hydrogen. In other embodiments, R2 is alkyl or substituted alkyl. In other embodiments, R2 is aryl or substituted aryl. In other embodiments, R2 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R2 is heteroaryl or substituted heteroaryl. In other embodiments, R2 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R2 is acyloxy or substituted acyloxy. In other embodiments, R2 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R2 is acyl or substituted acyl. In other embodiments, R2 is thiol. In other embodiments, R2 is amino or substituted amino. In other embodiments, R2 is aminoacyl or substituted aminoacyl. In other embodiments, R2 is azido. In other embodiments, R2 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R2 is cyano. In other embodiments, R2 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R2 is nitro.
[00181] In some embodiments, R3 is hydrogen. In certain instances, R3 is methyl. In other embodiments, R3 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In other embodiments, R3 is aryl or substituted aryl. In other embodiments, R3 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R3 is heteroaryl or substituted heteroaryl. In other embodiments, R3 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R3 is acyloxy or substituted acyloxy. In other embodiments, R3 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R3 is acyl or substituted acyl. In other embodiments, R3 is thiol. In other embodiments, R3 is amino or substituted amino. In other embodiments, R3 is aminoacyl or substituted aminoacyl. In other embodiments, R3 is azido. In other embodiments, R3 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R3 is cyano. In other embodiments, R3 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R3 is chloro.
[00182] In some embodiments, R4 is hydrogen. In other embodiments, R4 is alkyl or
substituted alkyl. In other embodiments, R4 is aryl or substituted aryl. In other embodiments, R4 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R4 is heteroaryl or substituted heteroaryl. In other embodiments, R4 is
hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R4 is acyloxy or substituted acyloxy. In other embodiments, R4 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R4 is acyl or substituted acyl. In other embodiments, R4 is thiol. In other embodiments, R4 is amino or substituted amino. In other embodiments, R4 is aminoacyl or substituted aminoacyl. In other embodiments, R4 is azido. In other embodiments, R4 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R4 is cyano. In other embodiments, R4 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R4 is nitro.
[00183] In some embodiments, R5 is hydrogen. In other embodiments, R5 is alkyl or
substituted alkyl. In other embodiments, R5 is aryl or substituted aryl. In other embodiments, R5 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R5 is heteroaryl or substituted heteroaryl. In other embodiments, R5 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R5 is acyloxy or substituted acyloxy. In other embodiments, R5 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R5 is acyl or substituted acyl. In other embodiments, R5 is thiol. In other embodiments, R5 is amino or substituted amino. In other embodiments, R5 is aminoacyl or substituted aminoacyl. In other embodiments, R5 is azido. In other embodiments, R5 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R5 is cyano. In other embodiments, R5 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R5 is nitro.
[00184] In some embodiments, R6 is hydrogen. In other embodiments, R6 is alkoxy, such as methoxy or ethoxy. In other embodiments, R6 is alkyl or substituted alkyl. In other embodiments, R6 is aryl or substituted aryl. In other embodiments, R6 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R6 is heteroaryl or substituted heteroaryl. In other embodiments, R6 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R6 is acyloxy or substituted acyloxy. In other embodiments, R6 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R6 is acyl or substituted acyl. In other embodiments, R6 is thiol. In other embodiments, R6 is amino or substituted amino. In other embodiments, R6 is aminoacyl or substituted aminoacyl.
In other embodiments, R6 is azido. In other embodiments, R6 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R6 is cyano.
In other embodiments, R6 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R6 is nitro. In certain embodiments, R6 is alkoxylcarbonyl, such as ethoxycarbonyl.
[00185] In some embodiments, R7 is hydrogen. In other embodiments, R7 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R7 is methyl. In other embodiments, R7 is aryl or substituted aryl. In other embodiments, R7 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R7 is heteroaryl or substituted heteroaryl. In other embodiments, R7 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R7 is acyloxy or substituted acyloxy. In other embodiments, R7 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other
embodiments, R7 is acyl or substituted acyl. In other embodiments, R7 is thiol. In other embodiments, R7 is amino or substituted amino. In other embodiments, R7 is aminoacyl or substituted aminoacyl. In other embodiments, R7 is azido. In other embodiments, R7 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R7 is cyano. In other embodiments, R7 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R7 is nitro. In certain embodiments, R7 is amino.
[00186] In some embodiments, R9 is alkyl or substituted alkyl, such as methyl, ethyl or propyl. In certain instances, R9 is pentalfuoro ethyl. In other embodiments, R9 is hydrogen. In other embodiments, R9 is aryl or substituted aryl. In other embodiments, R9 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R9 is heteroaryl or substituted heteroaryl. In other embodiments, R9 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R9 is acyloxy or substituted acyloxy. In other embodiments, R9 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R9 is acyl or substituted acyl. In other embodiments, R9 is thiol. In other embodiments, R9 is amino or substituted amino. In other embodiments, R9 is aminoacyl or substituted aminoacyl. In other embodiments, R9 is azido. In other embodiments, R9 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R9 is cyano. In other embodiments, R9 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R9 is nitro. In certain embodiments, R7 is amino.
[00187] In some embodiments, R10 is hydrogen. In other embodiments, R10 is alkyl or substituted alkyl. In other embodiments, R10 is aryl or substituted aryl. In other
embodiments, R10 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R10 is heteroaryl or substituted heteroaryl. In other embodiments, R10 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R10 is acyloxy or substituted acyloxy. In other embodiments, R10 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R10 is acyl or substituted acyl. In other embodiments, R10 is thiol. In other embodiments, R10 is amino or substituted amino. In other embodiments, R10 is aminoacyl or substituted aminoacyl. In other embodiments, R10 is azido. In other embodiments, R10 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R10 is cyano. In other embodiments, R10 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R10 is nitro. In certain embodiments, R10 is amino.
[00188] In some embodiments, R11 is hydrogen. In other embodiments, R11 is alkyl or substituted alkyl. In other embodiments, R11 is aryl or substituted aryl. In other embodiments, R11 is heterocycloalkyl or substituted heterocycloalkyl. In other embodiments, R11 is heteroaryl or substituted heteroaryl. In other embodiments, R11 is hydroxyl, alkoxyl or substituted alkoxyl. In other embodiments, R11 is acyloxy or substituted acyloxy. In other embodiments, R11 is alkoxylcarbonyl or substituted alkoxycarbonyl. In other embodiments, R11 is acyl or substituted acyl. In other embodiments, R11 is thiol. In other embodiments, R11 is amino or substituted amino. In other embodiments, R11 is aminoacyl or substituted aminoacyl. In other embodiments, R11 is azido. In other embodiments, R11 is carboxyl, substituted carboxyl, carboxyalkyl or substituted carboxyalkyl. In other embodiments, R11 is cyano. In other embodiments, R11 is a halogen, such as -F, -Cl, -Br and -I. In other embodiments, R11 is nitro. In certain embodiments, R11 is amino.
[00189] In certain embodiments, a compound of interest and salts or solvates or
stereoisomers thereof, include:
(“RO-4929097”) ((2,2-dimethyl-N-[(l0S)-9-oxo-8-azatricyclo[9.4.0.02,7]pentadeca- l,2,4,6,l l,l3-hexaene-l0-yl]-N’-(2,2,3,3,3-pentafluoropropyl)propanediamide)
Compounds of Formula X
[00190] Compositions which find use in the methods of the present disclosure can include compounds of Formula X, shown below, which formula encompasses Fmoc-leucine and pharmaceutically acceptable salts and derivatives thereof.
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein R 1 i s selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR2, -C(0)OR2, -C(0)NR2R3, - C=NR2, -OR2, -OC(0)R2, -S(0)t-R2, -NR2R3, -NR2C(0)R3, -N=CR2R3, wherein t is 0, 1, 2 or 3 and R8 and R9 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen; and PG is a hydroxyl protecting group such as benzyl ether, methyl ester, benzoic acid ester, t-butyl ester, t-butyl ether (TBDMS, TBDPS), methoxymethyl ether (MOM), allyl ether, tetrahydropyranyl ether (THP). In some embodiments, PG is
fluorenylmethyloxycarbonyl (FMOC).
[00192] In certain embodiments, a compound of interest and salts or solvates or
stereoisomers thereof, include:
O
OH
Fmoc
(“Fmoc-Leucine”)
FORMULATIONS, DOSAGES, AND ROUTES OF ADMINISTRATION
[00193] In general, an active agent (e.g., a compound of Formulae I-X, or a
pharmaceutically acceptable salt or derivative thereof) is prepared in a pharmaceutically acceptable composition(s) for delivery to a host.
[00194] Pharmaceutically acceptable carriers preferred for use with active agents (and optionally one or more additional therapeutic agent) may include sterile aqueous or non- aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, and microparticles, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. A composition comprising an active agent (and optionally one or more additional therapeutic agent) may also be lyophilized using means well known in the art, for subsequent reconstitution and use according to the invention.
Formulations
[00195] An active agent is generally administered to an individual in need thereof in a formulation with a pharmaceutically acceptable excipient(s). A wide variety of pharmaceutically acceptable excipients is known in the art and need not be discussed in detail herein. Pharmaceutically acceptable excipients have been amply described in a variety of publications, including, for example, A. Gennaro (2000)“Remington: The Science and Practice of Pharmacy”, 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems (1999) H. C. Ansel et ak, eds 7th ed., Lippincott, Williams, & Wilkins; and Handbook of Pharmaceutical Excipients
(2000) A. H. Kibbe et al., eds., 3rd ed. Amer. Pharmaceutical Assoc. For the purposes of the following description of formulations,“active agent” includes an active agent as described above, and optionally one or more additional therapeutic agent.
[00196] In a subject method, an active agent may be administered to the host using any convenient means capable of resulting in treatment of cardiac valve disease, e.g., CAVD. Thus, an active agent can be incorporated into a variety of formulations for therapeutic administration. For example, an active agent can be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable carriers or diluents, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosols. In an exemplary embodiment, an active agent is formulated as a gel, as a solution, or in some other form suitable for intravaginal administration. In a further exemplary embodiment, an active agent is formulated as a gel, as a solution, or in some other form suitable for rectal (e.g., intrarectal)
administration.
[00197] In pharmaceutical dosage forms, an active agent may be administered in the form of its pharmaceutically acceptable salts, or it may also be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds. The following methods and excipients are merely exemplary and are in no way limiting.
[00198] In some embodiments, an active agent is formulated in an aqueous buffer.
Suitable aqueous buffers include, but are not limited to, acetate, succinate, citrate, and phosphate buffers varying in strengths from about 5 mM to about 100 mM. In some embodiments, the aqueous buffer includes reagents that provide for an isotonic solution. Such reagents include, but are not limited to, sodium chloride; and sugars e.g., mannitol, dextrose, sucrose, and the like. In some embodiments, the aqueous buffer further includes a non-ionic surfactant such as polysorbate 20 or 80. Optionally the formulations may further include a preservative. Suitable preservatives include, but are not limited to, a benzyl alcohol, phenol, chlorobutanol, benzalkonium chloride, and the like. In many cases, the formulation is stored at about 4°C. Formulations may also be lyophilized, in which case they generally include cryoprotectants such as sucrose, trehalose, lactose,
maltose, mannitol, and the like. Lyophilized formulations can be stored over extended periods of time, even at ambient temperatures.
[00199] For oral preparations, an active agent can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules, for example, with conventional additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators, such as com starch, potato starch or sodium
carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents.
[00200] An active agent can be formulated into preparations for injection by dissolving, suspending or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.
[00201] An active agent can be utilized in aerosol formulation to be administered via inhalation. An active agent can be formulated into pressurized acceptable propellants such as dichlorodifluoromethane, propane, nitrogen and the like.
[00202] Furthermore, an active agent can be made into suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases. An active agent can be administered rectally via a suppository. The suppository can include vehicles such as cocoa butter, carbowaxes and polyethylene glycols, which melt at body temperature, yet are solidified at room temperature.
[00203] Unit dosage forms for oral or rectal administration such as syrups, elixirs, and suspensions may be provided wherein each dosage unit, for example, teaspoonful, tablespoonful, tablet or suppository, contains a predetermined amount of the
composition containing one or more active agents. Similarly, unit dosage forms for injection or intravenous administration may comprise the active agent(s) in a
composition as a solution in sterile water, normal saline or another pharmaceutically acceptable carrier.
[00204] Unit dosage forms for intravaginal or intrarectal administration such as syrups, elixirs, gels, and suspensions may be provided wherein each dosage unit, for example, teaspoonful, tablespoonful, tablet, unit gel volume, or suppository, contains a predetermined amount of the composition containing one or more active agents.
[00205] The term“unit dosage form,” as used herein, refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of an active agent, calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier or vehicle. The specifications for a given active agent will depend in part on the particular compound employed and the effect to be achieved, and the pharmacodynamics associated with each compound in the host.
[00206] Other modes of administration will also find use with the subject invention. For instance, an active agent can be formulated in suppositories and, in some cases, aerosol and intranasal compositions. For suppositories, the vehicle composition will include traditional binders and carriers such as, polyalkylene glycols, or triglycerides. Such suppositories may be formed from mixtures containing the active ingredient in the range of about 0.5% to about 10% (w/w), e.g. about 1% to about 2%.
[00207] An active agent can be administered as an injectable. Typically, injectable
compositions are prepared as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation may also be emulsified or the active ingredient encapsulated in liposome vehicles.
[00208] An active agent will in some embodiments be formulated for vaginal delivery. A subject formulation for intravaginal administration comprises an active agent formulated as an intravaginal bioadhesive tablet, intravaginal bioadhesive microparticle, intravaginal cream, intravaginal lotion, intravaginal foam, intravaginal ointment, intravaginal paste, intravaginal solution, or intravaginal gel.
[00209] An active agent will in some embodiments be formulated for rectal delivery. A subject formulation for intrarectal administration comprises an active agent formulated as an intrarectal bioadhesive tablet, intrarectal bioadhesive microparticle, intrarectal
cream, intrarectal lotion, intrarectal foam, intrarectal ointment, intrarectal paste, intrarectal solution, or intrarectal gel.
[00210] A subject formulation comprising an active agent includes one or more of an excipient (e.g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate or calcium carbonate), a binder (e.g., cellulose, methylcellulose, hydroxymethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, poly(ethylene glycol), sucrose or starch), a disintegrator (e.g., starch, carboxymethylcellulose, hydroxypropyl starch, low substituted hydroxypropylcellulose, sodium bicarbonate, calcium phosphate or calcium citrate), a lubricant (e.g., magnesium stearate, light anhydrous silicic acid, talc or sodium lauryl sulfate), a flavoring agent (e.g., citric acid, menthol, glycine or orange powder), a preservative (e.g., sodium benzoate, sodium bisulfite, methylparaben or propylparaben), a stabilizer (e.g., citric acid, sodium citrate or acetic acid), a suspending agent (e.g., methylcellulose, polyvinylpyrrolidone or aluminum stearate), a dispersing agent (e.g.,
hydroxypropylmethylcellulose), a diluent (e.g., water), and base wax (e.g., cocoa butter, white petrolatum or polyethylene glycol).
[00211] Tablets comprising an active agent may be coated with a suitable film-forming agent, e.g., hydroxypropylmethyl cellulose, hydroxypropyl cellulose or ethyl cellulose, to which a suitable excipient may optionally be added, e.g., a softener such as glycerol, propylene glycol, di ethyl phthal ate, or glycerol triacetate; a filler such as sucrose, sorbitol, xylitol, glucose, or lactose; a colorant such as titanium hydroxide; and the like.
[00212] Suitable excipient vehicles are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the vehicle may contain minor amounts of auxiliary substances such as wetting or emulsifying agents or pH buffering agents. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., l7th edition, 1985. The composition or formulation to be administered will, in any event, contain a quantity of the agent adequate to achieve the desired state in the subject being treated.
[00213] The pharmaceutically acceptable excipients, such as vehicles, adjuvants, carriers or diluents, are readily available to the public. Moreover, pharmaceutically acceptable
auxiliary substances, such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are readily available to the public.
Dosages
[00214] Although the dosage used will vary depending on the clinical goals to be
achieved, a suitable dosage range of an active agent is one which provides up to about 1 mg to about 5000 mg, e.g., from about 1 mg to about 25 mg, from about 25 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 200 mg, from about 200 mg to about 250 mg, from about 250 mg to about 500 mg, from about 500 mg to about 1000 mg, or from about 1000 mg to about 5000 mg of an active agent, which can be administered in a single dose.
[00215] Those of skill will readily appreciate that dose levels can vary as a function of the specific compound, the severity of the symptoms and the susceptibility of the subject to side effects. Preferred dosages for a given compound are readily determinable by those of skill in the art by a variety of means.
[00216] In some embodiments, a suitable dose of a compound of Formulae I-X a
pharmaceutically acceptable salt or derivative thereof, is in the range of from about 1 mg/kg body weight to about 500 mg/kg body weight, e.g., from about 5 mg/kg body weight to about 500 mg/kg body weight, from about 10 mg/kg body weight to about 500 mg/kg body weight, from about 20 mg/kg body weight to about 500 mg/kg body weight, from about 30 mg/kg body weight to about 500 mg/kg body weight, from about 40 mg/kg body weight to about 500 mg/kg body weight, from about 50 mg/kg body weight to about 500 mg/kg body weight, from about 60 mg/kg body weight to about 500 mg/kg body weight, from about 70 mg/kg body weight to about 500 mg/kg body weight, from about 80 mg/kg body weight to about 500 mg/kg body weight, from about 90 mg/kg body weight to about 500 mg/kg body weight, from about 100 mg/kg body weight to about 500 mg/kg body weight, from about 200 mg/kg body weight to about 500mg/kg body weight, from about 300 mg/kg body weight to about 500mg/kg body weight, or from about 400 mg/kg body weight to about 500mg/kg body weight.
[00217] In some embodiments, a suitable dose of a compound of Formulae I-X or a
pharmaceutically acceptable salt or derivative thereof, is in the range of from about 1
mg/kg body weight to about 5 mg/kg body weight, from about 5 mg/kg body weight to about 10 mg/kg body weight, from about 10 mg/kg body weight to about 20 mg/kg body weight, from about 20 mg/kg body weight to about 30 mg/kg body weight, from about 30 mg/kg body weight to about 40 mg/kg body weight, from about 40 mg/kg body weight to about 50 mg/kg body weight, from about 50 mg/kg body weight to about 100 mg/kg body weight, or from about 100 mg/kg body weight to about 500 mg/kg body weight.
[00218] In some embodiments, a single dose of an active agent is administered. In other embodiments, multiple doses of an active agent are administered. Where multiple doses are administered over a period of time, an active agent is administered, e.g., twice daily (qid), daily (qd), every other day (qod), every third day, three times per week (tiw), or twice per week (biw) over a period of time. For example, an active agent is administered qid, qd, qod, tiw, or biw over a period of from one day to about 2 years or more. For example, an active agent is administered at any of the aforementioned frequencies for one week, two weeks, one month, two months, six months, one year, or two years, or more, depending on various factors.
[00219] Where two different active agents are administered, e.g., any two or more
compounds selected from compounds of Formulae I-X. a first active agent and a second active agent can be administered in separate formulations. A first active agent and a second active agent can be administered substantially simultaneously, or within about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 8 hours, about 16 hours, about 24 hours, about 36 hours, about 72 hours, about 4 days, about 7 days, or about 2 weeks of one another. The separate pharmaceutical compositions comprising the different agents may be administered using the same or different routes of administration in accordance with any medically acceptable method known in the art.
[00220] In some embodiments, a compound of Formula I is administered in combination with a compound of Formula III. In a nonlimiting example, XCT-790 (2E-3-(4-{[2,4- bis(trifluoromethyl)benzyl]oxy}-3-methoxyphenyl)-2-cyano-N-[5-(trifluoromethyl)- l,3,4-thiadiazol-2-yl]acrylamide) is administered in combination with GSK-837149A (4,4’-(carbonyldiimino)bis[N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide).
[00221] In some embodiments, a compound of Formula I is administered in combination with a compound of Formula II and a compound of Formula II. In a nonlimiting example, XCT-790 (2E-3-(4-{[2,4-bis(trifluoromethyl)benzyl]oxy}-3-methoxyphenyl)- 2-cyano-N-[5-(trifluoromethyl)-l,3,4-thiadiazol-2-yl]acrylamide) is administered in combination with TG-003 ((Z)-l-(3-ethyl-5-methoxy-2,3-dihydrobenzothiazol-2- ylidene)propan-2-one) and GSK-837149A (4,4’-(carbonyldiimino)bis[N-(4-methyl-2- pyrimidinyl)-benzenesulfonamide).
[00222] The compound of Formula I (e.g., XCT-790) can be administered prior to,
concurrent with, or subsequent to the compound of Formula III (e.g., GSK-837149A) and/or the compound of Formula II (e.g., TG-003). If provided at the same time as the compound of Formula III (e.g., GSK-837149A) and/or the compound of Formula II (e.g., TG-003), the compound of Formula I (e.g., XCT-790) can be provided in the same or in a different composition. Thus, the three agents, or two of the three agents can be presented to the individual by way of concurrent therapy. By“concurrent therapy” is intended administration to a human subject such that the therapeutic effect of the combination of the substances is caused in the subject undergoing therapy. For example, concurrent therapy may be achieved by administering at least one therapeutically effective dose of a pharmaceutical composition comprising a compound of Formula I (e.g., XCT-790) and at least one therapeutically effective dose of a pharmaceutical composition comprising a compound of Formula III (e.g., GSK-837149A) and, optionally, at least one therapeutically effective dose of a composition comprising a compound of Formula II (e.g., TG-003) according to a particular dosing regimen.
Administration of the separate pharmaceutical compositions can be at the same time (i.e., simultaneously) or at different times (i.e., sequentially, in either order, on the same day, or on different days), as long as the therapeutic effect of the combination of these compounds is caused in the subject undergoing therapy.
Routes of Administration
[00223] An active agent is administered to an individual using any available method and route suitable for drug delivery, including in vivo and ex vivo methods, as well as systemic and localized routes of administration.
[00224] Conventional and pharmaceutically acceptable routes of administration include intranasal, intramuscular, intratracheal, transdermal, subcutaneous, intradermal, topical application, intravenous, vaginal, nasal, and other parenteral routes of administration. In some embodiments, an active agent is administered via an intravaginal route of administration. In other embodiments, an active agent is administered via an intrarectal route of administration. Routes of administration may be combined, if desired, or adjusted depending upon the agent and/or the desired effect. The composition can be administered in a single dose or in multiple doses.
[00225] An active agent can be administered to a host using any available conventional methods and routes suitable for delivery of conventional drugs, including systemic or localized routes. In general, routes of administration contemplated by the invention include, but are not necessarily limited to, enteral, parenteral, or inhalational routes.
[00226] Parenteral routes of administration other than inhalation administration include, but are not necessarily limited to, topical, vaginal, transdermal, subcutaneous, intramuscular, and intravenous routes, i.e., any route of administration other than through the alimentary canal. Parenteral administration can be carried to effect systemic or local delivery of the agent. Where systemic delivery is desired, administration typically involves invasive or systemically absorbed topical or mucosal administration of pharmaceutical preparations.
[00227] An active agent can also be delivered to the subject by enteral administration.
Enteral routes of administration include, but are not necessarily limited to, oral and rectal (e.g., using a suppository) delivery.
[00228] By treatment is meant at least an amelioration of the symptoms associated with the pathological condition afflicting the host, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g. symptom, associated with the pathological condition being treated, such as the degree of calcification of an aortic valve. As such, treatment also includes situations where the pathological condition, or at least symptoms associated therewith, are completely inhibited, e.g.
prevented from happening, or stopped, e.g. terminated, such that the host no longer suffers from the pathological condition, or at least the symptoms that characterize the pathological condition.
Subjects Suitable for Treatment
[00229] A variety of hosts (wherein the term“host” is used interchangeably herein with the terms“subject” and“patient”) are treatable according to the subject methods.
Generally such hosts are“mammals” or“mammalian,” where these terms are used broadly to describe organisms which are within the class mammalia, and primates (e.g., humans, chimpanzees, and monkeys). In many embodiments, the hosts will be humans. A suitable subject may be a subject that has been identified as at risk of or diagnosed with a cardiac valve disease, e.g., CAVD, including aortic sclerosis, and/or calcific aortic stenosis.
[00230] Total cholesterol, increased low-density lipoprotein (LDL) cholesterol, increased lipoprotein(a), increased triglycerides, decreased high-density lipoprotein cholesterol, male sex, cigarette smoking, hypertension, and diabetes mellitus have been reported to increase the incidence of aortic stenosis, and may contribute to endothelial dysfunction and leaflet damage. In addition, patients with familial hypercholesterolaemia develop peripheral vascular disease, coronary artery disease and aortic valve lesions, which calcify with age. Oxidised LDL (oxLDL) is implicated in vascular calcification associated with atherosclerosis. Elevated blood levels of oxLDL correlate with aortic valve calcification and fibrosis, and oxLDL accumulation in calcific, stenotic aortic valves has been described. Metabolic bone diseases, e.g., Paget’s disease, secondary hyperparathyroidism and renal disease, as well as increased serum creatinine and calcium are also linked to progression of valve calcification. Patients with valve malformations, e.g. bicuspid aortic valve, are also at risk for valve calcification.
Additionally, patients identified as having a mutation in one of the multiple genes found to be associated with valve calcification may be identified as at-risk patients where preventative treatment is recommended, e.g., patients identified as having a mutation in one or more of NOTCH1, SMAD6, and GATA5. A suitable subject may also be a subject that has a NOTCH1 haploinsufficiency. Accordingly, a suitable subject may be a subject having one or more of the above clinical and/or genetic risk factors.
Kits, Containers, Devices, Delivery Systems
[00231] Kits with unit doses of the active agent, e.g. in oral, vaginal, rectal, transdermal, or injectable doses (e.g., for intramuscular, intravenous, or subcutaneous injection), are provided. In such kits, in addition to the containers containing the unit doses will be an informational package insert describing the use and attendant benefits of the drugs in treating or preventing cardiac valve disease. Suitable active agents and unit doses are those described herein above.
[00232] In many embodiments, a subject kit will further include instructions for
practicing the subject methods or means for obtaining the same (e.g., a website URL directing the user to a webpage which provides the instructions), where these instructions are typically printed on a substrate, which substrate may be one or more of: a package insert, the packaging, formulation containers, and the like.
[00233] In some embodiments, a subject kit includes one or more components or features that increase patient compliance, e.g., a component or system to aid the patient in remembering to take the active agent at the appropriate time or interval. Such components include, but are not limited to, a calendaring system to aid the patient in remembering to take the active agent at the appropriate time or interval.
[00234] The present invention provides a delivery system comprising a compound of Formulae I-X, or a pharmaceutically acceptable salt or derivative thereof. In some embodiments, the delivery system is a delivery system that provides for injection of a formulation comprising an active agent subcutaneously, intravenously, or
intramuscularly. In other embodiments, the delivery system is a vaginal or rectal delivery system.
[00235] In some embodiments, an active agent is packaged for oral administration. The present invention provides a packaging unit comprising daily dosage units of an active agent. For example, the packaging unit is in some embodiments a conventional blister pack or any other form that includes tablets, pills, and the like. The blister pack will contain the appropriate number of unit dosage forms, in a sealed blister pack with a cardboard, paperboard, foil, or plastic backing, and enclosed in a suitable cover. Each blister container may be numbered or otherwise labeled, e.g., starting with day 1.
[00236] In some embodiments, a subject delivery system comprises an injection device. Exemplary, non-limiting drug delivery devices include injections devices, such as pen injectors, and needle/syringe devices. In some embodiments, the invention provides an injection delivery device that is pre-loaded with a formulation comprising an effective amount of a compound of Formulae I-X or a pharmaceutically acceptable salt or derivative thereof. For example, a subject delivery device comprises an injection device pre-loaded with a single dose of a compound of Formulae I-X or a pharmaceutically acceptable salt or derivative thereof. A subject injection device can be re-usable or disposable.
[00237] Pen injectors are well known in the art. Exemplary devices which can be adapted for use in the present methods are any of a variety of pen injectors from Becton
Dickinson, e.g., BD™ Pen, BD™ Pen II, BD™ Auto-Injector; a pen injector from Innoject, Inc.; any of the medication delivery pen devices discussed in U.S. Pat. Nos. 5,728,074, 6,096,010, 6,146,361, 6,248,095, 6,277,099, and 6,221,053; and the like. The medication delivery pen can be disposable, or reusable and refillable.
[00238] The present invention provides a delivery system for vaginal or rectal delivery of an active agent to the vagina or rectum of an individual. The delivery system comprises a device for insertion into the vagina or rectum. In some embodiments, the delivery system comprises an applicator for delivery of a formulation into the vagina or rectum; and a container that contains a formulation comprising an active agent. In these embodiments, the container (e.g., a tube) is adapted for delivering a formulation into the applicator. In other embodiments, the delivery system comprises a device that is inserted into the vagina or rectum, which device includes an active agent. For example, the device is coated with, impregnated with, or otherwise contains a formulation comprising the active agent.
[00239] In some embodiments, the vaginal or rectal delivery system is a tampon or
tampon-like device that comprises a subject formulation. Drug delivery tampons are known in the art, and any such tampon can be used in conjunction with a subject drug delivery system. Drug delivery tampons are described in, e.g., U.S. Pat. No. 6,086,909.
If a tampon or tampon-like device is used, there are numerous methods by which an active agent can be incorporated into the device. For example, the drug can be
incorporated into a gel-like bioadhesive reservoir in the tip of the device. Alternatively, the drug can be in the form of a powdered material positioned at the tip of the tampon. The drug can also be absorbed into fibers at the tip of the tampon, for example, by dissolving the drug in a pharmaceutically acceptable carrier and absorbing the drug solution into the tampon fibers. The drug can also be dissolved in a coating material which is applied to the tip of the tampon. Alternatively, the drug can be incorporated into an insertable suppository which is placed in association with the tip of the tampon.
[00240] In other embodiments, the drug delivery device is a vaginal or rectal ring.
Vaginal or rectal rings usually consist of an inert elastomer ring coated by another layer of elastomer containing an active agent to be delivered. The rings can be easily inserted, left in place for the desired period of time (e.g., up to 7 days), then removed by the user. The ring can optionally include a third, outer, rate-controlling elastomer layer which contains no drug. Optionally, the third ring can contain a second drug for a dual release ring. The drug can be incorporated into polyethylene glycol throughout the silicone elastomer ring to act as a reservoir for drug to be delivered.
[00241] In other embodiments, a subject vaginal or rectal delivery system is a vaginal or rectal sponge. The active agent is incorporated into a silicone matrix which is coated onto a cylindrical drug-free polyurethane sponge, as described in the literature.
[00242] Pessaries, tablets, and suppositories are other examples of drug delivery systems which can be used, e.g., in carrying out a method of the present disclosure. These systems have been described extensively in the literature.
[00243] Bioadhesive microparticles constitute still another drug delivery system suitable for use in the present invention. This system is a multi-phase liquid or semi-solid preparation which does not seep from the vagina or rectum as do many suppository formulations. The substances cling to the wall of the vagina or rectum and release the drug over a period of time. Many of these systems were designed for nasal use but can be used in the vagina or rectum as well (e.g. U.S. Pat. No. 4,756,907). The system may comprise microspheres with an active agent; and a surfactant for enhancing uptake of the drug. The microparticles have a diameter of 10-100 pm and can be prepared from starch, gelatin, albumin, collagen, or dextran.
[00244] Another system is a container comprising a subject formulation (e.g., a tube) that is adapted for use with an applicator. The active agent is incorporated into creams, lotions, foams, paste, ointments, and gels which can be applied to the vagina or rectum using an applicator. Processes for preparing pharmaceuticals in cream, lotion, foam, paste, ointment and gel formats can be found throughout the literature. An example of a suitable system is a standard fragrance free lotion formulation containing glycerol, ceramides, mineral oil, petrolatum, parabens, fragrance and water such as the product sold under the trademark JERGENS™ (Andrew Jergens Co., Cincinnati, Ohio). Suitable nontoxic pharmaceutically acceptable systems for use in the compositions of the present invention will be apparent to those skilled in the art of pharmaceutical formulations and examples are described in Remington's Pharmaceutical Sciences, l9th Edition, A. R. Gennaro, ed., 1995. The choice of suitable carriers will depend on the exact nature of the particular vaginal or rectal dosage form desired, e.g., whether the active ingredient(s) is/are to be formulated into a cream, lotion, foam, ointment, paste, solution, or gel, as well as on the identity of the active ingredient(s). Other suitable delivery devices are those described in ET.S. Pat. No. 6,476,079.
[00245] In some embodiments, more than one active agent is included in the kit, e.g., any two or more compounds selected from compounds of Formulae I-X. For example, the kit may comprise a compound of Formula I and a compound of Formula III, or a compound of Formula I, a compound of Formula II, and a compound of Formula III. In one embodiment, the kit comprises XCT-790, and GSK-837149A. In another embodiment, the kit comprises XCT-790, TG-003, and GSK-837149A.
METHODS OF IDENTIFYING A CANDIDATE COMPOUND FOR TREATMENT OF CARDIAC VALVE DISEASE
[00246] The present disclosure provides screening methods for identifying a candidate compound for treatment of cardiac valve disease. In some embodiments, the methods include contacting human NOTCHl+/ endothelial cells with a compound; performing targeted RNA sequencing (RNA-seq) to provide an expression profile for the human NOTCHl+/ endothelial cells resulting from the contacting, wherein the targeted RNA- seq comprises sequencing RNA transcripts for a plurality of the genes listed in Table 1;
comparing the expression profile resulting from the contacting with an isogenic WT expression profile for the plurality of genes listed in Table 1; and identifying the compound as a candidate compound for treatment of cardiac valve disease when the expression profile resulting from the contacting is corrected to the isogenic WT expression profile.
Table 1
[00247] In some embodiments, the plurality includes one or more or all of the following genes: NOTCH1, SOX7, TCF4, and SMAD1. In some embodiments, the plurality includes NOTCH1, SOX7, TCF4, and SMAD1 and at least 1, e.g., 2, 3, 4, 5, 6, 7, 8, 9,
10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, or 115 additional genes selected from Table 1. In some embodiments, the plurality includes at least one housekeeping gene. In some embodiments, the at least one housekeeping gene is selected from CHMP2A, Clorf43, and REEP5. In some embodiments, one, two or all of the housekeeping genes CHMP2A, Clorf43, and REEP5 are excluded from the expression profile. For example, in some embodiments, the targeted RNA-seq does not include sequencing RNA transcripts for one, two or all of the housekeeping genes CHMP2A, Clorf43, and REEP5.
[00248] In some embodiments, the human NOTCHl+/ endothelial cells are derived from human induced pluripotent stem cells (iPSC) derived from a subject having CAVD, e.g., iPSC derived from fibroblasts of a subject having CAVD. In other embodiments, wild type cells, e.g., wild type human endothelial cells, genetically engineered to have the Nl mutation, are used in place of human NOTCHl+/ endothelial cells derived from human induced pluripotent stem cells (iPSC) derived from a subject having CAVD. In still other embodiments, endothelial cells are derived from human induced pluripotent stem cells (iPSC) e.g., iPSC derived from fibroblasts, wherein the endothelial cells are genetically engineered to have the Nl mutation.
[00249] One or more suitable machine learning algorithms, e.g., K-nearest neighbors (KNN) algorithm, may be utilized to determine when the expression profile resulting
from the contacting is corrected to the isogenic WT expression profile. A suitable isogenic WT expression profile can be obtained, e.g., by deriving isogenic control lines, wherein the Nl mutation is corrected using an appropriate gene editing tool, e.g., Meganuclease, TALEN, ZFN, or CRISPR/Cas system.
EXEMPLARY NON-LIMITING ASPECTS OF THE DISCLOSURE
[00250] Aspects, including embodiments, of the present subject matter described above may be beneficial alone or in combination, with one or more other aspects or
embodiments. Without limiting the foregoing description, certain non-limiting aspects of the disclosure are provided below. As will be apparent to those of ordinary skill in the art upon reading this disclosure, each of the individually numbered aspects may be used or combined with any of the preceding or following individually numbered aspects. This is intended to provide support for all such combinations of aspects and is not limited to combinations of aspects explicitly provided below. It will be apparent to one of ordinary skill in the art that various changes and modifications can be made without departing from the spirit or scope of the invention.
1. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
n is an integer from 1 to 8;
X is O or S;
Y is O or S; and
each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted
heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR12, - C(0)0R12, -C(0)NR12R13, -C=NR12, -OR12, -0C(0)R12, -S(0)t-R7, -NR12R13, -NR12C(0)R13, - N=CR12R13, wherein t is 0, 1, 2 or 3 and R12 and R13 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted
heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
2. The method according to 1, wherein R1 is cyano.
3. The method according to any one of 1-2, wherein R1 is methoxy.
4. The method according to any one of 1-3, wherein X is S.
5. The method according to any one of 1-4, wherein Y is O.
6. The method according to any one of 1-5, wherein n is 1.
7. The method according to 1, wherein the compound is XCT-790 (2E-3-(4-{ [2,4- bis(trifluoromethyl)benzyl]oxy}-3-methoxyphenyl)-2-cyano-N-[5-(trifluoromethyl)-l,3,4- thiadiazol-2-yl]acrylamide):
8. The method according to any one of 1-7, wherein the cardiac valve disease is a calcific aortic valve disease.
9. The method according to any one of 1-7, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
10. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula II:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
X is O or S; and
each of R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR12, -C(0)0R12, -
C(0)NR12R13, -C=NR12, -OR12, -OC(0)R12, -S(0)t-R7, -NR12R13, -NR12C(0)R13, -N=CR12R13, wherein t is 0, 1, 2 or 3 and R12 and R13 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
11. The method according 10, wherein R2 is methoxy.
12. The method according to any one of 10-11, wherein R5 is methyl.
13. The method according to any one of 10-12, wherein R6 is methyl.
14. The method according to any one of 10-13, wherein X is O.
15. The method according to 10, wherein the compound is TG-003 ((Z)-l-(3-ethyl-5- methoxy-2,3-dihydrobenzothiazol-2-ylidene)propan-2-one):
16. The method according to any one of 10-15, wherein the cardiac valve disease is a calcific aortic valve disease.
17. The method according to any one of 10-15, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
18. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula III:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR15, -C(0)0R15, -C(0)NR15R16, -C=NR15, -OR15, -0C(0)R15, -S(0)t-R15, -NR15R16, - NR15C(0)R16, -N=CR15R16, wherein t is 0, 1, 2 or 3 and R15 and R15 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
19. The method according to 18, wherein R3 is methyl.
20. The method according to any one of 18-19, wherein R12 is methyl.
21. The method according to 18, wherein the compound is GSK-837149A (4,4’- (carbonyldiimino)bis[N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide):
22. The method according to any one of 18-21, wherein the cardiac valve disease is a calcific aortic valve disease.
23. The method according to any one of 18-21, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
24. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula IV:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4 and R5 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR15, -C(0)0R15, - C(0)NR15R16, -C=NR15, -OR15, -0C(0)R15, -S(0)t-R15, -NR15R16, -NR15C(0)R16, -N=CR15R16, wherein t is 0, 1, 2 or 3 and R15 and R15 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
25. The method according to 24, wherein R1 is hydroxyl.
26. The method according to any one of 24-25, wherein R4 is hydroxyl.
27. The method according to any one of 24-26, wherein R5 is allyl.
28. The method according to 24, wherein the compound is Naloxone ((4R,4aS,7aR, l2bS)- 4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,l3-hexahydro-lH-4, l2-methanobenzofuro[3,2- e]isoquinoline-7-one):
29. The method according to any one of 24-28, wherein the cardiac valve disease is a calcific aortic valve disease.
30. The method according to any one of 24-28, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
31. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula V:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6, R7, R8 and R9 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR10, -C(0)OR10, - C(O)NR10Ru, -C=NR10, -OR10, -OC(0)R10, -S(0)t-R10, -NR10RU, -NR10C(O)Ru, -N=CR10RU, wherein t is 0, 1, 2 or 3 and R10 and R11 are independently selected from hydrogen, substituted
or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
32. The method according to 31, wherein R6 is hydrogen.
33. The method according to any one of 31-32, wherein R7 is methyl.
34. The method according to any one of 31-33, wherein R8 is hydroxyl.
35. The method according to any one of 31-34, wherein R9 is methyl.
36. The method according to 31, wherein the compound is Cytochalasin:
37. The method according to any one of 31-36, wherein the cardiac valve disease is a calcific aortic valve disease.
38. The method according to any one of 31-36, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
39. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula VI:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6, R7 and R8 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR9, -C(0)0R9, -
C(0)NR9R10, -C=NR9, -OR9, -0C(0)R9, -S(0)t-R9, -NR9R10, -NR9C(0)R10, -N=CR9R10, wherein t is 0, 1, 2 or 3 and R9 and R10 are independently selected from hydrogen, substituted or
unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
40. The method according to 39, wherein each of R1, R2, R3, R4, R5, R6, R7 and R8 are hydrogen.
42. The method according to any one of 39-41, wherein the cardiac valve disease is a calcific aortic valve disease.
43. The method according to any one of 39-41, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
44. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula VI:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2 and R3 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR4, -C(0)0R4, -C(0)NR4R5, -C=NR4, -OR4, -0C(0)R4, -S(0)t-R4, -NR4R5, -NR4C(0)R5, -N=CR4R5, wherein t is 0, 1, 2 or 3 and R4and R5 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
45. The method according to 44, wherein each of R1, R2 and R3 are hydrogen.
46. The method according to 44, wherein the compound is CB-1954 (5-(l-aziridinyl)-2,4- dinitrobenzamide):
47. The method according to any one of 44-46, wherein the cardiac valve disease is a calcific aortic valve disease.
48. The method according to any one of 44-46, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
49. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula VIII:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6 and R7 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR8, -C(0)0R8, - C(0)NR8R9, -C=NR8, -OR9, -0C(0)R8, -S(0)t-R8, -NR8R9, -NR8C(0)R9, -N=CR8R9, wherein t is 0, 1, 2 or 3 and R8 and R9 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
50. The method according to 49, wherein R1 is hydrogen.
51. The method according to 49, wherein R1 is hydroxyl.
52. The method according to any one of 49-51, wherein each of R2, R3, R4, R5, R6 and R7 are hydrogen.
53. The method according to 49, wherein the compound is biperiden ((lRS,2SR,4RS)-l- (bicyclo[2.2.l]hept-5-en-2-yl)-l-phenyl-3-(piperidin- l-yl)propan-l-ol)):
54. The method according to any one of 49-53, wherein the cardiac valve disease is a calcific aortic valve disease.
55. The method according to any one of 49-53, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
56. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula IX:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted
amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR12, -
C(0)0R12, -C(0)NR12R13, -C=NR12, -OR12, -0C(0)R12, -S(0)t-R12, -NR12R13, -NR12C(0)R13, -
N=CR12R13, wherein t is 0, 1, 2 or 3 and R12 and R13 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted
heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
57. The method according to 56, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R10 and R11 are hydrogen.
58. The method according to 56, wherein R9 is pentafluoroethyl.
59. The method according to 56, wherein the compound is RO-4929097 ((2,2-dimethyl-N- [(l0S)-9-oxo-8-azatricyclo[9.4.0.02,7]pentadeca-l,2,4,6, l l,l3-hexaene-l0-yl]-N’-(2,2,3,3,3- pentafluoropropyl)propanediamide):
60. The method according to any one of 56-59, wherein the cardiac valve disease is a calcific aortic valve disease.
61. The method according to any one of 56-59, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
62. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula X:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
R1 is selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl,
heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl,
alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR2, -C(0)0R2, -C(0)NR2R3, -C=NR2, -OR2, -0C(0)R2, -S(0)t-R2, - NR2R3, -NR2C(0)R3, -N=CR2R3, wherein t is 0, 1, 2 or 3 and R8 and R9 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen; and
PG is a hydroxyl protecting group selected from the group consisting of a benzyl ether, methyl ester, benzoic acid ester, t-butyl ester, t-butyl ether (TBDMS, TBDPS), methoxymethyl ether (MOM), allyl ether, tetrahydropyranyl ether (THP), a fluorenylmethyloxycarbonyl (Fmoc).
63. The method according to 62, wherein each of R1 is hydrogen.
64. The method according to 63, wherein PG is fluorenylmethyloxycarbonyl (Fmoc).
66. The method according to any one of 62-65, wherein the cardiac valve disease is a calcific aortic valve disease.
67. The method according to any one of 62-65, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
68. A method of identifying a candidate compound for treatment of cardiac valve disease, the method comprising:
contacting human NOTCH 1_/ endothelial cells with a compound;
performing targeted RNA sequencing (RNA-seq) to provide an expression profile for the human NOTCHl+/ endothelial cells resulting from the contacting, wherein the targeted RNA- seq comprises sequencing RNA transcripts fora plurality of genes selected from Table 1;
comparing the expression profile resulting from the contacting with an isogenic WT expression profile; and
identifying the compound as a candidate compound for treatment of cardiac valve disease when the expression profile resulting from the contacting is corrected to the isogenic WT expression profile.
69. The method of 68, wherein the plurality of genes comprises one or more or all of NOTCH1, SOX7, TCF4, and SMAD1.
70. The method of 68 or 69, wherein the plurality of genes further comprises one or more or all of NOTCH4, HES1, ACE, and GREM1.
71. The method of any one of 68-70, wherein the plurality of genes further comprises one or more or all of CHMP2A, Clorf43, and REEP5.
72. The method of any one of 68-71, wherein the plurality of genes further comprises one or more or all of JAG2, ARHGEF17, MMP10, IRF6, DKK3, AN04, MMP19, SOX11, SOX13, RUNX2, and RUNXl.
73. The method of any one of 68-72, wherein the plurality of genes further comprises one or more or all of ITGA5, CD34, ETS1, CSDA, IGFBP3, SDPR, CDH5, LXN, CXCR4, TNFSF4, GJA4, NRP1, CD24P4, HMGA2, THSD1, RASSF2, HHIP, TERF1, NID2, ALDH1A1, HEY1, ETS2, ITGA9, NRCAM, HOXB5, HOXB6, PRDM1, ClOorflO, ALDH2, COL12A1, SNCA, SFRP1, NPPB, CA8, GNA14, VCAN, HOXB7, ITGA8, ACP5, TMEM178, HOXB3, PLAGL1, NR5A2, VLDLR, BICD1, MAML3, NRG3, FOXF1, CXCL12, HLX, MEIS2, HOXB4, TCF7L1, FGF2, ALX1, CARHSP1, DNER, TGFBR3, TOX3, PDE2A, HOXB2, CA2,
COL15A1, PPARG, IER3, TNFRSF25, FLT4, PRRX1, HOXD1, AFF3, CXCR7, PDE3A, SMTN, BMP6, BMP4, PGF, TXNIP, and DACH1.
74. The method of any one of 68-73, wherein the plurality of genes further comprises one or more or all of F2R, F2RL2, THBS1, FAM124B, PLOD2, COX6A1, KIAA0494, RNF19A, CLEC14A, DIAPH2, NDUFA12, FAM89A, NNMT, MLF1, Clorf54, HAPLN1, IL1RL1, ITPKB, and CD97.
75. The method of any one of 68-74, wherein the human NOTCHl+/ endothelial cells are derived from human induced pluripotent stem cells (iPSC) derived from a subject having CAVD.
76. The method of 75, wherein the iPSC are dervived from fibroblasts of a subject having CAVD.
77. The method of any one of 68-76, wherein the identifying comprises applying a machine learning algorithm to determine when the expression profile resulting from the contacting is corrected to the isogenic WT expression profile.
78. A composition comprising at least one compound of any one of Formulae I-X for use in the treatment of cardiac valve disease.
EXAMPLES
[00251] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of the invention nor are they intended to represent that the experiments below are all or the only experiments performed.
Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric. Standard abbreviations may be used, e.g., bp, base pair(s); kb, kilobase(s); pi, picoliter(s); s or sec, second(s); min, minute(s); h or hr, hour(s); aa, amino acid(s); kb, kilobase(s); bp, base pair(s); nt, nucleotide(s); i.m., intramuscular(ly); i.p.,
intraperitoneal(ly); s.c., subcutaneous(ly); and the like.
MATERIALS AND METHODS
[00252] The following materials and methods generally apply to the results presented in the Examples described herein except where noted otherwise. Additional materials and methods are provided below for each Example as applicable.
Isogenic iPSC Derivation and EC Differentiation
[00253] TALEN-engineered isogenic human iPSCs that were either WT (wild-type) or Nl+/~ were derived and characterized as detailed in Theodoris et ah, Cell.
2015;160: 1072-1086. Isogenic iPSCs (induced pluripotent stem cells) were differentiated into ECs as previously described (Theodoris et al., 2015; White et al., Stem Cells. 2012;31 :92-103). On day 13 of the differentiation process, ECs were greater than 90% double-positive for CD31 (BD #558068) and CD144 (#FAB938lP) by FACS (fluorescence-activated cell sorting) analysis (Figures 9G-H). Small molecule experiments (described below) were conducted at day 15 of differentiation.
Small Molecule Screen and Validation
[00254] Starting on day 15 of differentiation, WT ECs were exposed to 10mM DMSO (dimethyl sulfoxide) (n=80) while isogenic N I ECs were exposed to either 10mM DMSO (n=80) or one of the small molecules from the LOP AC (1280 molecules) (Sigma LO1280) or Sheng Ding (315 molecules) chemical libraries. DMSO or small molecules were renewed with EC media (ScienCell #1001) changes on alternating days until the cells were ultimately collected for analysis on day 21. ECs were imaged using the IN Cell Analyzer on day 21 to evaluate morphology and cell death; wells with extensive cell death were eliminated from final analyses. For validation experiments, promising small molecules identified from the initial screen were applied to Nl+/~ ECs in duplicate or triplicate along with controls of DMSO-exposed WT and Ml ECs (n=4 each) using the same process as the initial screen described above.
Targeted RNA-seq and Analysis Pipeline
[00255] ECs were lysed and RNA was isolated using the Qiagen RNeasy 96-well
purification kit. RNA was diluted so that it was between the lOpg-lng range accepted by the Cellular Research Precise targeted RNA-seq (RNA sequencing) system. Targeted RNA-seq libraries were prepared as per the Cellular Research Precise protocol (Rev 03092015), which includes both molecule and sample barcoding. The selected 119 target genes (see Table 1) included 3 low-expressing housekeeping genes for normalization (CHMP2A, Clorf43, REEP5 ) and either predicted central regulatory nodes or peripheral genes positioned within varied regions of the Nl network to permit identification of small molecules that affected central nodes as well as those that may have a synergistic effect in combination due to regulating different aspects of the network. Briefly, RNA
was added to the Precise Encoding Plate containing indexed dT primer, dNTPs, and Spike-in mRNA controls and incubated at 65°C for 3 minutes followed by cooling on ice. A master-mix of RT enzyme, RNase inhibitor, and buffer was then added to the samples, and they were incubated at 42°C for 30 minutes followed by 80°C for 5 minutes. Each plate of samples was combined into a single 2ml tube and purified with AMPureXP beads. Nl PCR master-mix was added and samples were incubated for 94°C for 2 minutes, followed by 15 cycles of 94°C for 30 seconds, 55°C for 3 minutes, and 68°C for 1 minute, followed by 68°C for 7 minutes. Samples were purified with
AMPureXP beads and N2 PCR master-mix was added. Samples were incubated with the same thermal cycler program as above for 12 cycles. These final libraries were then purified with AMPureXP beads and analyzed for quality and concentration by Agilent Bioanalyzer and Illumina Library Quantification Kit (KAPA Biosystems), respectively. Libraries were normalized to equivalent concentration and pooled for paired-end 100 bp sequencing on an Illumina HiSeq 2500 instrument.
[00256] Sequencing data was analyzed using Cellular Research Precise Analysis Pipeline on the SevenBridges platform, which included analyzing sequencing quality with FASTQC, trimming adapters and filtering reads, demultiplexing based on sample barcodes, aligning reads with Bowtie 2, and determining the number of unique molecular indices per gene. Network inference was based on mutual information of gene expression from all DMSO- and small molecule-exposed samples as described in Margolin et ak, BMC Bioinformatics . 2006;7 Suppl l :S7. Network diagram was generated using NetworkX (Hagberg et ak, Exploring Network Structure, Dynamics, and Function using NetworkX. SciPy. 2008) based on network connections inferred from the small molecule screen data as described above with colors based on whole transcriptome RNA-seq gene expression of isogenic Nl+/~ compared to WT ECs.
EXAMPLE 1
MAP OF GENE NETWORK DYSREGULATED BY Nl HAPLOINSUFFICIENCY
Results
[00257] To map the network disrupted by Nl haploinsufficiency and identify small molecules that correct the network back to the normal state, targeted RNA-seq of 119 genes was performed in isogenic wild-type ( WT) or Nl+/ iPSC-derived ECs exposed to either DMSO or one of 1595 small molecules. The selected 119 target genes were either predicted central regulatory nodes or peripheral genes positioned within varied regions of the Nl network to facilitate identification of small molecules that affected central nodes as well as those that may have a synergistic effect in combination due to regulating different aspects of the network.
[00258] The large number of replicates of WT and Nl-haploinsufficient ECs treated with DMSO or small molecules allowed mapping of the gene network regulated by Nl to a higher degree of confidence than experiments with fewer observations of the network state. Network inference predicted that SOX7 and WNT signaling effector TCF4 , both of which are upregulated by Nl haploinsufficiency and are potentially pro-osteogenic genes, were highly connected within the dysregulated network, with SOX7 being the third most highly connected gene overall (Figures 1 A and 4A-B). Concordant with prior perturbation experiments, BMP signaling effector SMAD1 , which is also upregulated by Nl haploinsufficiency, was predicted to be more peripheral within the network. The most highly interconnected gene was CSDA, which is downregulated by Nl
haploinsufficiency and serves as an anti-inflammatory repressor of the GM-CSF promoter.
EXAMPLE 2
NETWORK-BASED SCREEN IDENTIFIED NETWORK-CORRECTING SMALL MOLECULES
Materials and Methods
[00259] Promising small molecules were identified using either K-nearest neighbor
(KNN) or hierarchical clustering algorithms. A KNN algorithm (k=2) was trained on 73 DMSO-exposed WT and 78 DMSO-exposed
ECs and had an accuracy of 99.3% by leave-one-out (LOO) cross-validation. The KNN algorithm was then applied to the small molecule-exposed ECs to identify small molecules that sufficiently corrected the network gene expression such that treated Nl+/~ ECs were classified as WT. Hierarchical clustering was applied using a complete agglomeration method to identify small
molecules that promoted Nl+/~ ECs to cluster with WT ECs and separately from DMSO- ex posed N I ECs. Promising small molecules identified by the two aforementioned methods were applied to Nl+/~ ECs in duplicate or triplicate with controls of DMSO- exposed WT or N I ECs (n=4 each) and analyzed by targeted RNA-seq as described above. The previously-trained KNN algorithm was applied to the validation samples and compounds that sufficiently corrected the network gene expression such that one or more replicates of treated Nl+/~ ECs classified as WT were selected for further analysis.
Results
[00260] Having mapped the key regulatory nodes within the network dysregulated by Nl haploinsufficiency, small molecules were identified that corrected the network back to the normal state. A K-nearest neighbors (KNN) algorithm was trained to classify the network gene expression by targeted RNA-seq
based on isogenic ECs of each genotype exposed to DMSO. The KNN algorithm classified ECs as either WT or Nl+/~ with 99.3% accuracy by leave-one-out (LOO) cross-validation. The single N I
EC replicate that was misclassified as WT appeared near the boundary of the two classes when mapped onto two principle components (Figure 1B).
[00261] The trained KNN algorithm was then applied to Nl+/~ ECs exposed to one of 1595 small molecules, with the vast majority remaining classified as Nl+/~, but eleven molecules sufficiently corrected the network gene expression such that the treated N I ECs were classified as WT (Figures 1C and 10A-C). These network-correcting molecules were Cytochalasin; Fmoc-leu; GSK837149A; RO-4929097; Alprostadil; Norfloxacin; YC-l; CB_l954; L-74l,626; Naloxone benzoylhydrazone; and
Tul obuterol hy drochl ori de .
[00262] Increased cell migration and proliferation were hypothesized to contribute to valve thickening and calcification in CAVD (cardiac aortic valve disease), and concordantly, two additional network-correcting molecules were anti -proliferative, including CB1954 and cytochalasin. The network-correcting molecules also included two vasodilating compounds, prostaglandin El (alprostadil) and beta-adrenoreceptor agonist tulobuterol hydrochloride.
[00263] To enhance the diversity of algorithms used to select initial candidates, hierarchical clustering was applied using a complete agglomeration method to identify additional small molecules that promoted Nl-haploinsufficient ECs to cluster with WT ECs (Figures 1D, 5A-B, 6A-B, 7A-B, 8A-B, and 10A-C). Among the compounds identified were multiple additional vasodilators including beta-adrenoreceptor- modulating molecules alprenolol and amiodarone, alpha-adrenoreceptor antagonist phentolamine mesylate, and acetylcholine receptor agonist carbachol. This method also identified potentially anti-inflammatory molecules BWB70C and cyclooxygenase inhibitor piroxicam. Additional candidates included potentially anti-atherogenic TG003 and potentially anti-osteogenic XCT790.
[00264] Of the candidates identified by the aforementioned complete or single linkage methods, nine compounds sufficiently corrected the network gene expression such that one or more replicates of treated Nl+/~ ECs were classified as WT by the KNN algorithm in validation trials. When plotted on two principle components, Nl-haploinsufficient ECs treated with the validated molecules localized more closely to WT ECs than those treated with molecules that did not validate. The validated molecules were Cytochalasin; Fmoc-leu; GSK837149A; RO-4929097; CB 1954; Biperiden hydrochloride; Putrescine dihydrochloride, TG003, and XCT790.
EXAMPLE 3
NETWORK-CORRECTING MOLECULES RESTORED PATHWAYS GOVERNING ARTERIAL
THROMBOSIS AND ANGIOGENESIS
Materials and Methods
Whole Transcriptome RNA-seq and Analysis Pipeline
[00265] ECs were lysed and RNA was isolated using the Qiagen RNeasy Micro
purification kit. RNA-seq libraries were constructed using the Clontech SMRTer Stranded RNA-seq Library Prep Kit for Illumina per kit protocol. Libraries were analyzed by Agilent Bioanalyzer, normalized to equivalent concentration, pooled, gel purified, and sequenced 75 bp paired-end on an Illumina NextSeq instrument with 10% PhiX.
[00266] Sequencing quality was assessed with FASTQC (located on the web by placing “www.” in front of“bioinformatics.babraham.ac.uk/projects/fastqc/”). Reads were aligned to the hgl9 (Homo sapiens assembly February 2009) transcriptome and genome using the Spliced Transcripts Alignment to a Reference (STAR) Aligner (Dobin et al., Bioinformatics. 2012;29:15-21) and differential expression was analyzed using Cuffdiff (Trapnell et al., Nat Biotechnol. 20l2;31 :46-53). HOPACH was used for clustering with the correlation metric (van der Laan and Pollard; located on the web by placing“www.” in front of“bioconductor.org/packages/devel/bioc/manuals/hopach/man/hopach.pdf’. GO analyses were completed using GO-Elite and ToppGene (Chen et al., Nucleic Acids Research. 2009;37:W305-W3 l l; Zambon et al., Bioinformatics. 2012;28:2209-2210). Network diagrams were generated using NetworkX (Hagberg et al., SciPy. 2008) based on network connections inferred from mRNA-seq gene expression of isogenic N I
compared to WT ECs with colors based on whole transcriptome RNA-seq gene expression of DMSO- vs small molecule-treated WT and N I ECs.
Results
[00267] Whole transcriptome RNA-seq was performed to determine the effect of the identified network- correcting small molecules on the transcriptional landscape as a whole (Figure 2A). Overall, XCT790 was the most effective at repressing genes aberrantly activated in Nl-haploinsufficient ECs, including those genes involved in extracellular matrix for elasticity, cell motility, arterial thrombosis, T cell signaling, and peroxisomes. TG003 was also broadly effective at repressing these genes, albeit to a lesser degree, with less effect specifically on peroxisome-related genes. Cytochalasin was effective at downregulating arterial thrombosis and T cell signal genes, but worsened the dysregulation of cell motility genes. XCT790, TG003, and cytochalasin had the strongest repressive effect on cadherin-l 1, repression of which prevents CAVD in Nl+/ mice exposed to high fat diet (Figure 9A). XCT790 also effectively restored the transcription of mesoderm and cell cycle checkpoint genes, and GSK837149A restored transcription of a complementary group of genes involved in angiogenesis and cardiovascular development. As a single agent, XCT790 was most effective at restoring
both aberrantly activated and repressed genes, and XCT790-treated ECs correlated most strongly with the transcriptional profile of WT ECs (Figure 2B).
[00268] Given SOX7 and TCF4’ s predicted role as central regulatory nodes within the network dysregulated by Nl haploinsufficiency, correction of these nodes was predicted to have a broad restorative effect on the network as a whole. Indeed, siRNA directly targeting these nodes broadly corrected both upregulated and downregulated genes in Nl-haploinsufficient ECs back towards their normal state (Figures 2C and 9B).
Concordantly, the compound with the strongest restorative effect on these regulatory nodes, XCT790, drove Nl-haploinsufficient ECs to correlate most strongly with WT ECs and corrected the greatest number of genes to the greatest degree from the compounds identified in the network-based screen (Figure 2B, D-E). Thus, treatment that corrected the expression of central regulatory nodes SOX7 and TCF4 was the most effective at restoring the network as a whole.
[00269] Determining the region of the network impacted by each small molecule was hypothesized to inform the selection of molecule combinations to further restore the network to the normal state. When mapping the effects of each small molecule as well as the combination of siRNA targeting SOX7 and TCF4 , XCT790 had the strongest restorative effect on central regions of the network and most closely mimicked the effects of direct siRNA targeting of key nodes SOX7 and TCF4 (Figure 3 A). TG003 also had a strong restorative effect but closely overlapped with the genes affected by
XCT790. Conversely, GSK837149A restored more complementary genes to XCT790 including inflammatory regulator CEACAM1 and INK signaling factor NRK. The complementary network-correcting effects of XCT790 and GSK837149A suggest they may be even more effective in combination.
EXAMPLE 4
NETWORK-CORRECTING MOLECULES REDUCED CARDIAC VALVE STENOSIS IN VIVO
Materials and Methods
In vivo small molecule treatment, echocardiography, and staining of calcification
[00270] Protocols were reviewed/approved by ETCSF Institutional Animal Care and ETse Committee, San Francisco, CA. Nl+h and mTRhet C57B16 mice (purchased from Jackson
Labs: #002797 and #004132, respectively) were used to generate double mutant animals. Breedings were performed as previously described (Theodoris et al., The Journal of Clinical Investigation. 2017;127:1683) to generate Nl m ill'2 mice. Mice were treated with XCT790 (5mg/kg/day), TG003 (0.3mg/kg/day or 2mg/kg/day, results pooled for analysis), Fmoc-leu (0.6mg/kg/day), GSK837149A (4.5 mg/kg/day), biperiden (10 mg/kg/day), CB1954 (15 mg/kg/day), putrescine (0.26 mg/kg/day), naloxone
(25 mg/kg/day), all by intraperitoneal injection, and RO4929097 (60 mg/kg/day) by oral gavage, or equivalent volume of solvent (DMSO or saline) for four weeks starting at the fourth postnatal week.
[00271] Echocardiography was performed under isofluorane anesthesia with standard measurement techniques using the Vevo 770 Imaging System (VisualSonics) equipped with an RMV-707B transducer with central frequency of 30 MHz. Peak blood flow velocity through AVs and PVs was obtained by pulsed wave Doppler in the modified parasternal long and short axis views. The average of three cardiac cycles was used for each measurement.
[00272] Hearts were fixed by perfusion fixation under anesthesia using isofluorane by ventricular KC1 injection followed by PBS wash and fixation with 4%
paraformaldehyde. Hearts were then incubated in 10% formalin overnight. The cardiac apex was cut parallel to the aortic root, and the heart tissue was then paraffin processed using standard protocols and embedded with the cut surface down. The resulting paraffin block was trimmed and angled to obtain a full three-leaflet view of the aortic root. The root was serially sectioned at 5 pm intervals from the base of the aortic sinus and mounted on slides. The slides were then deparaffmized, and calcification was stained with 2% Alizarin Red (pH 4.1-4.3) as previously described (Theodoris et al., The Journal of Clinical Investigation. 2017;127: 1683).
Results
[00273] Nl+/~ mice with shortened telomeres develop age-dependent AV and pulmonary valve (PV) stenosis, mimicking the range of human disease caused by Nl
haploinsufficiency (Theodoris et al., The Journal of Clinical Investigation.
2017;127: 1683). To determine whether the identified network-correcting molecules were
sufficient to prevent cardiac valve disease caused by N1 haploinsufficiency in vivo, Ml mice with shortened telomeres (generation 2 (G2) mice lacking telomerase activity due to mutations in the telomerase RNA component Terc ( mTR )) were treated with either XCT790 or TG003 for four weeks starting at the fourth postnatal week. Compared to DMSO-treated mice, TG003 reduced the number of mice that developed calcification by 68% (p=0.09) and the extent of calcification by 80% (p=0.09) by Alizarin red staining (Figures 3B-C), though did not significantly impact AV or PV stenosis by
echocardiography (Figures 9C-D). XCT790, which most effectively restored the network in vitro, was sufficient to prevent PV stenosis in vivo by echocardiography (p=0.022) and showed a trend of reducing AV stenosis by echocardiography (p=0.068) (Figure 3D- E). Compared to DMSO, XCT790 also reduced the number of mice that developed calcification by 64%, and the single XCT790-treated mouse that developed calcification had 99% less calcification than the average DMSO-treated mouse, though these effects did not meet statistical significance (Figures 9E-F). Overall, XCT790 significantly prevented PV stenosis, and both XCT790 and TG003 showed a trend of reducing AV calcification in Nl+//mTRG2 mice. The network-based drug screen thus effectively identified network- correcting molecules promising for preventing cardiac valve disease in vivo.
[00274] Additional compounds, Fmoc-leu, GSK837149A, biperiden, CB1954, putrescine, naloxone, and RO4929097, were tested in vivo (see above methods for Example 4) in a small initial cohort with results as shown in Figures 11 A-15B. Based on the small number of initial mice tested, there is insufficient statistical power to conclude statistical significance thus far.
REFERENCES
1. Theodoris CV, Li M, White MP, Liu L, He D, Pollard KS, Bruneau BG, Srivastava D.
Human Disease Modeling Reveals Integrated Transcriptional and Epigenetic
Mechanisms ofNOTCHl Haploinsufficiency. Cell. 2015;160: 1072-1086.
2. White MP, Rufaihah AJ, Liu L, Ghebremariam YT, Ivey KN, Cooke JP, Srivastava D.
Limited Gene Expression Variation in Human Embryonic Stem Cell and Induced
Pluripotent Stem Cell Derived Endothelial Cells. Stem Cells. 2012;31 :92-103.
Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R,
Califano A. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics. 2006;7 Suppl 1 :S7.
Hagberg AA, Schult DA, Swart PJ. Exploring Network Structure, Dynamics, and
Function using NetworkX. SciPy. 2008;
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 20l2;29: l5- 21
Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol.
2012;31 :46-53.
van der Laan MJ, Pollard KS. A new algorithm for hybrid hierarchical clustering with visualization and the bootstrap [Internet] stat-www.berkeley.edu. [cited 2014 Dec l2];Available from: http://stat- www.berkeley.edu/~laan/Research/Research_subpages/Papers/hopach.pdf
Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Research. 2009;37:W305- W311.
Zambon AC, Gaj S, Ho I, Hanspers K, Vranizan K, Evelo CT, Conklin BR, Pico AR, Salomonis N. GO-Elite: a flexible solution for pathway and ontology over-representation. Bioinformatics. 2012;28 :2209-2210.
Theodoris CV, Mourkioti F, Huang Y, Ranade S, Liu L, Blau HM, Srivastava D. Long telomeres protect against age-dependent cardiac disease caused by NOTCH1
haploinsufficiency. The Journal of Clinical Investigation. 2017; 127: 1683.
Mercer TR, Gerhardt DJ, Dinger ME, Crawford J, Trapnell C, Jeddeloh JA, Mattick JS, Rinn JL. Targeted RNA sequencing reveals the deep complexity of the human
transcriptome. Nat Biotechnol. 2011;30:99-104. Thomas M Blomquist ELC JLL J YLM S AL JLMLL SKM J C W . Targeted RNA-Sequencing with Competitive Multiplex -PCR Amplicon Libraries. PLoS ONE. 20l3;8:e79l20. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, Srivastava D. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437:270- 274. Mohamed SA, Aherrahrou Z, Liptau H, Erasmi AW, Hagemann C, Wrobel S, Borzym K, Schunkert H, Sievers HH, Erdmann J. Novel missense mutations (p.T596M and r.R1797H) in NOTCH1 in patients with bicuspid aortic valve. Biochemical and
Biophysical Research Communications. 2006;345: 1460-1465.
L S Coles PDFOMAVMFS. Cold shock domain proteins repress transcription from the GM-CSF promoter . Nucleic Acids Research. l996;24:23 l l.
Schneider JG, Yang Z, Chakravarthy MV, Lodhi IJ, Wei X, Turk J, Semenkovich CF. Macrophage Fatty-acid Synthase Deficiency Decreases Diet-induced Atherosclerosis. J Biol Chem. 2010;285:23398-23409. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor g ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:523-531. Cheang WS, Fang X, Tian XY. Pleiotropic Effects of Peroxisome Proliferator-Activated Receptor A|Agamma; and A|Adelta; in Vascular Diseases. Circ J. 2013;77:2664-2671. Liu S-L, Li Y-H, Shi G-Y, Chen Y-H, Huang C-W, Hong J-S, Wu H-L. A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. J Am Coll Cardiol. 2006;48: 1871-1879. Tsou CY, Chen CY, Zhao JF, Su KH, Lee HT, Lin SJ, Shyue SK, Hsiao SH, Lee TS. Activation of soluble guanylyl cyclase prevents foam cell formation and atherosclerosis. Acta Physiol. 2013;210:799-810. Mahler GJ, Farrar EJ, Butcher JT. Inflammatory Cytokines Promote Mesenchymal Transformation in Embryonic and Adult Valve Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;33: 121-130. Fedorov O, Huber K, Eisenreich A, Filippakopoulos P, King O, Bullock AN, Szklarczyk D, Jensen LJ, Fabbro D, Trappe J, Rauch U, Bracher F, Knapp S. Specific CLK
Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing. Chemistry & Biology. 2011;18:67-76. Clark CR, Bowler MA, Snider JC, Merryman WD. Targeting Cadherin-l 1 Prevents Notch 1 -Mediated Calcific Aortic Valve Disease. Circulation. 2017;135:2448-2450. Gray-Owen SD, Blumberg RS. CEACAM1 : contact-dependent control of immunity. Nat Rev Immunol. 2006;6:433-446. Nakano K, Yamauchi J, Nakagawa K, Itoh H, Kitamura N. NESK, a Member of the Germinal Center Kinase Family That Activates the c-Jun N-terminal Kinase Pathway and Is Expressed during the Late Stages of Embry ogenesis. JBiol Chem. 2000;275:20533- 20539. Foffa I, Ait Ali L, Panesi P, Mariani M, Festa P, Botto N, Vecoli C, Andreassi MG. Sequencing of NOTCH1, GATA5, TGFBR1 and TGFBR2 genes in familial cases of bicuspid aortic valve. BMC Med Genet. 2013; 14:44.
27. Hadji F, Boulanger M-C, Guay S-P, Gaudreault N, Amellah S, Mkannez G, Bouchareb R, Marchand JT, Nsaibia MJ, Guauque-Olarte S, Pibarot P, Bouchard L, Bosse Y, Mathieu P. Altered DNA Methylation of Long Noncoding RNA H19 in Calcific Aortic Valve Disease Promotes Mineralization by Silencing NOTCH1. Circulation.
2016;134:1848-1862.
[00275] While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.
Claims
1. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
n is an integer from 1 to 8;
X is O or S;
Y is O or S; and
each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR12, - C(0)0R12, -C(0)NR12R13, -C=NR12, -OR12, -0C(0)R12, -S(0)t-R7, -NR12R13, -NR12C(0)R13, - N=CR12R13, wherein t is 0, 1, 2 or 3 and R12 and R13 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted
heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
2. The method according to claim 1, wherein R1 is cyano.
3. The method according to any one of claims 1-2, wherein R1 is methoxy.
4. The method according to any one of claims 1-3, wherein X is S.
5. The method according to any one of claims 1-4, wherein Y is O.
6. The method according to any one of claims 1-5, wherein n is 1.
7. The method according to claim 1, wherein the compound is XCT-790 (2E-3-(4-{[2,4- bis(trifluoromethyl)benzyl]oxy}-3-methoxyphenyl)-2-cyano-N-[5-(trifluoromethyl)-l,3,4- thiadiazol-2-yl]acrylamide):
8. The method according to any one of claims 1-7, wherein the cardiac valve disease is a calcific aortic valve disease.
9. The method according to any one of claims 1-7, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
10. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula II:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
X is O or S; and
each of R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR12, -C(0)0R12, - C(0)NR12R13, -C=NR12, -OR12, -0C(0)R12, -S(0)t-R7, -NR12R13, -NR12C(0)R13, -N=CR12R13, wherein t is 0, 1, 2 or 3 and R12 and R13 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
11. The method according claim 10, wherein R2 is methoxy.
12. The method according to any one of claims 10-11, wherein R5 is methyl.
13. The method according to any one of claims 10-12, wherein R6 is methyl.
14. The method according to any one of claims 10-13, wherein X is O.
15. The method according to claim 10, wherein the compound is TG-003 ((Z)-l-(3-ethyl-5- methoxy-2,3-dihydrobenzothiazol-2-ylidene)propan-2-one):
16. The method according to any one of claims 10-15, wherein the cardiac valve disease is a calcific aortic valve disease.
17. The method according to any one of claims 10-15, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
18. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula III:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR15, -C(0)0R15, -C(0)NR15R16, -C=NR15, -OR15, -0C(0)R15, -S(0)t-R15, -NR15R16, - NR15C(0)R16, -N=CR15R16, wherein t is 0, 1, 2 or 3 and R15 and R15 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
19. The method according to claim 18, wherein R3 is methyl.
20. The method according to any one of claims 18-19, wherein R12 is methyl.
21. The method according to claim 18, wherein the compound is GSK-837149A (4,4’- (carbonyldiimino)bis[N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide):
22. The method according to any one of claims 18-21, wherein the cardiac valve disease is a calcific aortic valve disease.
23. The method according to any one of claims 18-21, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
24. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula IV:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4 and R5 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR15, -C(0)0R15, - C(0)NR15R16, -C=NR15, -OR15, -0C(0)R15, -S(0)t-R15, -NR15R16, -NR15C(0)R16, -N=CR15R16, wherein t is 0, 1, 2 or 3 and R15 and R15 are independently selected from hydrogen, substituted
or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
25. The method according to claim 24, wherein R1 is hydroxyl.
26. The method according to any one of claims 24-25, wherein R4 is hydroxyl.
27. The method according to any one of claims 24-26, wherein R5 is allyl.
28. The method according to claim 24, wherein the compound is Naloxone
((4R,4aS,7aR,l2bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,l3-hexahydro-lH-4,l2- methanobenzofuro[3,2-e]isoquinoline-7-one):
29. The method according to any one of claims 24-28, wherein the cardiac valve disease is a calcific aortic valve disease.
30. The method according to any one of claims 24-28, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
31. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula V:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6, R7, R8 and R9 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR10, -C(0)OR10, - C(O)NR10Ru, -C=NR10, -OR10, -OC(0)R10, -S(0)t-R10, -NR10RU, -NR10C(O)Ru, -N=CR10RU, wherein t is 0, 1, 2 or 3 and R10 and R11 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
32. The method according to claim 31, wherein R6 is hydrogen.
33. The method according to any one of claims 31-32, wherein R7 is methyl.
34. The method according to any one of claims 31-33, wherein R8 is hydroxyl.
35. The method according to any one of claims 31-34, wherein R9 is methyl.
36. The method according to claim 31, wherein the compound is Cytochalasin:
37. The method according to any one of claims 31-36, wherein the cardiac valve disease is a calcific aortic valve disease.
38. The method according to any one of claims 31-36, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
39. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula VI:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6, R7 and R8 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR9, -C(0)0R9, -
C(0)NR9R10, -C=NR9, -OR9, -0C(0)R9, -S(0)t-R9, -NR9R10, -NR9C(0)R10, -N=CR9R10, wherein t is 0, 1, 2 or 3 and R9 and R10 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
40. The method according to claim 39, wherein each of R1, R2, R3, R4, R5, R6, R7 and R8 are hydrogen.
42. The method according to any one of claims 39-41, wherein the cardiac valve disease is a calcific aortic valve disease.
43. The method according to any one of claims 39-41, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
44. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula VI:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2 and R3 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR4, -C(0)0R4, -C(0)NR4R5, -C=NR4, -OR4, -0C(0)R4, -S(0)t-R4, -NR4R5, -NR4C(0)R5, -N=CR4R5, wherein t is 0, 1, 2 or 3 and R4and R5 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
45. The method according to claim 44, wherein each of R1, R2 and R3 are hydrogen.
46. The method according to claim 44, wherein the compound is CB-1954 (5-(l-aziridinyl)- 2,4-dinitrobenzamide):
47. The method according to any one of claims 44-46, wherein the cardiac valve disease is a calcific aortic valve disease.
48. The method according to any one of claims 44-46, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
49. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula VIII:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
each of R1, R2, R3, R4, R5, R6 and R7 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR8, -C(0)0R8, - C(0)NR8R9, -C=NR8, -OR9, -0C(0)R8, -S(0)t-R8, -NR8R9, -NR8C(0)R9, -N=CR8R9, wherein t is 0, 1, 2 or 3 and R8 and R9 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
50. The method according to claim 49, wherein R1 is hydrogen.
51. The method according to claim 49, wherein R1 is hydroxyl.
52. The method according to any one of claims 49-51, wherein each of R2, R3, R4, R5, R6 and R7 are hydrogen.
53. The method according to claim 49, wherein the compound is biperiden ((lRS,2SR,4RS)- 1 -(bicyclo[2.2.1 ]hept-5-en-2-yl)- 1 -phenyl-3 -(piperidin- 1 -yljpropan- 1 -ol)) :
54. The method according to any one of claims 49-53, wherein the cardiac valve disease is a calcific aortic valve disease.
55. The method according to any one of claims 49-53, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
56. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula IX:
wherein:
each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR12, - C(0)0R12, -C(0)NR12R13, -C=NR12, -OR12, -0C(0)R12, -S(0)t-R12, -NR12R13, -NR12C(0)R13, - N=CR12R13, wherein t is 0, 1, 2 or 3 and R12 and R13 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted
heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen.
57. The method according to claim 56, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R10 and R11 are hydrogen.
58. The method according to claim 56, wherein R9 is pentafluoroethyl.
59. The method according to claim 56, wherein the compound is RO-4929097 ((2,2- dimethyl-N-[(l0S)-9-oxo-8-azatricyclo[9.4.0.02,7]pentadeca-l,2,4,6, l l,l3-hexaene-l0-yl]-N’- (2,2, 3 ,3 , 3 -pentafluoropropyl)propanedi amide) :
60. The method according to any one of claims 56-59, wherein the cardiac valve disease is a calcific aortic valve disease.
61. The method according to any one of claims 56-59, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
62. A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula X:
or a pharmaceutically acceptable salt, solvate or prodrug thereof,
wherein:
R1 is selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl,
heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, hydroxyl, alkoxyl, substituted alkoxyl, substituted acyloxy, alkoxycarbonyl, substituted alkoxycarbonyl, thiol, acyl, amino, substituted amino, aminoacyl, acylamino, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, -COR2, -C(0)0R2, -C(0)NR2R3, -C=NR2, -OR2, -0C(0)R2, -S(0)t-R2, - NR2R3, -NR2C(0)R3, -N=CR2R3, wherein t is 0, 1, 2 or 3 and R8 and R9 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy or halogen; and
PG is a hydroxyl protecting group selected from the group consisting of a benzyl ether, methyl ester, benzoic acid ester, t-butyl ester, t-butyl ether (TBDMS, TBDPS), methoxymethyl ether (MOM), allyl ether, tetrahydropyranyl ether (THP), a fluorenylmethyloxycarbonyl (Fmoc).
63. The method according to claim 62, wherein each of R1 is hydrogen.
64. The method according to claim 63, wherein PG is fluorenylmethyloxycarbonyl (Fmoc).
65. The method according to claim 64, wherein the compound is Fmoc-leucine:
O
OH
Fmoc
66. The method according to any one of claims 62-65, wherein the cardiac valve disease is a calcific aortic valve disease.
67. The method according to any one of claims 62-65, wherein the subject has a NOTCH1 haploinsufficiency, the subject is at risk of developing calcific aortic valve disease, and/or the subject has been diagnosed as having calcific aortic valve disease.
68. A method of identifying a candidate compound for treatment of cardiac valve disease, the method comprising:
contacting human NOTCHl+/ endothelial cells with a compound;
performing targeted RNA sequencing (RNA-seq) to provide an expression profile for the human NOTCHl+/ endothelial cells resulting from the contacting, wherein the targeted RNA- seq comprises sequencing RNA transcripts fora plurality of genes selected from Table 1;
comparing the expression profile resulting from the contacting with an isogenic WT expression profile; and
identifying the compound as a candidate compound for treatment of cardiac valve disease when the expression profile resulting from the contacting is corrected to the isogenic WT expression profile.
69. The method of claim 68, wherein the plurality of genes comprises one or more or all of NOTCH1, SOX7, TCF4, and SMAD1.
70. The method of claim 68 or 69, wherein the plurality of genes further comprises one or more or all of NOTCH4, HES1, ACE, and GREM1.
71. The method of any one of claims 68-70, wherein the plurality of genes further comprises one or more or all of CHMP2A, Clorf43, and REEP5.
72. The method of any one of claims 68-71, wherein the plurality of genes further comprises one or more or all of JAG2, ARHGEF17, MMP10, IRF6, DKK3, AN04, MMP19, SOX11, SOX13, RUNX2, and RUNX1.
73. The method of any one of claims 68-72, wherein the plurality of genes further comprises one or more or all of ITGA5, CD34, ETS1, CSDA, IGFBP3, SDPR, CDH5, LXN, CXCR4, TNFSF4, GJA4, NRP1, CD24P4, HMGA2, THSD1, RASSF2, HHIP, TERF1, NID2,
ALDH1A1, HEY1, ETS2, ITGA9, NRCAM, HOXB5, HOXB6, PRDM1, ClOorflO, ALDH2, COL12A1, SNCA, SFRP1, NPPB, CA8, GNA14, VCAN, HOXB7, ITGA8, ACP5, TMEM178, HOXB3, PLAGL1, NR5A2, VLDLR, BICD1, MAML3, NRG3, FOXF1, CXCL12, HLX, MEIS2, HOXB4, TCF7L1, FGF2, ALX1, CARHSP1, DNER, TGFBR3, TOX3, PDE2A, HOXB2, CA2, COL15A1, PPARG, IER3, TNFRSF25, FLT4, PRRX1, HOXD1, AFF3, CXCR7, PDE3A, SMTN, BMP6, BMP4, PGF, TXNIP, and DACH1.
74. The method of any one of claims 68-73, wherein the plurality of genes further comprises one or more or all of F2R, F2RL2, THBS1, FAM124B, PLOD2, COX6A1, KIAA0494, RNF19A, CLEC14A, DIAPH2, NDUFA12, FAM89A, NNMT, MLF1, Clorf54, HAPLN1, IL1RL1, ITPKB, and CD97.
75. The method of any one of claims 68-74, wherein the human NOTCHl+/ endothelial cells are derived from human induced pluripotent stem cells (iPSC) derived from a subject having CAVD.
76. The method of claim 75, wherein the iPSC are dervived from fibroblasts of a subject having CAVD.
77. The method of any one of claims 68-76, wherein the identifying comprises applying a machine learning algorithm to determine when the expression profile resulting from the contacting is corrected to the isogenic WT expression profile.
78. A composition comprising at least one compound of any one of Formulae I-X for use in the treatment of cardiac valve disease.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19853073.5A EP3840749B1 (en) | 2018-08-22 | 2019-08-20 | Compounds for treating cardiac valve disease |
US17/269,623 US20210228594A1 (en) | 2018-08-22 | 2019-08-20 | Methods for treating cardiac valve disease |
EP23182183.6A EP4316477A1 (en) | 2018-08-22 | 2019-08-20 | Methods for treating cardiac valve disease |
JP2021533376A JP7476198B2 (en) | 2018-08-22 | 2019-08-20 | Pharmaceutical Composition for Treating Heart Valve Disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862721389P | 2018-08-22 | 2018-08-22 | |
US62/721,389 | 2018-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020041333A1 true WO2020041333A1 (en) | 2020-02-27 |
Family
ID=69591175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/047295 WO2020041333A1 (en) | 2018-08-22 | 2019-08-20 | Methods for treating cardiac valve disease |
Country Status (4)
Country | Link |
---|---|
US (1) | US20210228594A1 (en) |
EP (2) | EP4316477A1 (en) |
JP (1) | JP7476198B2 (en) |
WO (1) | WO2020041333A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111557937A (en) * | 2020-03-16 | 2020-08-21 | 浙江大学 | Application of XCT790 in preparing medicine for treating calcified aortic valve diseases |
CN112603918A (en) * | 2020-12-28 | 2021-04-06 | 中国人民解放军空军军医大学 | Application of kappa-opioid receptor agonist U50,488H in preparation of medicines for treating vascular calcification |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4756907A (en) | 1978-10-17 | 1988-07-12 | Stolle Research & Development Corp. | Active/passive immunization of the internal female reproductive organs |
US5728074A (en) | 1994-03-09 | 1998-03-17 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
US6086909A (en) | 1997-06-11 | 2000-07-11 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
US6096010A (en) | 1998-02-20 | 2000-08-01 | Becton, Dickinson And Company | Repeat-dose medication delivery pen |
US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
US6221053B1 (en) | 1998-02-20 | 2001-04-24 | Becton, Dickinson And Company | Multi-featured medication delivery pen |
US6248095B1 (en) | 1998-02-23 | 2001-06-19 | Becton, Dickinson And Company | Low-cost medication delivery pen |
US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
US6476079B1 (en) | 1999-12-23 | 2002-11-05 | Leiras Oy | Devices for the delivery of drugs having antiprogestinic properties |
US20170058349A1 (en) * | 2014-03-04 | 2017-03-02 | The Children's Hospital Of Philadelphia | Methods for managing care of patients predisposed to progressive mitral valve diseases |
US20170332686A1 (en) * | 2016-05-20 | 2017-11-23 | Nestec Sa | Mct-based nutrition blend for cardiac protection and treating degenerative mitral valve disease in companion animals |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005072731A1 (en) * | 2004-01-29 | 2005-08-11 | X-Ceptor Therapeutics, Inc. | 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders |
SI2132188T1 (en) | 2007-03-07 | 2012-04-30 | Janssen Pharmaceutica Nv | Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators |
CN101628913B (en) | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | Compound as estrogen-related receptor modulator and application thereof |
-
2019
- 2019-08-20 US US17/269,623 patent/US20210228594A1/en active Pending
- 2019-08-20 EP EP23182183.6A patent/EP4316477A1/en active Pending
- 2019-08-20 EP EP19853073.5A patent/EP3840749B1/en active Active
- 2019-08-20 WO PCT/US2019/047295 patent/WO2020041333A1/en unknown
- 2019-08-20 JP JP2021533376A patent/JP7476198B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4756907A (en) | 1978-10-17 | 1988-07-12 | Stolle Research & Development Corp. | Active/passive immunization of the internal female reproductive organs |
US5728074A (en) | 1994-03-09 | 1998-03-17 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
US6086909A (en) | 1997-06-11 | 2000-07-11 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
US6096010A (en) | 1998-02-20 | 2000-08-01 | Becton, Dickinson And Company | Repeat-dose medication delivery pen |
US6221053B1 (en) | 1998-02-20 | 2001-04-24 | Becton, Dickinson And Company | Multi-featured medication delivery pen |
US6248095B1 (en) | 1998-02-23 | 2001-06-19 | Becton, Dickinson And Company | Low-cost medication delivery pen |
US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
US6476079B1 (en) | 1999-12-23 | 2002-11-05 | Leiras Oy | Devices for the delivery of drugs having antiprogestinic properties |
US20170058349A1 (en) * | 2014-03-04 | 2017-03-02 | The Children's Hospital Of Philadelphia | Methods for managing care of patients predisposed to progressive mitral valve diseases |
US20170332686A1 (en) * | 2016-05-20 | 2017-11-23 | Nestec Sa | Mct-based nutrition blend for cardiac protection and treating degenerative mitral valve disease in companion animals |
Non-Patent Citations (36)
Title |
---|
"Pharmaceutical Dosage Forms and Drug Delivery Systems", 1999, LIPPINCOTT, WILLIAMS, & WILKINS |
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY |
CHEANG WS, FANG X, TIAN XY: "Pleiotropic Effects of Peroxisome Proliferator-Activated Receptor AlAgamma; and AlAdelta; in Vascular Diseases", CIRC J, vol. 77, 2013, pages 2664 - 2671 |
CHEN JBARDES EEARONOW BJJEGGA AG: "ToppGene Suite for gene list enrichment analysis and candidate gene prioritization", NUCLEIC ACIDS RESEARCH, vol. 37, 2009, pages W305 - W311 |
CLARK CRBOWLER MASNIDER JCMERRYMAN WD: "Targeting Cadherin-11 Prevents Notchl-Mediated Calcific Aortic Valve Disease", CIRCULATION, vol. 135, 2017, pages 2448 - 2450 |
DOBIN ADAVIS CASCHLESINGER FDRENKOW JZALESKI CJHA SBATUT PCHAISSON MGINGERAS TR: "STAR: ultrafast universal RNA-seq aligner", BIOINFORMATICS, vol. 29, 2012, pages 2209 - 2210 |
DU ET AL.: "The discovery of novel, potent ERR-alpha inverse agonists for the treatment of triple negative breast cance l", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 136, 22 April 2017 (2017-04-22), pages 457 - 467, XP055688737 * |
FEDOROV OHUBER KEISENREICH AFILIPPAKOPOULOS PKING OBULLOCK ANSZKLARCZYK DJENSEN LJFABBRO DTRAPPE J: "Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing", CHEMISTRY & BIOLOGY, vol. 18, 2011, pages 67 - 76, XP028131175, DOI: 10.1016/j.chembiol.2010.11.009 |
FOFFA IAIT ALL LPANESI PMARIANI MFESTA PBOTTO NVECOLI CANDREASSI MG: "Sequencing of NOTCH1, GATA5, TGFBR1 and TGFBR2 genes in familial cases of bicuspid aortic valve", BMC MED GENET, vol. 14, 2013, pages 44, XP021145214, DOI: 10.1186/1471-2350-14-44 |
GARG VMUTH ANRANSOM JFSCHLUTERMAN MKBARNES RKING INGROSSFELD PDSRIVASTAVA D: "Mutations in NOTCH1 cause aortic valve disease", NATURE, vol. 437, 2005, pages 270 - 274 |
GRAY-OWEN SDBLUMBERG RS: "CEACAM1: contact-dependent control of immunity", NAT REV IMMUNOL, vol. 6, 2006, pages 433 - 446, XP002605706 |
HADJI FBOULANGER M-CGUAY S-PGAUDREAULT NAMELLAH SMKANNEZ GBOUCHAREB RMARCHAND JTNSAIBIA MJGUAUQUE-OLARTE S: "Altered DNA Methylation of Long Noncoding RNA H19 in Calcific Aortic Valve Disease Promotes Mineralization by Silencing NOTCH 1", CIRCULATION, vol. 134, 2016, pages 1848 - 1862 |
HAGBERG AASCHULT DASWART PJ: "Exploring Network Structure, Dynamics, and Function using NetworkX", SCIPY, 2008 |
HAGBERG ET AL., SCIPY, 2008 |
HIMURA ET AL.: "Short-term effects of naloxone hemodynamics and baroreflex function in conscious dogs with pacing-induced congestive heart failure", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 23, January 1994 (1994-01-01), pages 194 - 200, XP009053395 * |
L S COLES: "Cold shock domain proteins repress transcription from the GM-CSF promoter", NUCLEIC ACIDS RESEARCH, vol. 24, 1996, pages 2311, XP002262397, DOI: 10.1093/nar/24.12.2311 |
LI ACBROWN KKSILVESTRE MJWILLSON TMPALINSKI WGLASS CK: "Peroxisome proliferator-activated receptor y ligands inhibit development of atherosclerosis in LDL receptor-deficient mice", J CLIN INVEST, vol. 106, 2000, pages 523 - 531 |
LIU S-LLI Y-HSHI G-YCHEN Y-HHUANG C-WHONG J-SWU H-L: "A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice", JAM COLL CARDIOL, vol. 48, 2006, pages 1871 - 1879 |
LOUDON: "Organic Chemistry", 2002, OXFORD UNIVERSITY PRESS, pages: 360 - 361,1084-1085 |
MAHLER GJFARRAR EJBUTCHER JT: "Inflammatory Cytokines Promote Mesenchymal Transformation in Embryonic and Adult Valve Endothelial Cells", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 33, 2012, pages 121 - 130 |
MARGOLIN AANEMENMAN IBASSO KWIGGINS CSTOLOVITZKY GDALLA FAVERA RCALIFANO A: "ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context", BMC BIOINFORMATICS, vol. 7, 2006, pages S7, XP021014000, DOI: 10.1186/1471-2105-7-S1-S7 |
MERCER TRGERHARDT DJDINGER MECRAWFORD JTRAPNELL CJEDDELOH JAMATTICK JSRINN JL: "Targeted RNA sequencing reveals the deep complexity of the human transcriptome", NAT BIOTECHNOL, vol. 30, 2011, pages 99 - 104, XP055152367, DOI: 10.1038/nbt.2024 |
MOHAMED SAAHERRAHROU ZLIPTAU HERASMI AWHAGEMANN CWROBEL SBORZYM KSCHUNKERT HSIEVERS HHERDMANN J: "Novel missense mutations (p.T596M and p.P1797H) in NOTCH1 in patients with bicuspid aortic valve", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 345, 2006, pages 1460 - 1465, XP024925248, DOI: 10.1016/j.bbrc.2006.05.046 |
NAKANO KYAMAUCHI JNAKAGAWA KITOH HKITAMURA N: "NESK, a Member of the Germinal Center Kinase Family That Activates the c-Jun N-terminal Kinase Pathway and Is Expressed during the Late Stages of Embryogenesis", J BIOL CHEM., vol. 275, 2000, pages 20533 - 20539, XP002266890, DOI: 10.1074/jbc.M001009200 |
SCHNEIDER JGYANG ZCHAKRAVARTHY MVLODHI IJWEI XTURK JSEMENKOVICH CF: "Macrophage Fatty-acid Synthase Deficiency Decreases Diet-induced Atherosclerosis", J BIOL CHEM., vol. 285, 2010, pages 23398 - 23409 |
See also references of EP3840749A4 |
SMITHMARCH: "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 2001, WILEY-INTERSCIENCE |
SUN ET AL.: "Novel endocrine therapeutic strategy in endometrial carcinoma targeting estrogen- related receptor a by XCT790 and siRNA", CANCER MANAGEMENT AND RESEARCH, vol. 2018, 10 August 2018 (2018-08-10), pages 2521 - 2535, XP055688732 * |
THEODORIS CVLI MWHITE MPLIU LHE DPOLLARD KSBRUNEAU BGSRIVASTAVA D: "Human Disease Modeling Reveals Integrated Transcriptional and Epigenetic Mechanisms of NOTCH I Haploinsufficiency", CELL, vol. 160, 2015, pages 1072 - 1086, XP029203794, DOI: 10.1016/j.cell.2015.02.035 |
THEODORIS CVMOURKIOTI FHUANG YRANADE SLIU LBLAU HMSRIVASTAVA D: "Long telomeres protect against age-dependent cardiac disease caused by NOTCH 1 haploinsufficiency", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 127, 2017, pages 1683 |
THOMAS M: "Targeted RNA-Sequencing with Competitive Multiplex-PCR Amplicon Libraries", PLOS ONE, vol. 8, 2013, pages e79120, XP055179283, DOI: 10.1371/journal.pone.0079120 |
TRAPNELL CHENDRICKSON DGSAUVAGEAU MGOFF LRINN JLPACHTER L: "Differential analysis of gene regulation at transcript resolution with RNA-seq", NAT BIOTECHNOL, vol. 31, 2012, pages 46 - 53 |
TSOU CYCHEN CYZHAO JFSU KHLEE HTLIN SJSHYUE SKHSIAO SHLEE TS: "Activation of soluble guanylyl cyclase prevents foam cell formation and atherosclerosis", ACTA PHYSIOL, vol. 210, 2013, pages 799 - 810 |
VAN DER LAAN MJPOLLARD KS, A NEW ALGORITHM FOR HYBRID HIERARCHICAL CLUSTERING WITH VISUALIZATION AND THE BOOTSTRAP, 12 December 2014 (2014-12-12), Retrieved from the Internet <URL:http://stat-www.berkeley.edu/~laan/Research/Research_subpages/Papers/hopach.pdf> |
WHITE MPRUFAIHAH AJLIU LGHEBREMARIAM YTIVEY KNCOOKE JPSRIVASTAVA D: "Limited Gene Expression Variation in Human Embryonic Stem Cell and Induced Pluripotent Stem Cell Derived Endothelial Cells", STEM CELLS, vol. 31, 2012, pages 92 - 103, XP055383022, DOI: 10.1002/stem.1267 |
ZAMBON ACGAJ SHO IHANSPERS KVRANIZAN KEVELO CTCONKLIN BRPICO ARSALOMONIS N: "GO-Elite: a flexible solution for pathway and ontology over-representation", BIOINFORMATICS, vol. 28, 2012, pages 2209 - 2210 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111557937A (en) * | 2020-03-16 | 2020-08-21 | 浙江大学 | Application of XCT790 in preparing medicine for treating calcified aortic valve diseases |
CN112603918A (en) * | 2020-12-28 | 2021-04-06 | 中国人民解放军空军军医大学 | Application of kappa-opioid receptor agonist U50,488H in preparation of medicines for treating vascular calcification |
CN112603918B (en) * | 2020-12-28 | 2021-09-03 | 中国人民解放军空军军医大学 | Application of kappa-opioid receptor agonist U50,488H in preparation of medicines for treating vascular calcification |
Also Published As
Publication number | Publication date |
---|---|
EP4316477A1 (en) | 2024-02-07 |
JP7476198B2 (en) | 2024-04-30 |
EP3840749A1 (en) | 2021-06-30 |
EP3840749B1 (en) | 2023-08-09 |
JP2021534254A (en) | 2021-12-09 |
EP3840749A4 (en) | 2022-05-25 |
US20210228594A1 (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Epigenetics in cardiac hypertrophy and heart failure | |
Corsten et al. | Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease | |
Grzeschik et al. | Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells | |
Bersano et al. | Heritable and non-heritable uncommon causes of stroke | |
EP4218773A1 (en) | Human functional corneal endothelial cell and application thereof | |
JP6797310B2 (en) | Peptide-based proteasome inhibitors for treating diseases mediated by senescent cells, and peptide-based proteasome inhibitors for treating cancer | |
CN107073137A (en) | Introne is reduced to retain | |
Narducci et al. | High telomerase activity in neutrophils from unstable coronary plaques | |
CA3116729C (en) | Inhibitors of sarm1 in combination with nad+ or a nad+ precursor | |
WO2007103114A2 (en) | Notch inhibition in the treatment or prevention of atherosclerosis | |
EP3145513B1 (en) | 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus | |
JP7212781B2 (en) | Inhibitors of SARM1 in combination with neuroprotective agents | |
EP3840749B1 (en) | Compounds for treating cardiac valve disease | |
Duygu et al. | miR-199b-5p is a regulator of left ventricular remodeling following myocardial infarction | |
US20090143451A1 (en) | Compounds that increase telomerase reverse transcriptase (tert) expression and methods for using the same | |
US20220144845A1 (en) | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | |
WO2020081556A2 (en) | Non-canonical swi/snf complex and uses thereof | |
CN116113436A (en) | Systems and methods for protecting nucleic acid molecules | |
JP2023179435A (en) | Multiple myeloma treatment | |
JP2024045611A (en) | Methods for predicting drug responsiveness in cancer patients | |
JPWO2018025923A1 (en) | Anti-HTLV-1 agent, HTLV-1-related myelopathy (HAM / TSP) therapeutic agent | |
JP2023164560A (en) | Methods of identifying patients likely to benefit from treatment with telomerase inhibitor | |
US20230032239A1 (en) | A method of treatment in predisposed subjects for lmna-related dilated cardiomyopathy | |
Nordquist et al. | Tgfβ1-cthrc1 signaling plays an important role in the short-term reparative response to heart valve endothelial injury | |
EP3716956B1 (en) | Antitumor tet2 modulating compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19853073 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021533376 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019853073 Country of ref document: EP Effective date: 20210322 |